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Hemodialysis (HD) is a life-saving treatment option for end stage kidney disease patients. 
It removes excess fluid and toxins which are normally removed by healthy kidneys. 
During HD, blood is passed through hollow fiber membranes, which remove accumulated 
toxins and fluid via diffusion and convection. This makes HD a perfect example of 
synergy between chemical engineering principles and medical care. Although HD 
sustains patients’ lives, poor patients’ outcome is a major concern. Hence, the broad focus 
of this research work is to improve HD care such that it will result in better patient 
outcome. One potential way to achieve this is to enhance the toxin removal, the mainstay 
of HD since its inception in 1950’s. One effective way to accomplish this is via process 
systems engineering (PSE) principles, especially mathematical modeling. 
In HD, compartmental toxin kinetic modeling continues to play an important role in 
understanding the toxin removal behavior. The present work proposes a comprehensive 
kinetic model for middle-sized marker toxin (β2-microglobulin) in HD patients. One of 
the major advantages of mathematical models is that, they are not restricted to explain the 
underlying phenomena only, but also can be extrapolated to simulate other relevant 
scenarios. Guided by this, the proposed model is expanded to explain the enhanced toxin 
removal due to exercise during dialysis. Simulation results suggest that the increased 
toxin removal can only be explained by a decrease in inter-compartmental resistance, the 
major barrier for toxin removal. In order to verify the simulation results, a pilot scale 
clinical study was conducted in the National University Hospital, Singapore. Results 
indicate that exercise can lead to improved toxin removal. It is also found that the 
exercise during dialysis increases the body core temperature and cardiac output resulting 






clinical study which thoroughly investigated the exercise induced physiological changes 
in HD care. 
However, the clinical experiment did not quantify the decrease in inter-compartmental 
resistance, which can provide better understanding of exercise induced physiological 
changes and pave way for personalized prescription of intra-dialytic exercise. The inter-
compartmental resistance cannot be measured, but it can be inferred from one of the 
parameters in the proposed toxin kinetic model. To estimate the model parameters, good 
data should be collected. In this context, model based design of experiments (MBDoE) 
techniques would be effective. However, the existing MBDoE techniques increase the 
correlation among parameters, which may lead to inaccurate estimates. Therefore, they 
are improved by proposing a multi-objective framework. The proposed framework is first 
tested for example case studies and then for the developed toxin kinetic model. This is the 
first study to investigate the optimal sampling for improving the HD model. 
Overall, the thesis combines the in silico approach (of model development and 
improvement via better estimation of model parameters) with the in vivo approach (of 
clinical study to test the model generated hypothesis in HD care), and provides useful 
results and improved techniques for improving the HD care. 
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“The dialysis lets the patient live a close to normal life  
so they can be a grandparent or go to work.” 
- Nora Daludado 
1.1 Engineering and Medicine 
Engineering and medicine have been working synergistically for a long time. An 
engineer’s hand is visible in the ubiquitous stethoscope often seen as the symbol of 
doctor’s profession, prosthetics (artificial limbs), pacemaker, advanced imaging devices 
for diagnosis of diseases, artificial blood purification system, etc. Accordingly, the role of 
engineers in medicine has always been appreciated in invention of new devices, 
equipment, medical peripherals, and ensuring their optimal function, i.e. pre-dominantly 
in the hardware segment of medical care. It will not be a mistake to say that if doctors 
save life, then engineers sustain it (via medical equipment). Lately, with increasing 
collaboration among doctors and engineers, the medical field is being rapidly 
revolutionized, and process system engineers are playing a pivotal role in this revolution. 
Process system engineering (PSE) has changed the way we think about various diseases 
conditions such as tumor growth modeling in cancer diagnosis and treatment, organs and 
tissue level modeling in diabetes care, electrical equivalent of cerebral and cardiovascular 
system, population based modeling of pandemic spread, modeling of circadian rhythm to 
understand the aging process, and HIV modeling, to name a few. Biomedical engineering 
bridging medicine and technology has emerged as a new branch of engineering [1]. 
“Medicine by numbers” is a new buzzword [2]. 
The PSE approach deals with the analysis and design of complex systems, resulting in 





wealth of information, which cannot be assessed by direct human perception. Presently, a 
disease can be modeled on the computer platform and the cause-effect relationship can be 
established for exogenous and endogenous inputs. A disease model allows testing of 
novel interventions before their trial and subsequent deployment in physical world. The 
present thesis employs these strengths of PSE to suggest ways of improving the 
hemodialysis care for kidney patients. This chapter comprises a brief overview of kidney 
and its failure (Section 1.2), available treatment options (Section 1.3), disease statistics 
(Section 1.4), research motivation (Section 1.5), and finally concludes with a description 
of how this thesis is organized (Section 1.6).  
1.2 Kidneys and Kidney Failure 
Human body constitutes several organs working in harmony to ensure healthy living. Of 
these organs, kidneys are a pair of vital organs responsible for homeostatic functions: (i) 
salt and water balance; and (ii) electrolytes and acid-base balance. More importantly, 
kidneys serve as natural filter of blood removing waste products and excess water via 
urine. Kidneys are medically termed as renal, which is derived from Latin renalis means 
kidneys. Although Mother Nature endowed the human body with two kidneys, only one 
of them is sufficient to sustain the necessary physiological functions. This is nature’s way 
of building reliability by design such that an individual can survive on 50% renal capacity 
alone, should one of the kidneys dysfunction. However, if both kidneys malfunction, then 
waste products and fluid starts accumulating and their levels may well go beyond 
physiologically acceptable limits. Increased fluid levels and high concentrations of toxins 
cause myriad of complications, and eventually death. 
Traditionally, kidney failure is classified as acute and chronic. Acute renal failure refers 




failure (CRF) is a slow progressive decline of kidney function over a period of months or 
years. It can occur due to reasons like diabetes, hypertension, glomerulonephritis, 
polycystic kidney disease, family history of kidney disease, kidney stones, urinary tract 
infection, etc. [3]. The advanced stage of CRF is known as stage five CRF or end stage 
renal disease (ESRD), where patient’s daily urine output is negligibly small. At this stage, 
available treatment options are renal transplant or dialysis. Renal transplant is the best 
known treatment option because it has the potential to function as the native kidney, but 
renal graft (i.e. kidney transplant) compatibility is a serious issue and is subject to a high 
probability of rejection. Unavailability of donor graft and patient-donor graft mismatch 
prohibits widespread use of transplant, and the patient has to resort to an artificial blood 
purification system, known as artificial kidney or dialysis. 
1.3 Dialysis 
Dialysis is defined as the diffusion of molecules in solution across a semi-permeable 
membrane along an electrochemical concentration gradient [4]. For ESRD patients, the 
primary functions of dialysis are to remove accumulated toxins and excess fluid. Two 
modes of dialysis known as peritoneal dialysis (PD) and hemodialysis (HD) are 
universally employed renal replacement therapies (RRTs). 
1.3.1 Peritoneal dialysis  
PD uses body’s own peritoneum membrane surrounding the abdomen i.e. blood is 
cleaned inside the body. Fluid exchange and toxin removal occurs between the capillary 
blood and dialysate solution in peritoneal cavity. Dialysate is usually concentrated 
glucose solution with desired concentration of solutes such as sodium, potassium, 
calcium, magnesium, chloride, and bicarbonate. High concentration of glucose in 





cavity, and solutes are transferred due to concentration gradient i.e. by diffusion [3]. A 
catheter is surgically placed inside the peritoneal cavity through the abdominal wall. 
Dialysate enters the abdominal cavity through the catheter, where it remains in contact 
with peritoneum membrane for 24 hours except for the short periods of time when 
dialysate exchange is performed. Schematic of PD is shown in Figure 1.1A.  
1.3.2 Hemodialysis 
Hemodialysis (‘hemo’ means blood) is an RRT where blood is taken out from the 
patient’s body at a constant rate and purified in a dialyzer (Figure 1.1B). Dialyzer is a 
hollow fiber membrane module through which blood and dialysate flow in the counter-
current direction to maximize the toxin mass transfer. In ESRD patients, both small- and 
large-sized toxins co-exist. The blood is taken out from the patient’s body at constant rate 
and passed through the hollow fibers in the dialyzer while dialysate flows in the shell 
side. The clean blood is then returned to the patient’s body and the cycle continues. The 
dialysate composition in HD differs from that in PD. In HD, dialysate is essentially 
ultrapure water with solutes: sodium, potassium, bicarbonate, magnesium, chloride, 
calcium, and glucose [5]. Dialysate composition can be altered based on patient’s disease 
condition; for example, in HD patients with diabetes, dialysate with less glucose is 
prescribed. Standard HD prescription is for 4 hours × 3 times per week, and generally 
performed at dialysis centers. A patient either follows Monday, Wednesday, Friday or 
Tuesday, Thursday, Saturday dialysis schedule. Before a patient can be initiated on HD, 
an artificial blood access is created. This allows repeated puncturing and sufficiently high 
blood flow for dialysis. The access is a surgically created connection of artery and vein in 





Figure 1.1 Schematics of (A) peritoneal dialysis [6] and (B) hemodialysis [7]   
Based on the toxin exchange mechanism across dialyzer membrane, HD is classified into 
three sub-categories, namely, conventional hemodialysis (CHD), hemofiltration (HF), and 
hemodiafiltration (HDF). HD is an umbrella term for all extracorporeal RRTs, where 
extracorporeal means that the procedure is performed outside body. 
1) Conventional hemodialysis is primarily based on diffusion of toxins across dialyzer 
membrane. Diffusion is more efficient for small-sized toxins, and CHD is therefore 
inefficient for removal of large-sized toxins. 
2) Hemofiltration is the convection based RRT where large amount of fluid is 
removed from blood stream along the dialyzer length. To compensate for the 
removed fluid volume, the output stream is replenished by ultrapure replacement 
fluid. The excessive fluid movement from blood to dialysate drags large-sized 
molecules; however, diffusion-based toxin removal is inhibited. There is no 
dialysate stream in HF. 
3) Hemodiafiltration combines both diffusion and convection in a single system, and 
removes both large-sized toxins (via convection) and small-sized toxins (via 







Figure 1.2: Block representation of Hemodialysis, Hemofiltration, and Hemodiafiltration 
PD has a distinct advantage over HD, as the former is a continuous process where patient 
need not come to the dialysis center regularly, but only has to exchange the dialysate 
several times a day. It has been found that PD may be advantageous initially but is 
associated with poor patient outcomes after 12 months from the start of PD [8]. The 
foremost reason is the high possibility of PD site infection, especially during dialysate 
exchange. Also, the long term use of dialysate in peritoneum cavity reduces the functional 
efficiency of peritoneal membrane [9]. Long-term outcomes for PD patients are not 
desirable, and are worse than HD patients [10]. According to the recent USRDS (United 
States Renal Data System) report, the December 2010 prevalent population included 
383,992 patients on HD and 29,733 on PD [11]. According to Fresenius Medical Care 
(FMC), leading provider of dialysis products and medical care for patients with chronic 
kidney disease (CKD), only 8% ESRD patients were on PD in 2012 [12]. HD allows 
patients to be fully rehabilitated and to have a satisfactory nutritional intake. Owing to 
these reasons, the focus of this thesis is on HD. 
1.4 Statistics 
According to FMC, the number of patients being treated for ESRD globally was 

















































150 out of 230 countries where FMC has market share, and so more ESRD patients can 
be expected. With a ~7% growth rate, the ESRD patients continue to increase at a 
significantly higher rate than the 1.1% growth rate of world population [12]. According to 
recent USRDS report, a total of 116,946 new patients began ESRD therapy in 2010, of 
which 97.5% patients were initiated on dialysis. 
Despite the advantages of HD over PD, mortality and morbidity rates of HD patients are 
still high. Mortality can be defined as the condition of being subjected to death due to 
disease or treatment condition, while morbidity is anything that is exceptional or 
abnormal, and usually occurs as a result of treatment side-effects, when prescribed 
treatment is inappropriate or inadequate. Mortality among dialysis remains 10 times 
greater than the patients of similar age without kidney diseases. Despite decades of HD 
practice and innovations, only 1 out of 2 dialysis patients is still alive 3 years after start of 
dialysis therapy. The annual mortality rate exceeds 20% in chronic HD patients. All-cause 
mortality adjusted for age, gender, race, and co-morbidity is 6.3–8.2 times greater for 
dialysis patients than for individuals in the general population [11]. Notably, mortality 
among dialysis patients is significantly higher than the patients in the general population 
who have diabetes, cancer, congestive heart failure, stroke, or acute myocardial infarction 
(Figure 1.3). 
 





Certainly, the dialysis population is at relatively high risk of death, and plausible reason 
for this is the high prevalence of co-morbid factors such as diabetes and hypertension 
[13]. With the current dialysis regimen, patients with ESRD exhibit the retention of large 
variety of uremic toxins [14]. Accumulated toxins result in a wide range of undesired 
biological functions, such as chronic inflammatory state, mineral metabolism disorders, 
etc. which contribute towards cardiovascular disease [15]. Though cardiovascular 
mortality is the single largest cause of mortality in general population, the cardiac 
mortality of dialysis patients aged 45 years or younger is 100-folds greater than that in the 
general population [16]. Other important co-morbid factors are anemia (reduced 
hemoglobin levels or red blood cell concentration), dyslipidemia (very high lipid levels), 
inadequate nutrition, abnormalities in bones, etc. Complications during dialysis such as 
cramps, giddiness, nausea, etc. also add to the mortality and morbidity numbers. These 
intra-dialytic episodes are commonly described as incidence of intra-dialytic hypotension 
(IDH), and occur in as much as 30-35% of HD patients [4]. 
Though dialysis patients are small in number compared to the patients on modern age 
epidemics such as diabetes, cancer, or hypertension, the cost involved for dialysis care is 
enormous. In US, the total expenditure for ESRD patients alone was $47.5 billion in the 
year 2010, where $33 billion came from Medicare. This ESRD expenditure combines 
transplant, HD, and PD. But, as mentioned earlier, HD is the most prevalent renal 
replacement therapy for ESRD patients; thus the major contribution to expenditure is by 
HD alone (Figure 1.4). The total expenditure per HD patient per month is $7,300. This 
number corresponds to Medicare payment alone [11]. Additional expenditure by non-






Figure 1.4: Yearly total Medicare expenditure in US by modality [11]. 
1.5 Motivation and Objectives 
Following the opening quote of this chapter, the focal point of this research is to move the 
performance of HD from close to normal life to closer to normal life. Improving the 
performance of any process can have numerous facets. In the context of improving HD 
care, numerous aspects such as control of inter-dialysis fluid retention, optimal fluid 
removal during dialysis, prevention of IDH episodes, maintaining optimal hemoglobin 
level, sodium control, precise electrolyte balance etc. can be considered; however, 
increasing the toxin removal can possibly have the greatest impact [17]. Current HD 
process is far from decreasing the toxin concentration as found in healthy subjects of age-
matched group, and the ultimate goal is to achieve similar toxin removal as achieved by 
24 × 7 functioning of healthy kidney. It is impossible to completely replace the native 
healthy kidney function with artificial kidney i.e. HD, but improving the efficiency of HD 
process can significantly decrease the existing co-morbidities and bring down the 
mortality. Thus, increasing toxin removal is the central theme of the current clinical 
research. 
A number of clinicians and researchers have advocated increasing the frequency or 





toxin removal. These modalities include short daily HD and long nocturnal HD, referred 
as intensive HD [18]. Nevertheless, these modalities are (i) logistically expensive, (ii) 
inconvenient to patients, and (iii) have not been tested in randomized controlled clinical 
trials for studying the hard outcomes like decrease in mortality or hospitalization rate. 
Hence, interventions which can work during routine dialysis settings are necessary. HDF 
is proclaimed as one such solution for enhancing the toxin removal [19]. HDF’s long-
term toxin removal outcomes are comparable to CHD [20] and the process is costlier than 
CHD. Hence, the immediate question is how to improve toxin removal without disturbing 
the existing dialysis operation mode and without incurring additional cost. 
Identifying the major resistances to toxin removal and ways to overcome them can pave 
way for enhanced toxin removal. This demands a very good understanding of patient-
dialysis system. PSE tools and techniques have potential to guide research efforts in this 
direction. These can be loosely categorized into four areas, namely experimentation, 
modeling, control, and optimization. Understanding a system and representing that 
understanding into the form of a mathematical model is an important step to solve a 
problem. Model simulations can provide new insights and hypotheses which need to be 
tested in real setting, or a model can be refined further so that better prediction of system 
behavior can be obtained. This refinement requires new experiments and collection of 
data. This thesis work primarily addresses in silico modeling and the in vivo testing of 
hypotheses in clinical setting, and further improvement of models using intelligent 
experimental designs. The important objectives of thesis are highlighted below. 
• Mathematical modeling (Chapter 3): The PSE approach to understand the patient-
dialysis system starts with modeling. Hence, the first focus is on modeling the 








 (Chapter 3): The model should not be limited to explain the 
underlying phenomenon only. A model can be used to simulate the system 
behavior under certain conditions before observing the system response in real 
settings. In this direction, the developed HD model will be employed to study the 
toxin removal due to exercise during dialysis. Exercise during dialysis is known to 
improve toxin removal. How exercise augments the toxin removal will be 
explored in greater detail, and new inferences and hypotheses will be elucidated. 
Clinical trial design
• 
 (Chapter 4): Testing the model-generated hypothesis in real-
time settings completes the loop of any investigation. Hence, to test/substantiate 
the hypotheses, a prospective clinical trial is necessary. In this clinical research, 
the effect of exercise on physiological changes will be explored. Also, the toxin 
removal aspects for HD, HDF, and HD with exercise will be explored. 
Model-based design of experiments
1.6 Thesis Organization 
 (Chapters 5 and 6): Developing a model is the 
first step to understand the system. To further improve the model, more 
experiments are required. Experimenters often ensure data quantity, but overlook 
the data quality aspects. Experiments should be designed beforehand because 
fixing the data quality later is more expensive. In this context, concepts of model-
based design of experiments (MBDOE) will be explored. 
The thesis is divided into two parts. In Part 1, the modeling aspects in hemodialysis, 
originated hypotheses, clinical trial design, and clinical testing of hypotheses are 
presented. The aspects related to experimental design are detailed in Part 2 of the thesis. 





kinetic modeling (TKM) and emphasizes the utility of TKM in HD literature. Also, the 
challenges that can be addressed by PSE methodologies are highlighted. In Chapter 3, a 
comprehensive diffusion-adjusted regional blood flow model for toxin β2-microglobulin 
(β2M) is proposed (β2M is one of the many toxins present in excess in dialysis patients). 
The developed model is also validated with clinical data. The model is further employed 
to explain the effect of exercise during dialysis, and new hypotheses are proposed. To test 
the proposed hypotheses, a prospective clinical trial is designed. The clinical trial not only 
aims to study physiological changes associated with exercise during CHD, but also 
intends to compare the toxin removal outcomes with the most efficient and clinically 
employed renal replacement therapy, HDF. The clinical trial design aspects and obtained 
results are presented in Chapter 4.  
In Part 2, MBDOE aspects are explored. It is observed that traditional alphabetical design 
techniques suffer from increased correlation among parameters, which can be detrimental 
to parameter estimation and their precision. To overcome these drawbacks, a novel multi-
objective optimization (MOO) based design of experiments framework is proposed and 
first tested on two example case studies. The MBDOE description, existing drawbacks, 
proposed solution, and results from two example case studies are presented in Chapter 5. 
In Chapter 6, the proposed MOO based DOE framework is applied to the developed toxin 
kinetic model (presented in Chapter 3) and important insights are developed. Finally, 
Chapter 7 summarizes important conclusions of the thesis and provides recommendations 









Part 1  















2. Literature Review: Toxin Kinetic Modeling 
“Literature always anticipates life.  
It does not copy it, but moulds it to its purpose.” 
- Oscar Wilde 
As Sir Isaac Newton prophesied “To explain all nature is too difficult a task for any one 
man or even for any one age”, the review in this chapter does not intend to provide the 
complete picture of toxins and their kinetics, rather it highlights the importance of TKM 
in HD research; consequently, existing nephrology literature is molded accordingly. After 
an introduction to toxin environment, classification, pathology of various toxins (Section 
2.1), choice of marker toxin(s) (Section 2.2), TKM paradigm in HD, and concept of 
dialysis adequacy (Section 2.3), existing modeling studies for a number of toxins are 
presented (Section 2.4).  
2.1 Toxins 
Dialysis patients are often loaded with a number of uremic toxins, which have known 
biological effects leading to malfunction of cells or organ systems. When these biological 
effects are clinically visible, the patient is said to be in the state of uremia meaning urine 
in the blood [21]. A solute is characterized as uremic toxin based on the following 
criteria, commonly known as Massry/Koch postulates [22]. 
1. Toxin must be identified and characterized as a unique chemical entity. 
2. Quantitative analysis of the toxin in bodily fluids must be possible. 
3. The level of the presumed toxin must be elevated in bodily fluids of subjects with 
uremia. 
4. The level of presumed toxin in bodily fluids should correlate with one of the 





5. Decreasing the levels of presumed toxin in the bodily fluids must improve the 
associated symptoms. 
6. Adding the presumed toxin to achieve levels similar to those in uremia should 
reproduce the associated symptoms. 
Based on the above criteria, more than 115 uremic toxins have been identified which 
correlate with pathological dysfunction [23, 24]. It is good to identify and characterize all 
the uremic toxins so that non-dialytic ways of toxin removal can be discovered or ways to 
curb their generation can be identified. However, unlike kidneys, dialysis is a non-
selective way of toxin removal and primarily depends on size of concerned toxin. Hence, 
all the identified toxins are classified in 4 major classes. These four classes are based on 
physiochemical characteristics namely, molecular mass, protein binding, and polarity 
[25]. 
1. Small-sized toxins (polar, water soluble, non-protein bound, molecular weight < 
500 Da) 
2. Small-sized protein-bound solutes (polar, water soluble, molecular weight < 500 
Da) 
3. Middle-sized toxins (non-protein bound, molecular weight between 500 – 12000 
Da) 
4. Large-sized toxins (molecular weight > 12000 Da) 
The two classes of middle-sized and large-sized toxins are often combined into a single 
class referred as middle-large-sized toxins. In uremia, molecular weight of toxin can 
range from 60 Da (Urea) to 32,000 Da (Interleukin-1β), and serum concentrations order 
can range from g/L for urea to ng/L for methionine enkephalin [24]. However, high 
concentration does not imply equally large biologic toxicity e.g. urea is a time-honored 





Johnson et al. proved it by adding urea in dialysate stream thus inhibiting urea removal, 
and it did not impact the clinical status of ESRD patients [26]. Protein bound solutes are 
difficult to remove due to increased combined size of toxin-protein. These solutes also 
alter the protein binding characteristics such as reduced drug-binding capacity owing to 
unavailability of protein molecules for binding with drug molecules. 
2.2 Uremic Toxicity and Marker Toxin(s) 
Retention of myriad uremic toxins that under normal conditions are excreted by healthy 
kidney exerts toxicity. The condition is also referred as uremic syndrome, which is a 
complex mixture of organ dysfunction [27]. It is impractical to recount the biological 
effect of all known uremic toxins; hence, some of the extensively studied uremic toxins 
with their toxicity are presented below. 
Among the non-protein bound small-sized toxins such as urea, guanidino compounds 
(GCs), reactive carbonyl compounds, polyamines have shown to induce deleterious effect 
on organ systems. Increased levels of urea alone may not induce clinically significant 
symptoms, but its increased levels does denote the increased levels of other uremic toxins 
[26]. The GCs comprise guanidinosuccinic acid, creatine, guanidinovaleric acid, 
guanidinoacetic acid, creatinine, arginine, methylguanidine, asymmetric dimethylarginine 
(ADMA) etc. These compounds are found in high concentration in cerebrospinal fluid as 
well as in serum [28, 29], and proposed as candidate neurotoxins. Reactive carbonyl 
compounds, derived from metabolism of carbohydrates and polyunsaturated fatty acids 
can exert their toxicity directly or indirectly i.e. via increased formation of advanced 
glycation end-products (AGEs) or advanced lipoxidation end-products (ALEs). Both 
AGE and ALE group of toxins are associated with poor cardiovascular outcomes. 





abnormally low body core temperature, vomiting, immune deficiency, etc. [30]. It is 
impractical to measure all the toxins in routine dialysis, and urea is considered as 
representative of small-sized non-protein bound toxins. 
The second class of uremic toxins with protein-binding characteristics behaves like large-
sized uremic toxins. Removal of such toxins with CHD remain abysmally low, because 
only the small fraction of the solute is available for diffusion [31]. Important toxins in this 
category, namely, p-cresol, indoxyl sulphate, and AGEs, have been studied extensively 
[32]. p-cresol, a representative from this group of molecules, has been shown to associate 
with uremic immunodeficiency and endothelial (interior of blood vessels) dysfunction, 
conceivably linking its serum levels to mortality [33]. Indoxyl sulphate is associated with 
vascular calcification (calcium deposition), vascular stiffness, progression of glomerular 
sclerosis (tissue hardening), and mortality in CKD patients [34]. AGEs are believed to 
contribute towards inflammatory response in dialysis patients. They also play a role in 
atherosclerosis (thickening of arterial wall) and worsening of renal failure [35]. 
Homocysteine is another protein bound toxins and is associated with increased risk of 
cardiovascular disease in CRF patients [36], and may also relate with irregular 
intracellular metabolism [27]. Briefly, protein bound uremic solutes contribute to a 
number of functional disturbances in uremia, but at present, no effective extracorporeal 
renal replacement therapy is available for removal of such toxins. 
The last category of uremic toxins i.e. middle/large-sized toxins has increasingly been 
recognized to contribute towards uremic syndrome. Some of the toxins in this class are 
β2M, leptins, proinflammatory cytokines, etc. [14, 24], of which, β2M is recognized as a 
marker [37, 38]. In ESRD patients, β2M levels can increase up to 60 folds or more. 
Increased levels of β2M have been associated with amyloid deposits leading to bone 





speculated to mediate anorexia (poor appetite) and muscle wasting [39]. Large-sized 
toxins are also associated with cardiovascular damage [40]. 
There is yet another small and water soluble toxin – phosphate, whose removal 
characteristics are completely different from any other toxin mentioned above. High 
phosphate levels are associated with pruritus (itching) and hyperparathyroidism (excess of 
parathyroid hormone), which is related to osteodystrophy (dystrophic or imperfect bone 
development), cardiovascular disease including calcification. Phosphate is also engaged 
in intestinal dysfunction. ESRD patients are often in the state of hyperphosphatemia, and 
are advised to restrict their phosphate intake. 
In summary, uremic syndrome is a multifaceted state due to retention of numerous toxins. 
These toxins result in chronic inflammatory state, oxidative stress, endothelial 
dysfunction, vascular stiffness or calcification, oxidative stress responsible for 
cardiovascular disease, etc. Some of the protein bound uremic toxins modify proteins, act 
on receptors, and (de)activate cell signaling pathways. Uremic toxins and associated 
toxicity have received unique attention among dialysis research community, which is 
evident from the number of scholarly contributions. A monograph devoted to uremic 
toxins and toxicity was published in scientific journal Seminars in Dialysis in 2002 [21]. 
A recent book Uremic Toxins from Wiley & Sons [25] further expounds about uremic 
toxins, their toxicity, and known biological pathways through which these toxins damage 
the organ system. To increase the toxin removal via artificial kidney i.e. via HD requires 
an understanding of toxin build up and their subsequent removal, information about major 





2.3 Toxin Kinetic Modeling 
It is now understood that dialysis is associated with a number of co-morbid factors and 
uremia is purportedly the major contributor for poor outcomes in patients [17]. It is also 
understood that conventional dialysis is always inadequate when compared with the 
native kidney function. Hence, increasing the toxin removal is the mainstay of present 
dialysis research. Before we aim for increasing the toxin removal, it is important to 
understand the toxin removal characteristics, known as TKM in HD literature. 
Kinetics is the study of motion and its cause. In the context of TKM, it refers to 
movement of toxins from patient to the dialysate. From the chemical engineering point of 
view, reaction kinetics is the study of rate of chemical reactions whereby substrate 
depletion or product formation occurs at certain rate. In dialysis, there is no chemical 
reaction involved but toxins are removed through dialyzer and their concentration in 
patients depletes with time. Hence, toxin kinetics during dialysis describes the rate of 
change of toxin mass. The driving force governing the toxin removal is concentration 
gradient between blood and dialysate stream, with dialyzer membrane offering resistance. 
In order to mathematically represent the toxin removal process, a control volume is 
considered first. Control volume, also referred as compartment or pool in TKM literature, 
is a region where the physical entity of interest (here toxin concentration) assumes the 
same value over the entire compartment [2]. The control volume assumption can be 
extrapolated to each organ and tissue level, but, in the context of TKM, limited number of 
compartments is sufficient to describe underlying toxin removal kinetics. Based on the 
control volume assumption and body fluid distribution, existing TKM paradigms are 





It is impossible to study each and every toxin in uremia; hence, generally marker toxins 
are studied, and it is assumed that the removal kinetics of other toxins will follow suit. 
Urea is a traditional choice of marker. It is not due to pathophysiological reasons, but due 
to the fact that several decades ago when concept of uremic toxicity was developed, not 
many uremic toxins were known and urea was found in significantly higher concentration 
in ESRD patients. Also, the cost of analysis for urea is relatively low when compared to 
that of other uremic toxins [25]. 
2.3.1 Single-pool Model 
In human body, approximately 60% of body weight is due to fluid where urea is 
distributed; e.g. in a 70 kg male, the fluid volume will be ~42 L. In the single-pool 
modeling assumption, the whole bodily fluid is assumed as single pool (Figure 2.1A). 
Blood is taken out at constant rate from patient’s body and flows through the dialyzer, 
where dialysate flows in counter-current direction. Gotch and co-workers started with 
concept of constant volume urea kinetic modeling (UKM), illustrated in Figure 2.1B [41]. 
However, during dialysis, excess fluid is also removed or body fluid volume continuously 
decreases. Typical fluid removal can range from 2.5–3.5L, which depends on the inter-
dialytic fluid gain, obtained from the difference between pre-dialysis weight and post-
dialysis weight at the end of previous HD session. To account for intra- and inter-dialytic 
fluid gains, constant volume UKM was further modified to variable volume UKM [42], 






Figure 2.1: (A) Patient (single-pool model) attached to hemodialyzer; (B) Constant volume 
single-pool model; and (C) Variable volume single-pool model. Vd and Cs are urea 
distribution volume and urea concentration in body, respectively. G is urea generation rate; 
KD is dialyzer urea clearance; Kr is residual renal clearance; α is fluid intake; and Quf is 
ultrafiltration rate. 
Variable volume single-pool UKM resulted in more realistic values of urea distribution 
volume (Vd). The rate of change of urea mass is equal to urea generation rate (G) minus 
removal rate via dialyzer and residual renal clearance (= (KD + Kr) Cs, where Cs is the 
toxin concentration). In variable volume single-pool model, distribution volume decreases 
continuously at constant ultrafiltration rate (Quf). The relevant equations are provided 
below.  
Constant volume single-pool model: 
 sd D r s
d ( )
dt
CV G K K C= − +    (2.1) 
Variable volume single-pool model:  
 d s D r s
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In equation 2.1, one can safely assume that toxin generation during dialysis period will be 
much smaller when compared to the removal. Also, the Kr is negligibly small in dialysis 
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= − ⇒ =  (2.4) 
where C0 and Cend are pre-dialysis and post-dialysis serum urea concentration, 't' is the 
dialysis duration, Vd is urea distribution volume and requires prior estimation. In equation 
2.4, increasing KD and/or 't' will result in smaller post-dialysis serum urea concentration. 
Based on this, the time on dialysis required to control the blood urea nitrogen (BUN) at 
desired levels was calculated [43]. 
Importance of UKM: Urea and other nitrogenous compounds are products of protein 
catabolism, thus knowledge of protein catabolism rate (PCR) can help dietitians to 
prescribe nutrition intake. Inadequate protein intake may lead to malnutrition, while 
excessive protein intake may be associated with high inorganic phosphate intake; so, 
optimal protein intake is important for dialysis patients. Gotch and co-workers [41] 
observed a wide range of pre-dialysis BUN levels in patients despite the same dialysis 
dose, which suggested that their dietary protein intake must vary widely. Since other toxic 
protein catabolites, such as H+ and inorganic phosphate were expected to correlate with 
urea generation [44], UKM was found to be a suitable method to measure the normalized 
PCR (nPCR, g/kg/day) in individual patients. As nPCR can assist in deciding protein 
intake, UKM also helped in assessing compliance with dietary protein prescription.  
Dialysis adequacy D ureat / VK: Increasing the  will result in lower end-dialysis 





formula, increasing the dialyzer clearance ( DK ) and/or dialysis duration (t) will culminate 
in increased toxin removal. ureaV  is urea distribution volume and needs prior estimation 
using patient data. It was observed that D ureat / VK  correlates with nPCR [45]. Thus, 
dialysis dose was quantified using D ureat / VK , which is a dimensionless parameter and 
describes the prescribed fractional clearance of body water. Though dialysis adequacy 
refers to urea, it was assumed that urea clearance will provide the proportional fractional 
clearance of other low molecular weight uremic toxins. This was the first step in 
quantifying the dose of dialysis, and used in clinical setting till date. Nevertheless, a 
number of researchers have proven the inadequacy of D ureat / VK ; this aspect is discussed 
in Section 2.4. 
2.3.2 Two-pool Model 
The single-pool assumption is too simple to describe the post-dialytic as well as intra-
dialytic characteristics of toxin concentration. Urea concentration or concentration of any 
toxin for that matter increases sharply immediately after dialysis. During dialysis also, the 
observed decline in urea concentration is much steeper than that predicted by the single-
pool model. This led to a theory that urea is distributed in intracellular (IC) and 
extracellular compartments (EC), with inter-compartmental membrane offering resistance 
to toxin transfer, and eventually resulted in the two-pool UKM [42], comprising two 






Figure 2.2: Two-pool model representation of physiology. Intracellular fluid volume is 
greater than extracellular fluid. Toxin generation is assumed to occur in intracellular 
compartment. 
During dialysis, only blood from EC comes in contact with dialyzer. Due to high dialyzer 
clearance, fluid and mass transfer between blood and dialyzer is rapid i.e. concentration in 
EC drops significantly faster than that of IC. When dialysis ends, toxin transfer from IC 
to EC, results in sharp increase in toxin concentration. This phenomenon is characterized 
as rebound, and any good TKM must reflect this physiological behavior. 
The model equations for two-pool model during dialysis are described below. 
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V Q= −  (2.8) 
where V and C are toxin distribution volume and toxin concentrations in the 
compartments, respectively. Subscript ‘i’ and ‘e’ represent IC and EC respectively; Kie is 

















constant ultrafiltration rate. Physiologically, the typical fluid distribution is such that 
approximately 66% of body fluid resides in IC and remaining 33% in EC. Following the 
early example of a 70 kg male, out of 42 L of fluid, 28 L will be in IC and the rest 14 L in 
EC. During dialysis, fluid is removed from both compartments, and cellular membrane 
presumably offers no resistance to fluid movement. The inter-compartmental fluid 
exchange occurs through water channels known as aquaporins, present on the cell wall. 
In the model equations 2.5–2.8, it is assumed that fluid removal from IC and EC occurs in 
proportion of their physiological fluid volume. Similar assumption is valid for fluid 
ingested during inter-dialytic period. The toxin mass balance for EC (equation 2.5) 
comprises inter-compartmental diffusive mass exchange, dialyzer and residual renal 
clearance, convective removal with ultrafiltered fluid, and convective mass transfer from 
IC to EC. The toxin generation is assumed to be intracellular because majority of toxins 
are byproducts of cellular metabolism. 
The model simulation for single-pool clearly shows its inability to capture the rebound 
phenomenon (Figure 2.3). Unlike the single-pool model simulation, the two-pool model 
predicts that the toxin concentration sharply decreases during the initial phase of dialysis, 






Figure 2.3: Urea kinetics modeling by single- and two-pool models. Sharp post-dialytic 
increase of urea concentration disproves the single-pool hypothesis for UKM 
The rebound for small-sized toxins lasts from 40 min to 1 hour, after which the toxin 
concentration equilibrates. For middle-sized toxins, the diffusive flux is much smaller 
because diffusion is inversely proportional to molecular size. Hence, the rebound for 
middle-sized toxins can be more pronounced than that of small-sized toxins, and persists 
for a longer period. Single-pool model does not consider this physiological behavior and 
over-estimates the delivered dose. On the other hand, the two-pool model enables 
calculation of the correct dialysis dose defined as D ureae t / VK  or equilibrated Kt/V. The 
presence of rebound discounts the actual delivered dose of dialysis. The two-pool model 
has two model parameters, Kie and Vd whose estimation is necessary before it can be used 
for calculation of dialysis adequacy. The parameter estimation aspects will be discussed 
later in Part 2 of the thesis. 
2.3.3 Multi-compartment Model 
The preceding model segregates physiology into two-pools, and explains the toxin 





capillary endothelium, resulting in three-compartmental representation of physiology 
(Figure 2.4). The interstitial compartment comprises ~75% of extracellular fluid volume 
and remaining 25% belongs to blood plasma. Using the earlier example of a 70 kg male 
with 42 L of total fluid volume, the blood plasma will constitute ~3.5 L from 14 L of EC 
fluid volume. Typical blood volume in humans is 5 L, which also includes the 
contribution from red blood cells, white blood cells, and platelets. 
 
Figure 2.4: Multi-compartmental representation of physiology. C and V denote 
concentration and toxin distribution volume. The suffix ‘i’ denotes intracellular 
compartment, ‘ei’ denote interstitial-extracellular and ‘ep’ is plasma-extracellular 
compartment. 
Writing the model equations based on these assumptions will result in additional mass 
transfer coefficient between interstitium and plasma compartments. The capillary 
endothelium might offer additional resistance to large-sized toxins, but it has been 
observed that transcapillary mass transfer coefficient for urea (60 Da), creatinine (113 
Da), and vitamin B-12 (1355 Da) are at least 10 folds larger than the transcellular mass 
transfer coefficient [46]. This suggests that transcellular resistance will be the major 
impediment for toxin removal. Also, estimating transcapillary mass transfer coefficient 
will require additional concentration measurement either from IC or interstitial, and both 
















not segregate EC into plasma and interstitial compartments. For experimental purposes, it 
is possible to measure intra-cellular concentration but the process is difficult to replicate 
in routine clinical settings. The additional benefit of multi-compartment model is that it 
can predict concentration changes in the inaccessible body compartments, which may be 
relevant to understanding side effects. 
2.3.4 Regional Blood Flow Model 
Earlier model representations consider the body as a series of compartments, and lacks 
sound physiological basis, e.g. administration of D2O or T2O bolus to the blood stream 
requires more than an hour to equilibrate in blood compartment [47]. This phenomenon 
cannot be explained by the two-pool representation of physiology. The delayed 
equilibration is explained by heterogeneous distribution of blood to the tissues. As shown 
in Figure 2.5, very small organs like kidneys, heart, brain etc. receive a major portion of 
blood flow. Based on this premise, the regional blood flow (RBF) model assumes that 
removal of toxins is flow limited rather than the diffusion limited. Small-sized organs like 
kidneys, heart, brain, and lungs in the body receives larger fraction of cardiac output 
(CO), while the large-sized organs receive only a small fraction of total CO. The former 
category of organs is designated as high flow region (HFR), while the latter as low flow 
region (LFR). The HFR constitutes only 20% of fluid volume, but receives almost 85% of 
total CO. On the other hand, LFR comprises 80% of fluid volume but receives only 15% 
of CO. This heterogeneous distribution of CO results in high clearance of HFR, and less 
or delayed clearance of LFR. This model representation was first proposed by Schneditz 






Figure 2.5: Blood flow/tissue water volume and water content of different organs under 
baseline condition [48] 
At the start of dialysis, toxins are equilibrated thorough out the body, i.e. toxin 
concentration is the same; hence, the LFR contains significantly more amounts of toxins 
than HFR, owing to the larger fluid volume of the former. Owing to heterogeneous 
distribution of CO, HFR is thoroughly cleared, and LFR is insufficiently cleared of 
toxins. After dialysis, the toxin starts equilibrating between regions, and thus explains the 
post-dialytic rebound. Such conceptualization lays the foundation for RBF representation 
of physiology. Unlike the two-compartment model where compartments are arranged in 
series, the RBF representation is referred as parallel flow model [49, 50]. The RBF 
representation of physiology is presented in Figure 2.6. The RBF model equations are 
illustrated below.  
 H L 1k k+ =  (2.9) 
 HFR H art H art r H uf H HFR
d( ) ( )
dt
VC Q C C C K k Q C G= − − − +  (2.10) 
 LFR L art L art r L uf L LFR
d( ) ( )
dt






Figure 2.6: Regional blood flow representation of physiology. The flow line thickness is 
approximately proportional to the amount of cardiac output received. QH and QL represent 
the amount of blood flow received by HFR and LFR, respectively; QB is the blood flow to 
dialyzer; Quf is ultrafiltration rate; CO is cardiac output; kH and kL are fluid fraction of 
HFR and LFR, respectively.  
Though this model is physiologically superior to the preceding two-pool model, it could 
not explain the kinetics of other smaller sized uremic toxins such as creatinine. This 
means that there is a need for further modification of RBF model – Chapter 3 will 
consider this problem in detail. Schneditz et al. [51] divided each region of RBF model 
into two-pool model, thus diffusion as well as flow was accounted in the new model, and 
the model was named as diffusion-adjusted RBF model. This model is complex due to the 
more number of unknown model parameters. This issue will also receive attention in 
Chapter 3. 
2.4 Kinetics of other toxins 
Urea based dialysis adequacy is the established marker of dialysis prescription. 
Insufficient removal of urea has been found to relate with morbidity and mortality [52]. 
However, it has been reported in the literature that increasing the dialysis dose defined by 
















adding urea in dialysate did not cause clinically significant complication [26]. Numerous 
studies pointed out that urea removal does not extrapolate to other middle-sized uremic 
toxins. Moreover, other small-sized uremic toxins behave differently than urea. Hence, 
researchers started focusing on toxins other than urea, with the postulate that urea kinetics 
is not representative for kinetics of most other uremic toxins. Kinetic study of other 
uremic toxins can provide better understanding on evolution of pathophyiologcally 
important solutes. Some of the toxin kinetics studies are briefly discussed below. 
2.4.1 Phosphate Kinetics 
ESRD patients are often overloaded with phosphate, a condition known as 
hyperphosphatemia, which results in secondary hyperparathyroidism and ultimately to 
osteodystrophy. An easy maneuver for low serum phosphate is to control phosphate via 
dietary intake, but this may lead to protein-calorie malnutrition. Serum phosphate levels 
decline significantly during dialysis, but post-dialytic rebound is also more pronounced. 
Sometimes, during dialysis itself, the phosphate level starts rising after a steep decline. 
This complicates the phosphate kinetics, and early phosphate kinetics model could not 
explain such behavior [54, 55]. The best model to-date explaining the phosphate kinetics 
was proposed by Spalding et al. [56]. Their model comprises four pools of phosphate; 
two of them are conventional EC and IC (Figure 2.7). In addition, it was hypothesized 
that dialysis patients are likely to have pathologic stores of phosphate in bones, from 
where phosphate can potentially efflux. This was designated as the third pool, comprising 
phosphate not yet incorporated into the bone matrix. When phosphate concentrations are 
critically low, the fourth pool of phosphate inside IC can activate. This fourth pool 
containing glycophosphates in the IC could be involved in a short-term regulatory 






Figure 2.7: Phosphate kinetics model comprising four pools [56]. 
Phosphate removal by dialysis is abysmally low due to its complex kinetic behavior. 
Clinically, phosphate removal is often achieved by non-dialytic means such as phosphate 
binders, which binds with intestinal phosphate and prevents its intestinal absorption [57]. 
Patients are advised to take phosphate binders just before the meal. These binders are 
generally calcium, aluminum, or lanthanum based salts. They bind with phosphate present 
in ingested food and prevent its absorption into blood stream. 
2.4.2 Sodium Kinetics and Profiling 
Sodium is an important electrolyte which is responsible for homeostatic balance. The 
ideal sodium concentration in the serum is 140 mEq/L, a condition known as 
normonatremia. However, dialysis patients are often overloaded with sodium 
(hypernatremia). Excess sodium cascades on to increased thirst, fluid overload, 
hypertension, and cardiovascular mortality or deterioration of residual kidney function. 
Although sodium is the main constituent in EC, clinicians have referred it as a toxin due 
to its pathophysiological contribution [58, 59]. Sodium levels in dialysis patients can 






















dialysate composition of 138 mEq/L. Slight decrease in serum sodium concentration 
below normonatremia can lead to condition known as hyponatremia, which immediately 
manifests in the form of cramps, giddiness, or similar intra-dialytic symptom, commonly 
known as intra-dialytic hypotensive (IDH) episodes. Incidence of IDH is observed in 30-
35% of dialysis sessions, and is suggested to play a major role in cardiovascular mortality 
[60]. 
Increasing the sodium concentration in dialysate will result in less sodium removal and 
thus prevents the incidence of IDH. The downside of increased dialysate sodium is that it 
will result in increased thirst and eventually hypertension. Clinicians have thus 
investigated the ramping of dialysate sodium. In ramping, clinicians start with high 
sodium concentration and decrease it in piecewise constant steps or linearly until the end 
of dialysis session. Ramping of dialysate sodium is commonly known as sodium 
profiling; however, such intervention did not result in improved patient outcomes [61]. In 
such a scenario, controlling dialysate sodium via feedback mechanism is an obvious 
scheme [62]. This will require continuous measurement of serum sodium concentration, 
so that controller can take corrective actions to keep sodium within desirable limits. 
However, continuous measurement of sodium is very difficult and so secondary inference 
using a mathematical model is required, which is commonly referred as soft-sensing in 
chemical engineering. Early developments in sodium kinetics were proposed by Coli and 
Ursino et al. [62, 63], who also proposed model-based sodium profiling. The model-based 
profiling simulation also results in improved dialysate sodium control and suggests that 
first the dialysate sodium should be increased and then ramped down to certain level, 
such that the plasma sodium concentration does not reach to a point where it may 
culminate in hypotensive episode. An example of sodium profiling is shown in Figure 2.8 






Figure 2.8: Dialysate sodium profile to control the serum sodium concentration 
The concept of sodium profiling seems to stabilize the model patient, but in routine 
clinical settings sodium profiling could not result in better outcomes [64]. The prescribed 
dialysate sodium profile (Figure 2.8) will stabilize the patient but at the same time it does 
not remove sufficient sodium and results in high post-dialysis serum sodium 
concentration. In other words, dialysate sodium is a good maneuver for stabilizing the 
patient in the short-term, but at the cost of poor patient outcomes in the long-term. Until 
sodium profiling is realized in routine clinical settings, the best strategy to control the 
serum sodium is to restrict its intake [59]. 
2.4.3 Kinetics of Guanidino Compounds 
Guanidino compounds (GCs) are large group of solutes resulting from protein and amino 
acid metabolism. Unlike urea, GCs can interfere with neuronal, cardiovascular, and blood 
cells functions, and are commonly referred to as neurotoxins [65]. In non-dialyzed 
subjects, the concentration of GCs was found to be very high when compared to controls, 
and correlated with morbidities [66]. The kinetics of GCs was first explored by Eloot et 
al. In their study, they employed two-pool model structure and considered 6 small and 




















































water soluble GCs, namely, creatinine, guanidinosuccinic acid, guanidine, 
methylguanidine, guanidinoacetic acid, and creatine [67]. It was noted that though GCs 
are present in small concentration, their total distribution volume can be much higher than 
that of urea. The total distribution volume for creatinine (54 L), guanidinosuccinic acid 
(30.6 L), guanidine (89.7 L), methylguanidine (102.6 L) , guanidinoacetic acid (123.8 L), 
and creatine (98 L), was significantly higher the distribution volume for urea (42.7 L), 
except for guanidinosuccinic acid. Only mean values of 7 recruited patients are presented 
[67]. Note that the estimates of toxin distribution volume are higher than the body weight 
itself, which is infeasible. The authors suggested that larger the toxin distribution, the 
longer it will take to clear the toxin, as more body fluid needs to be processed. The 
conclusion is that urea kinetics is not representative of other small-sized uremic toxins, 
thus D ureat / VK  based dialysis adequacy should be abolished [68]. 
All these researches corroborate the idea that urea is not the best marker toxin and 
concept of adequacy must be revised. After decades of practice, the adequate dialysis 
concept has not improved mortality and morbidity. Some researchers have even suggested 
the introduction of D ureat / VK  concept as an unfortunate one [59, 69]. In summary, 
attention should be shifted from urea, as it cannot be a suitable representative of other 
uremic toxins, and a better marker is definitely required. Recently, middle molecules have 
been discussed extensively. Particularly, β2-microglobulin (β2M) has been considered as a 
marker of middle molecules [68]. Its pre-dialysis concentration has been found to 
correlate with mortality [38, 70]. After urea, β2M is the most studied toxins. Numerous 
kinetic studies have been published to explain its kinetics [71-74]. In this thesis, β2M is 
considered as a marker of toxin milieu and its kinetics is studied. Further details will be 






More than 115 uremic toxins have been identified and supposedly more new toxins will 
be identified in the future. Dialysis, being a non-selective method (dependent on 
membrane pore size) of toxin removal, needs a marker whose removal can correlate with 
the removal of other uremic toxins. Urea is an established choice of marker and is the 
basis of current dialysis prescription. Urea based dialysis adequacy, emerged from kinetic 
studies of urea was an important step for standardizing the dialysis therapy. The kinetic 
studies are generally referred as toxin kinetic modeling (TKM), and a number of TKMs 
were reviewed in this chapter. TKM explained an important phenomenon known as 
rebound, which controls the net efficacy of dialysis. The advantage of these models is that 
predictions beyond the range of examined parameters are more robust, as they are based 
on fundamental physical principles (conservation of mass) [69]. TKM also assists in 
better understanding of physiology, based on which it is suggested that toxin transfer to 
dialysate is restricted both by physiological resistance as well as resistance in artificial 
































3. Diffusion-adjusted Regional Blood Flow Model for β2-
Microglobulin§
“All models are wrong, but some are useful.” 
 
- George E. P. Box  
In the previous chapter, the importance of TKM paradigm in HD literature was discussed. 
The inadequacy of urea as marker toxin was elucidated. Hence, clinicians started focusing 
on uremic toxins other than urea. β2-microglobulin (β2M) is one such toxin which has 
received major attention from the nephrology community (Section 3.1). In this chapter, a 
comprehensive model for explaining β2M kinetics is proposed (Section 3.2). The 
developed model comprises 7 unknown model parameters whose estimation is difficult 
from limited patient data. Hence, parameter reduction aspects using a priori identifiability 
analysis are discussed (Section 3.3). The model is calibrated using clinical data of 10 
maintenance HD patients and parameter estimates are compared with those obtained for 
the existing two-pool model for β2M (Section 3.4). The use of a mathematical model 
should not be limited to explaining the underlying phenomenon; rather it should also be 
employed to study interventions prior to their realization in clinical settings. In this 
direction, the calibrated model is employed to study the effect of exercise intervention 
during HD as exercise has been shown to improve the toxin removal. Based on the model 
simulations, a new hypothesis for explaining the exercise effect on physiology is 
presented (Section 3.5). 
                                                 
§ The contents of this chapter have been published in: Vaibhav Maheshwari, Lakshminarayanan 
Samavedham, and Gade Pandu Rangaiah, A regional blood flow model for β2-microglobulin 






3.1 β2-microglobulin and Kinetic Studies 
β2M is an undisputed marker of middle to large-sized uremic toxins [37, 68]. Higher pre-
dialysis serum concentrations of β2M have been associated with mortality and morbidity 
[38, 75]. β2M is found on the surface of all nucleated cells. After being shed from cell 
surface, it is excreted by glomerular filtration. In subjects with renal insufficiency, it 
accumulates in the interstitium and plasma, and deposits as amyloid fibrils in 
osteoarticular structures [76, 77]. These deposits can lead to amyloidosis, carpal tunnel 
syndrome, or formation of bone cysts, which are causes of morbidity in long-term 
hemodialysis subjects [78]. Vanholder et al. have recommended that monitoring the 
serum level of β2M alone might be sufficient for the evaluation of dialysis adequacy [68]. 
The kinetics of β2M differs from that of small molecules (e.g., urea and creatinine) in that 
the former is distributed in extracellular (plasma + interstitium) compartment only [72], 
while the latter are distributed in both extracellular and intracellular compartments 
(Figure 3.1). 
 
Figure 3.1: Compartmental representation of physiology. Toxins are distributed in 
intracellular (IC) and extracellular compartments (EC). Urea is distributed in both IC and 
EC, and β2M is distributed in EC. The hollow arrows between IC and interstitium denote 
fluid movement, while solid arrows between interstitium and plasma represent the fluid as 


















Though considerable interest has been shown for intra-dialytic removal of β2M, urea is 
still considered to be the standard marker of dialysis adequacy in clinical practice. 
Incorporating β2M in the prescription of adequate dialysis requires comprehensive 
mathematical models that can describe β2M kinetics and motivate clinicians to accept its 
clinical use. Such models can also help in realizing the goal of optimal individualized 
treatment. So far, the two-pool model has been used to describe the kinetics of urea, 
creatinine [79], β2M [73, 74, 80], guanidino compounds [29, 67], phosphate [80], and 
other toxins [81] in patients on renal replacement therapy. However, the practical 
application of the two-pool models has been limited, and primarily restricted to explain 
the effect of increased dialysis frequency or duration [80, 82, 83]. Alternatively, regional 
blood flow (RBF) model can also explain urea kinetics (Sub-section 2.3.4) [48]. It 
describes solute kinetics in terms of an unequal distribution of blood flow to different 
body organs, and appears to be better that the two-pool model. The reasons are that RBF 
model is closely related to physiology and explains certain aspects of kinetics which the 
two-pool model cannot, such as cardiopulmonary recirculation [84], and the effect of 
intra-dialytic exercise [85]. Recently, Schneditz et al. proposed a diffusion-adjusted RBF 
(DA-RBF) model structure [51], which encompasses the characteristics of both the two-
pool and the simple RBF model, and brings it much closer to physiology. 
Even after the improvements in the previous RBF model, the DA-RBF model has not 
been much valued by the research community. Probable reasons include the large number 
of parameters in the DA-RBF model [69, 86], which are difficult to estimate from limited 
patient data, and clinicians’ reluctance to shift to a more complex model. Additionally, 
the DA-RBF model has not been validated using real-time clinical data for any toxin. 
Nevertheless, these reasons alone do not undermine the relevance of DA-RBF model in 





kinetics of small molecules like urea and creatinine only [51]. The applicability of DA-
RBF model for larger molecules marker, such as β2M, and its relevance for renal subjects, 
has yet to be evaluated. 
3.2 Model Description 
The original DA-RBF model was developed for urea which is distributed in both IC and 
EC [51]. To account for the distribution characteristics of β2M, the existing DA-RBF 
model is modified in this study. Based on specific perfusion (ratio of blood flow rate to 
organ fluid volume), the body organs are divided into two major regions, namely, high 
flow region (HFR) and low flow region (LFR) (Figure 3.2). HFR comprises small organs 
like heart, brain, kidney, and liver with specific perfusion greater than 0.2 min-1. They 
sum up to 20% of total body fluid volume, but are highly perfused and almost 85% of 
cardiac output goes to them. The remaining organs are part of LFR which mainly 
comprises the large body organs like skin, muscles, and bones. They sum up to 80% of 
total fluid volume and perfused by only 15% of total cardiac output [86, 87]. Heart pumps 
blood to various body organs; HFR and LFR plasma flows (Qhp and Qlp) move the toxin 
between plasma compartments and dialyzer. Both HFR and LFR behave as a two-
compartmental structure where mass transfer between compartments is controlled by 
inter-compartmental mass transfer coefficient (Kip). It can be observed that this model 
structure comprises 2 two-pool compartments in parallel, or it can be called as parallel-
cum-series representation of physiology (Figure 3.2). In the following, all model 
equations are described. 
Toxin exchange between compartments depends on the concentration difference 
(diffusive flux), and fluid movement due to ultrafiltration (convective flux). Additionally, 
Mass balance during dialysis 




constant toxin generation and constant non-renal clearance (KNR) also contribute to toxin 
accumulation. For example, toxin accumulation in HFR plasma compartment depends on 
the following factors; (i) diffusive flux from interstitium to plasma, (ii) toxin transfer 
from interstitium to plasma with ultrafiltered fluid, (iii) toxin transfer from plasma to 
systemic circulation with ultrafiltered fluid, (iv) convective removal with systemic 
circulation, (v) non-renal clearance from plasma compartment, and (vi) constant toxin 
generation. Here systemic circulation refers to the distribution of cardiac output to various 
regions. All these factors appear in the same order in the right hand side of equation (3.1). 
Toxin balance equations for other compartments are written in the similar manner. 
 
Figure 3.2: Diffusion-adjusted regional blood flow model (parallel-cum-series 
representation of physiology) for explaining β2M kinetics. Toxin transfer is due to diffusion 
across capillary endothelium, and blood/plasma circulation causes convective transport. 
Qh/Qhp, Ql/Qlp, and Qb/Qbp are blood/plasma flows to HFR, LFR, and dialyzer, respectively. 
Qcr and Qar are cardiopulmonary and access recirculation, respectively. Shaded 
compartments represent contact with blood (A – arterial node and V – venous node). Here, 
IC is not presented because β2M distribution is restricted to EC alone. 

































HFR plasma mass balance: 
hp hp
h ip hi hp h uf hi h uf hp hp art hp h NR hp h 2M P
d( )
( ) ( )
dt
C V
k K C C k Q C k Q C Q C C k K C k G fβ= − + − + − − +
                                                                                                                                     (3.1) 
HFR interstitium mass balance: 
 hi hi h ip hi hp h uf hi h 2M P
d( ) ( ) (1 )
dt
C V k K C C k Q C +k G fβ= − − − −  (3.2) 
LFR plasma mass balance: 
 lp lp l ip li lp l uf li l uf lp hp art lp l NR lp l 2M P
d( )
( ) ( )
dt
C V
k K C C k Q C k Q C Q C C k K C k G fβ= − + − + − − +  
                                                                                                                                         (3.3)
  
LFR interstitium mass balance: 
 li li l ip li lp l uf li l 2M P
d( ) ( ) (1 )
dt
C V k K C C k Q C +k G fβ= − − − −     (3.4) 
During dialysis, blood is taken from the arterial port (Cart) and rendered to dialyzer; after 
purification, it is infused back through the venous port. Blood sampling is limited to this 
arterial blood, which is not purely from HFR or LFR; therefore, an expression relating 
arterial concentration to HFR and LFR plasma concentration is needed. According to 
Figure 3.2, plasma mass balance across dialyzer (in lumen side) can be described by: 
Calculation of arterial toxin concentration (Cart) 
 bp art bp uf ven D art( ) Amount transferred todialysateQ C Q Q C K C− − = =  (3.5) 
Fluid (blood/plasma) balance across arterial node (‘A’ in Figure 3.2): 
 h l bCO Q Q Q= + +  (3.6) 
 hp lp bp(1 HCT)CO Q Q Q− = + +  (3.7) 
Plasma mass balance across venous node (‘V’ in Figure 3.2): 
 art hp h uf hp lp l uf lp bp uf ven(1 HCT)CO. ( ) ( ) ( )C Q k Q C Q k Q C Q Q C− = + + + + −  (3.8) 
Rearrangement of equation (3.8) using equations (3.5) and (3.7) gives: 
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During dialysis fluid is removed from both IC and EC (interstitium + plasma). Fraction 
‘e’ of total ultrafiltered fluid comes from EC and rest from IC. The fluid removal from 
EC is further divided into two components, (i) removal from interstitial compartment and 
(ii) removal from plasma compartment, based on plasma volume fraction in EC (fP). It is 
assumed that fluid removal from any compartment will be in proportion of that 
compartment fluid volume [73, 74]. 
Volume balance during dialysis 
HFR plasma volume depletion: 




eQ k f= −  (3.10) 
HFR interstitial volume depletion: 
 hi uf h P
d (1 )
dt
V eQ k f= − −  (3.11) 
LFR plasma volume depletion: 




eQ k f= −  (3.12) 
LFR interstitial volume depletion: 
 li uf l P
d (1 )
dt
V eQ k f= − −  (3.13) 
Summing up all the volume balance equations (equations 3.10 to 3.13) will give the total 
fluid removal from extracellular compartment. 
Sum of HFR and LFR volume fraction must be equal to 1. Therefore, 
Auxiliary equations 





A part of cardiac output goes to dialyzer (Qb), and rest goes in systemic circulation 
(Figure 3.2). In blood, β2M is found in plasma only, so, only a portion of systemic 
circulation participates in mass transfer which is called as systemic plasma (Qs). 
 s b(1 HCT)(CO )Q Q= − −  (3.15) 
This systemic plasma is sub-divided into two parts, one going to HFR and other to LFR, 
thus plasma flow fraction to HFR and LFR: 







Sum of blood flow fraction to HFR and LFR must be equal to 1. Therefore, 
 h l 1f f+ =  (3.17) 
During inter-dialysis period, all the equations are modified by setting dialyzer clearance 
(KD), ultrafiltration rate (Quf), and blood flow to dialyzer (Qb) equal to zero. It is assumed 
that distribution of fluid intake will be in proportion to compartmental fluid volume, i.e. 
part of fluid intake, proportional to intracellular fluid volume will move to IC. Sample 
equation describing the HFR plasma compartment is shown below; toxin accumulation in 
HFR plasma compartment depends on (i) diffusive flux from interstitium to plasma, (ii) 
toxin transfer from plasma to systemic circulation, (iii) non-renal clearance from plasma 
compartment, (iv) constant toxin generation, and (v) convective flux from plasma to 
interstitium with fluid intake. Similar equations hold for mass and volume balances in 
other compartments as well. 
Model equations during inter-dialysis period 
HFR plasma mass balance: 
hp hp
h ip hi hp hp art hp h NR hp h 2M P h hp P
d( )
( ) ( ) (1 )
dt
C V
k K C C Q C C k K C k G f k C e fβ α= − + − − + − −   
  (3.18) 
 




HFR plasma volume balance: 




ek f α=  (3.19) 
3.3 Model Parameter Reduction and Estimation 
Patient data are obtained from a previously published study of 10 patients (8 men and 2 
women) treated with post-dilution hemodiafiltration (HDF) [74]. Briefly, HDF is also an 
extracorporeal method of blood purification, and has shown its superiority over 
conventional HD in the removal of middle-sized uremic toxins. Further details of HDF, 
associated clinical outcomes, modes of operation are detailed in Chapter 4. The data used 
for parameter estimation was obtained under same treatment conditions for all recruited 
patients [74]. Blood and dialysate flow rates were kept constant at 280 mL min-1 and 500 
mL min-1, respectively. Treatment time was 240 min for all patients. Blood samples from 
arterial line were collected at the beginning of dialysis and subsequently at 60, 120, and 
240 min during the session. Immediately after HDF, a sample was collected 20 sec later; 
subsequent samples were collected at 5, 10, 30, 60, 90, 120, and 240 min for capturing the 
post-dialysis rebound (Figure 3.3). Blood sample just before the next treatment session 
was also collected for each patient to calculate toxin generation rate (Gβ2M). 
 
Figure 3.3: Plasma β2M concentrations during 240 min dialysis treatment and for 4 hours 





The developed model has 7 unknown parameters, namely, inter-compartmental clearance 
or inter-compartmental mass transfer coefficient (Kip), toxin distribution volume (Vd), 
cardiac output (CO), HFR flow fraction (fh), HFR volume fraction (kh), EC volume 
fraction (e), and plasma volume fraction in EC (fP). It is not possible to estimate all these 
parameters with precision from limited patient data, and one should replace weakly 
identifiable parameters with constants. To reduce the number of parameters, a priori 
identifiability analysis proposed by Yao et al. is employed [88]. It helps to determine the 
subset of potentially identifiable parameters, and is based on the calculation of parametric 
sensitivities (equation 3.20). Large sensitivity indicates the strong influence of that 
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Scaled sensitivities are calculated at each sample time to form the scaled sensitivity 
matrix, which is evaluated for initial parameter estimates [88]. 
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  (3.21) 
Absolute sum of elements in all columns of matrix Z provides the basis to identify the 
significant parameters. Larger column sum suggests that corresponding sensitivities are 
large i.e. change in state (Cart) with respect to change in the parameter is significant. After 




selecting the most significant parameter, scaled sensitivity matrix is deflated (i.e., 
removing inter-dependence among parametric sensitivities to evaluate the “net influence” 
of each parameter) using the column corresponding to the largest sum, and second 
important parameter is then obtained. This process is iterative and continued till all the 
parameters are ranked according to their column sum. The involved steps are outlined 
below. 
1. Calculate the absolute column sum (corresponding to each parameter) of matrix Z. 
2. Select the first important parameter corresponding to largest column sum, and 
mark the corresponding column as XL (L = 1 for first iteration).  
3. Calculate ZL, the prediction of full sensitivity matrix, Z, using the XL: 
T 1 T
L L L L L( )Z X X X X Z
−=  
4. Calculate the deflated matrix/residual matrix: L LR Z Z= −  
5. Calculate the column sum and select the second most important parameter 
corresponding to highest column sum.  
6. Augment the XL by including new column. Repeat the procedure until all the 
parameters are ranked in the decreasing order of their column sum. 
The procedure can be understood by the following illustration, where following initial 
guesses are selected for individual patient. The initial guesses are close approximation of 
physiology. The initial guess for each parameter is stored in a parameter vector 0θ . 
 0 ip d h h P[ , ,CO, , , , ] [100, 14, 6, 0.85, 0.2, 0.4, 0.25]K V f k e fθ = =  
Using the Patient 1 data, the following estimates are obtained. 





Obtained estimates are used to calculate the scaled sensitivity matrix (Z) (equation 3.21), 
and following the above mentioned steps, all parameters are ranked. The column sums 




















   
   
   
   
   = ⇒ =   
   
   
   
        
It is evident that cumulative contribution of parameters Vd, fP, and Kip is ~99.9%, and thus 
selected as the important parameters. In other words, the effect of change in CO, fh, e, and 
kh on arterial blood plasma concentration (Cart) is very small in comparison to the effect of 
change in Vd, fP, and Kip. The remaining four parameters (CO, fh, e, and kh) are replaced 
by constants. The constants for model parameters and other physiological constants are 
presented in Table 3.1. Same parameter sub-set results are obtained for other patients too.  
Note that the previous two-pool β2M kinetic studies have assumed the removal of 
accumulated fluid from EC alone [73, 74], which is infeasible, as fluid removal from 
blood compartment will induce the fluid movement from interstitial compartment and 
then from IC. To make it realistic, the two-pool model assumption pertaining to fluid 
removal is modified, and is discussed in the following. The net fluid removal is 
considered from both EC and IC. Further, it is assumed that fluid removal from any 
compartment will be in proportion of that compartmental fluid volume [89]. Hence, fluid 
removal from EC will be in proportion of volume fraction of EC (e), which is later 
assumed to be a constant based on a priori identifiability analysis. It is assumed that 
about 33% of fluid is removed from EC and the remaining 67% comes from IC [89-91]. 




Considering this information, EC volume fraction (e) is replaced by factor of 1/3 in the 
equations for rate of volume depletion (Table 3.1). 
Table 3.1: Constant model parameters for all patients 
Symbol Description Value Reference 
HCT  Hematocrit 0.35  [74] 
kh Volume fraction of high flow region 0.2  [92] 
CO Cardiac output (L min-1) 5.8  [84, 93] 
e Extracellular fluid fraction 1/3 [89] 
fh Blood flow fraction to high flow region 0.85  [84, 92] 
KNR Non-renal clearance (mL min-1) 3 [74] 
After replacing the four insensitive parameters by suitable constant values, the three 
important parameters are re-estimated. The estimated post-dialysis toxin distribution 
volume (Vd) is 14.22±0.75 L (equivalent to 20.3±1.3% of end-dialysis body weight), 
plasma fraction in EC (fP) is 0.39±0.03, and inter-compartmental mass transfer coefficient 
(Kip) is 44±4.1 mL min-1. Estimated values of model parameters for each patient are listed 
in Table 3.2. For comparison, parameter estimates from two-compartment model 
approach are also presented [74]. Obtained estimates of Vd are larger than those obtained 
from the two-pool model (10.2±0.6 L). Also, the obtained estimates for fP are larger than 
fP of 0.25 in normal subjects. Toxin generation rate is 0.131±0.007 mg min-1, which is 
calculated using estimated Vd and toxin concentration measured at the beginning of next 









Diffusion adjusted regional blood flow model Two-compartment model (Ward et al. [74])  
Inter-compartmental 




















1 43 18.47 0.41 0.134 100 13.27 0.131 
2 46 10.51 0.43 0.121 86 7.52 0.131 
3 51 14.28 0.27 0.125 63 8.10 0.144 
4 48 15.03 0.38 0.091 75 12.31 0.091 
5 39 15.21 0.27 0.136 53 8.57 0.140 
6 28 16.26 0.33 0.128 57 9.25 0.125 
7 54 14.39 0.46 0.122 108 11.99 0.131 
8 24 10.84 0.54 0.155 102 9.91 0.165 
9 40 13.10 0.39 0.171 74 9.31 0.182 
10 70 14.12 0.42 0.126 107 11.37 0.115 
Mean ± s.e.m. 44 ± 4.1 14.22 ± 0.75 0.39 ± 0.03 0.131 ± 0.007 82.5 ± 6.7 10.2 ± 0.6 0.136 ± 0.008 
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The reduced DA-RBF model adopts similar assumptions as in the two-pool study [74]. In 
the absence of any literature evidence, membrane sieving coefficient is considered as one, 
inferred from the study by Harper et al., where they revealed in vivo that uremia enhances 
the membrane permeability [94]. However, as dialysis progresses, uremia decreases; 
hence, membrane permeability and Kip should continuously decrease. Nevertheless, the 
sieving coefficient and Kip are considered as constant, which is the assumption in all 
previously developed kinetic models for urea, creatinine, and β2M. This may not be valid 
in reality. Experimental studies are required to find out how the sieving coefficient and 
Kip changes with the decrease in uremia. Secondly, even though the DA-RBF model can 
account for access recirculation (Qar), it is neglected in the current study due to the 
absence of relevant individual patient data, and to make a valid comparison between the 
outputs of the developed model and that of the existing two-pool model [94]. Qar dilute 
the inlet blood to dialyzer and reduce the toxin concentration. As a result of this reduced 
concentration, toxin removal or access clearance reduces, or post-dialysis toxin 
concentration increases. The effect of Qar is not limited to β2M alone, rather affects all 
toxins equally, and leads to reduction in the measure of dialysis adequacy D ureat / VK . As 
dialyzer clearance (KD) and time of dialysis (t) are independent of recirculation, only 
increase in distribution volume (Vd) can explain the decreased adequacy index. Hence, 
inclusion of Qar will result in larger estimates of toxin distribution volume [92, 95].  
3.4 Interpretation of Parameter Estimates  
The toxin distribution volume for β2M obtained from fitting the model to experimental 
data (14.22±0.75 L or 20.3±1.3% of end-dialysis body weight) is greater than that 
estimated by anthropometric formulae given by Watson et al. [96], (12.62±0.57 L or 
17.6±0.4% of end dialysis body weight). The difference could be because anthropometric 





excess fluid. On the other hand, significant difference is observed between the results 
obtained here and from the two-pool study for Vd (10.2±0.6 L) [74]. This can be attributed 
to the improved physiological representation in the form of DA-RBF model, and the 
assumption that about 33% of ultrafiltered volume comes from EC and rest comes from 
IC. In clinical scenario, one can validate one of the two models by measuring the toxin 
concentration in blood serum, and comparing it with that obtained by both the models. 
The correct (validated) model can be used to decide the dialysis dose. The parameter 
estimate for plasma fraction in EC is 0.39±0.03, which is greater than plasma fraction 
found in normal subjects. It can be understood that this excess fluid contributes to blood 
volume; the obtained parameter estimates also explain the reason for most renal patients 
being hypertensive. Distinctively, fP for Patient 8 (0.54) is much higher than rest of the 
patients, probably because there is no fluid removal for this patient during dialysis (pre- 
and post-dialysis weight are same). 
Toxin generation is assumed to be in both interstitium and plasma compartments, and it is 
calculated after estimating toxin distribution volume. Toxin concentration at t = 480 min 
(with t = 0 min denoting start of dialysis) and pre-dialysis toxin concentration measured 
before next dialysis session are used for this purpose (assuming constant toxin generation 
rate). The calculated generation rate (0.131±0.007 mg min-1) is similar to the results 
obtained for the same patient group using the two-pool study (0.136±0.008 mg min-1) 
[74], and in other hemodialysis subjects using the two-pool modeling approach 
(0.132±0.006 mg min-1) [71]. Estimated inter-compartmental clearance (Kip) between 
interstitium and plasma compartment is 44±4.1 mL min-1, which is much smaller than 
reported value of 82±7 mL min-1 in the two-compartment study [74]. In this study, 
measured dialyzer clearance (KD) of β2M is 73±2 mL min-1. Despite this high KD, mass 
transfer is limited by smaller Kip, which is evident from the obtained parameter estimates 
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for individual patient, i.e. toxin removal is primarily controlled by membrane resistance. 
The smaller value of Kip than KD explains, why convection based dialysis 
(hemodiafiltration) does not result in significantly improved toxin removal, and is limited 
to toxin removal from blood compartment only [74]. This also implies that physiological 
resistance confer the major resistance for toxin removal [74].  
Measured toxin concentrations and model fit are shown in Figure 3.4, while toxin 
concentration in each compartment is illustrated in Figure 3.5 (for Patients 1 and 10). 
There is consistent difference between concentrations of Chp and Clp from the onset of 
dialysis, as the unequal distribution of cardiac output creates a concentration difference 
between HFR and LFR. Nevertheless, one can observe that HFR and LFR plasma 
concentration equilibrate immediately after dialysis due to systemic circulation (Figure 
3.5). This explains the cause of sharp rebound after dialysis. One can also observe that 
major contribution to rebound is concentration difference between interstitium and 
plasma compartment. In summary, the developed model gives better insight into toxin 
distribution in various compartments. It can be employed for precise estimation of toxin 
distribution volume i.e. extracellular fluid volume, which is one of the greatest challenges 
to practicing nephrologists [97]. This may further help in accurate dialysis dose prediction 
for hemodialysis subjects based on modified dialysis adequacy index considering β2M 






Figure 3.4: Arterial plasma concentration profile (model fit) and measured concentration of 
β2-microglobulin for Patient 1 (top) and Patient 10 (bottom) 
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Figure 3.5: β2-microglobulin concentration profile in different body compartments for 
Patient 1 (top) and Patient 10 (bottom). 



























































































3.5 Model Applications 
It is evident that DA-RBF model results in better parameter estimates for HD patients 
which explain the physiology of HD patients. Nevertheless, developing a good model is 
the first step to understand a system, and model is not restricted to predict the underlying 
behavior only. Hence, the developed model is employed to estimate the removed toxin 
mass and also study the effect of exercise on toxin removal. 
3.5.1 Estimation of Removed Toxin Mass 
The DA-RBF model is employed to estimate the removed toxin mass during HDF. This 
calculation can be performed using initial (at t = 0 min) and final toxin concentration after 
dialysis (at t = 240 min) and obtained estimates of toxin distribution volume, 
 0 240 0 0 240 240MR M M C V C V= − = −  (3.22) 
However, above formulation will overestimate the removed toxin mass due to post-
dialysis rebound. Thus, adjusting for post-dialysis rebound will result in, 
 0 480 0 0 480 480MR M M C V C V= − = −  (3.23) 
where C0, C240, and C480, represent pre-dialysis toxin concentration (at t = 0), 
concentration at the end of dialysis (at t = 240 min), and concentration after 240 min of 
dialysis (at 480th min from the beginning of dialysis), respectively. The estimates of 
removed toxin mass using the developed model are 196.31±19.7 mg, which are higher 
than 141.45±14.17 mg, obtained by the existing two pool model (Table 3.3). The larger 
estimates of removed toxin mass from DA-RBF model can be explained by the bigger 
estimates of Vd when comapred with that obtained in the two-pool model. This simple 
approach can be used to validate the superiority of one toxin kinetic model over another. 
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Table 3.3: Estimates of removed toxin mass (mean±s.e.m.) 
Patient No. Mass removed, mg (estimated 
by the DA-RBF model) 
Mass removed, mg (estimated 
by the Two-pool model [74]) 
1 268.63 208.42 
2 218.76 160.39 
3 190.19 112.99 
4 110.67 88.91 
5 189.69 115.47 
6 268.22 158.17 
7 241.70 199.41 
8 144.77 121.64 
9 236.25 171.38 
10 94.26 77.69 
Mean ± s.e.m. 196.31±19.7 141.45±14.17 
3.5.2 Simulating Effect of Exercise 
Exercise during dialysis (intra-dialytic exercise) has shown to improve the toxin removal 
[98, 99]. Smye et al. first employed the simple RBF model and demonstrated via 
simulations that increase in cardiac output or increased perfusion of the skeletal muscles 
results in reduced post-dialysis rebound [85]. It has been suggested in the past that, as a 
result of intra-dialytic exercise, a large fraction of increased CO reaches the LFR, where 
major portion of toxin is present in comparison to HFR [84]. This increased perfusion of 
LFR results in higher toxin removal through convection, and thus reduced post-dialysis 
rebound. To observe the same, the effect of increased CO (6 L min-1 in normal condition 
to 12 L min-1 during exercise [85]) on arterial plasma concentration is studied for all 10 
patients. Exercise is given to in silico patients at t = 150 min, and sustained till the end of 
session (t = 240 min). Quantitatively, the 100% increase of CO results in only ~1% 





for rest of the patients too (Table 3.4). Figure 3.6 illustrates the effect of 100% increase in 
cardiac output due to intra-dialytic exercise. However, exercise has shown to decrease the 
post-dialytic toxin rebound much more than 1 %; e.g. in the study of Kong et al., the 
creatinine rebound decreased 4% [100]. Similar results were obtained for phosphate 
removal, where weekly phosphate removal increased in exercises intervention [99]. 
Though there is no clinical trial studying the effect of intra-dialytic exercise on any of 
middle-sized uremic toxin removal, it can be assumed that exercise will result in similar 
quantum of decrease in % rebound. This leads to the question – how does intra-dialytic 
exercise lead to reduced rebound when the effect of increased cardiac output is not 
significant?  
To explain the phenomenon, it is hypothesized that intra-dialytic exercise increases both 
CO and Kip. It is known that exercise to lower extremity causes increased blood flow to 
LFR. The increased flow is hypothesized to dilate capillaries/membranes so that the 
excess blood flow can be accommodated [98]; this will increase the membrane surface 
area. Additionally, dilation will lead to larger membrane pore size. These two reasons, 
namely, increased surface area of capillaries and increased membrane pore size will 
increase the membrane permeability i.e. increase in inter-compartmental mass transfer 
clearance (Kip), and hence more toxin transfer to blood compartment. This transferred 
toxin will be swept away by increased blood flow. 




Figure 3.6: Simulation of effect of intra-dialytic exercise for Patient 1 (top) and Patient 10 
(bottom) – Decrease in post-dialysis rebound due to 100% increase in cardiac output. 
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To compare their individual effect on toxin removal, increase in both factors is studied 
independently. (i) The model is simulated for CO = 6 L min-1 (without exercise) and CO 
= 12 L min-1 (with intra-dialytic exercise) keeping Kip constant. To simulate the toxin 
kinetics during exercise, the HFR blood flow remained same as in no exercise condition 
[85], thus rest of the increased cardiac output will perfuse LFR. (ii) To observe the effect 
of increase in Kip, a hypothetical increase of 15% is studied (keeping cardiac output 
constant at 6 L min-1). In all the cases, the post-dialysis rebound is calculated using the 









Difference in percentage rebound is calculated for CO = 6 and 12 L min-1; similar 
calculations are performed between nominal Kip and 15% increased Kip. Table 3.4 
comprises the quantitative results corresponding to both scenarios. It is observed that 15% 
increase in Kip can result in similar decrease as obtained with 100% increase in CO. 
Hence, it can be concluded that intra-dialytic exercise not only increases the CO but also 
increases the Kip. To substantiate this hypothesis, further clinical studies need to be 
carried out so as to segregate the effect of CO and Kip on arterial toxin plasma 
concentration, and formulating a relationship between the effect of exercise and toxin 
removal. Such clinical studies can also help in quantifying the effect of exercise on inter-
compartmental clearance. 
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Table 3.4: Simulating effect of intra-dialytic exercise – Decrease in rebound % (a) for 100% increase in cardiac output (CO) and (b) for 15% 




Effect of increase in CO, keeping Kip constant Effect of increase in Kip, keeping CO constant 
Rebound % during 
normal dialysis 
(CO = 6 L min-1) 
Rebound % with 
intra-dialytic exercise 
(CO = 12 L min-1) 
Decrease in 
Rebound % due 
to exercise 
Rebound % during 
normal dialysis  
(Kip = nominal) 
Rebound % with 
intra-dialytic exercise 
(Kip = 1.15 × nominal) 
Decrease in 
Rebound % due 
to exercise 
1 31.37 30.07 1.30 31.76 31.00 0.75 
2 23.38 22.64 0.74 24.71 23.92 0.80 
3 32.91 32.06 0.85 34.95 33.60 1.35 
4 37.18 36.49 0.69 37.75 36.59 1.17 
5 39.21 38.78 0.43 40.48 39.31 1.17 
6 33.57 32.90 0.68 35.35 34.57 0.78 
7 25.63 24.25 1.38 25.31 24.30 1.01 
8 33.95 33.31 0.64 33.73 32.91 0.82 
9 33.38 32.70 0.68 34.13 33.17 0.97 







A comprehensive model (diffusion-adjusted regional blood flow model) describing the 
removal kinetics of middle-sized marker toxin, β2-microglobulin, has been presented. 
Based on a priori identifiability analysis, the number of estimable parameters is reduced 
from seven to three. The estimates for toxin distribution volume (Vd) are greater than 
those obtained with two-compartment models, which can be justified by the fact that 
patients on maintenance hemodialysis are fluid overloaded. Estimates of plasma fraction 
in extracellular compartment (fP) suggest that more of this excess fluid stores in plasma 
compartment, which explains the reason for renal patients being hypertensive. In 
summary, the reduced parameter DA-RBF model results in improved understanding of 
β2-microglobulin kinetics. The developed model results in higher estimate of removed 
toxin mass than that obtained by the two-pool model. This information can be used to 
validate the existing models and select the one that is the best representative of 
physiology. To demonstrate the clinical application of the developed model, the effect of 
intra-dialytic exercise is examined. Based on the simulation results, it is suggested that 
increase in cardiac output alone cannot explain the decrease in rebound, and it is 
hypothesized that stating that intra-dialytic exercise not only increases the cardiac output 
but also increases the inter-compartmental mass transfer coefficient (Kip). When 
combined together, both these manifests as lower post-dialysis rebound i.e. increased 
toxin removal. Further clinical studies are required to study the effect of exercise on toxin 
removal and to quantify the associated physiological changes. After confirming the intra-
dialytic exercise effect in prospective clinical trials, the developed model can be utilized 
for systematic introduction of intra-dialytic exercise and synergizing its effect with 







4. Clinical Study to Compare Toxin Removal in Hemodialysis, 
Hemodiafiltration, and Hemodialysis with Exercise§
“The strongest arguments prove nothing so long as the conclusions are not verified by 
experience. Experimental science is the queen of sciences and the goal of all 
speculation.” 
 
- Roger Bacon 
The previous chapter described a comprehensive model for β2-microglobulin kinetics. 
Employing the developed model, the effect of exercise during dialysis was studied. To 
explain the existing clinical evidence pertaining to enhanced toxin removal by exercise, it 
is hypothesized that intra-dialytic exercise not only increases the perfusion of remote 
body compartments, but also decreases the inter-compartmental resistance. To advance 
further, clinical studies are required to test the proposed hypotheses. In this direction, a 
pilot clinical research to investigate the effect of exercise during dialysis on toxin removal 
is designed. The primary focus of this clinical research is to investigate the physiological 
changes associated with intra-dialytic exercise.  
As discussed in sub-section 1.3.2, hemodiafiltration (HDF) has also shown to improve the 
toxin removal; hence, it is also studied for comparison purpose. The HDF details and 
associated literature evidence are presented in Section 4.1. In Section 4.2, clinical 
evidences for exercise and involved hypotheses are presented. The clinical trial design 
aspects are presented in Section 4.3. Information on study patients and dialysis 
                                                 
§ A portion of this chapter has been published in: Vaibhav Maheshwari, Lakshminarayanan 
Samavedham, Gade Pandu Rangaiah, Yijun Loy, Lieng Hsi Ling, Sunil Sethi and Titus Lau Wai 
Leong. Comparison of toxin removal outcomes in online hemodiafiltration and intra-dialytic 
exercise in high-flux hemodialysis: A prospective randomized open-label clinical study protocol; 






prescription are provided in Section 4.4. The results and discussion are presented in 
Sections 4.5 and 4.6, respectively.  
4.1 Hemodiafiltration 
According to single-pool assumption, the toxin removal is primarily hindered by dialyzer 
membrane pore size. Hence, an easy maneuver for increasing the toxin removal is to 
increase the membrane pore size. Two randomized clinical trials, Hemodialysis study and 
Membrane Permeability Outcome study have shown the superiority of large pore size 
membrane (high flux dialyzers) over small pore size membrane (low flux dialyzers) in 
decreasing the mortality and morbidity [101, 102]. Nevertheless, the removal of middle-
sized toxins is poor with high-flux membranes, and CHD patients are often overloaded 
with middle-sized uremic toxins. The reason is that toxin removal in CHD is primarily 
controlled by diffusion. Since diffusion is inversely proportional to molecular weight or 
size [103], removal of middle-sized toxins is relatively smaller than that of small-sized 
toxins. Also, membrane pore size cannot be increased beyond certain limits because it 
may translate in loss of important constituents of blood such as glucose, proteins, etc. 
HDF augments the toxin removal by convection, which mobilizes the toxins and thus 
enhances their removal. Understanding the toxin removal in dialyzer can clearly elucidate 
the role of diffusion and convection in toxin removal. In TKM, the dialyzer performance 
is quantified by dialyzer clearance (KD), which determines the removal rate. Following 
Figure 4.1, the KD can be calculated as [46],  
 D Bi Bi Bi Bo BoK C Q C Q C= −  (4.1) 
where BiQ   and BoQ   denote blood flow at the inlet and outlet of dialyzer (mL/min), CBi 








Figure 4.1: Blood and dialysate flow along dialyzer length. Horizontal arrows represent 
transfer of accumulated toxins and excess fluid from blood to dialysate stream 
Along the dialyzer length, fluid is removed at a certain rate. If the rate of fluid removal is 
QF, then 
 Bo Bi FQ Q Q= −  (4.2) 
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 (4.3) 
Hence, to calculate KD, blood samples at the inlet and outlet of dialyzer should be 
collected. During dialysis, the membrane permeability would decrease thus KD will also 
decrease; however, clinical studies found that KD remains almost constant during 4 hour 
dialysis [46, 74]. The first term in equation 4.3 describes the effect of diffusion on toxin 
removal and the second that of convection. In CHD, the fluid removal rate is 10-15 
mL/min, which is decided based on the amount of weight gain during inter-dialysis 
period. This is very small when compared with the diffusive component. In HDF, the QF 















compensated by addition of sterile fluid before blood goes back to the patient. Typical 
replacement fluid volume during 4 hour HDF process is ~20 L, which corresponds to QF 
= 80 mL/min. The HDF can be performed in pre-dilution and post-dilution mode, 
depending on the point of fluid infusion. Figure 4.2 schematically presents both modes of 
HDF.  
 
Figure 4.2: Pre- and post-dilution modes of hemodiafiltration. The given blood and dialysate 
flow rate are usual numbers practiced in routine dialysis settings. The replacement fluid 
rate is assumed to be 80 mL/min. 
The utmost requirement of HDF is the availability of non-pyrogenic sterile replacement 
fluid, which can be added to the blood stream. In the past, the replacement fluid was 
provided in sterile bags, but the extremely high cost prohibited this practice. On-line 
regeneration of replacement fluid has decreased this cost [104, 105], and resulted in 
increased acceptability of HDF. This mode of HDF is known as online-HDF. 
4.1.1 Clinical Evidences for HDF 
HDF is increasingly being considered as superior to CHD, and is a subject of major 
research [19, 106]. Numerous randomized controlled trials have studied its efficacy for 
toxin removal and clinical outcomes [20, 107-111]. As discussed earlier, the basic 
premise for encouraging HDF is the forced ultrafiltration rate that results in increased 
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removal of middle and large-sized toxins via convection [112, 113]. Despite numerous 
documented benefits of HDF, there is lack of evidence from various clinical trials that 
HDF can improve the toxin removal. This points to a need of properly designed 
randomized controlled clinical trials [19, 114]. 
Among clinical trials studying HDF, a prospective clinical study comparing online-HDF 
and high flux HD has shown that both small (urea and creatinine) and large (β2M and 
complement factor D) sized toxin removal were greater for HDF when compared to high-
flux HD. However, this increased removal of urea and creatinine did not result in lower 
pre-treatment serum concentration in both groups. In the context of large-sized molecules, 
it was found that, after one year, pre-treatment serum β2M levels were similar in both 
regimens, but significant decrease was observed for complement factor D [20]. 
Complement factor D is one of the toxins distributed in blood plasma. Based on these 
evidences, it was concluded that efficacy of HDF is largely limited to blood compartment 
only and is restricted by inter-compartmental resistance [74]. Toxins, which are 
distributed in intracellular and/or interstitial compartments, in addition to blood plasma 
compartment, are severely restricted by cellular membrane or capillary endothelium. This 
also explained the significant removal of complement factor D, for its distribution is 
limited to blood compartment only. Since majority of uremic toxins are distributed in 
both IC and EC, HDF and high-flux HD seem to detoxify the blood compartment 
primarily. These arguments also led to conclude that, after a certain volume of 
replacement fluid in HDF, there will not be significant benefit for toxin removal, as blood 
plasma compartment will almost be devoid of toxins and inflow of toxins from remote 
compartments is restricted by inter-compartmental resistance. This explains why even 
with very high volume of replacement fluid (60 L), there was no significant improvement 






intensive dialysis, i.e. prescribe long nocturnal dialysis or increased frequency of dialysis, 
which have been found to be more efficacious than the high flux HD [57, 116]. 
In another clinical study performed on 20 subjects, removal outcomes of HDF and low 
flux HD were compared for asymmetric dimethylarginine (ADMA), which is one of the 
guanidino compounds. There was no benefit from HDF over HD in lowering the ADMA 
concentration; rather, authors found that low-flux HD was superior in increasing the L-
arginine/ADMA ratio [117]. The reason for insignificant ADMA removal was associated 
with protein binding of ADMA. However, it is noted that ADMA is a metabolic by-
product of protein modification process in human cells, thus it may also be chiefly intra-
cellular, and so HDF will be inefficient for its removal. This further strengthens the 
conclusion of Ward et al. that inter-compartmental resistance is the major barrier for toxin 
removal [74].  
Recent Turkish online-HDF study [110] comparing high-flux HD and HDF observed 
decreased incidence of cardiovascular mortality in patients with high amount of 
replacement fluid. Nevertheless, the positive outcomes cannot be associated with 
increased toxin removal in HDF because authors could not find statistically significant 
difference in pre-dialysis serum concentration of urea, creatinine, phosphate, and β2M 
after two years [110]. The superiority of HDF over conventional high-flux HD in long 
term clinical trials is still debated [114], and this thesis does not intend to delve on this 
debate. Rather, the intention here is to see – how we can further improve the toxin 
removal performance of CHD or HDF by overcoming the physiological barrier. Exercise 
during dialysis has been found to improve the toxin removal, although acceptance of 






4.2 Exercise during Dialysis 
Intra-dialytic exercise was first studied by Painter et al. in prospective clinical trials for 
routine outpatient HD patients [118]. Since then, exercise has been proposed as 
adjunctive intervention for maintenance HD patients. It is known that exercise increases 
the cardiac output (CO). The major portion of this increased CO is rendered to LFR, 
where majority of toxins reside. Based on the model simulations (presented in Chapter 3), 
it is hypothesized that exercise decreases the inter-compartmental resistance, which is 
often termed as major resistance for toxin removal [74]. The decrease in inter-
compartmental resistance is anticipated due to increased capillary surface area and 
increased membrane pore size. Hence, both increased CO and decreased inter-
compartmental resistance supposedly lead to enhanced toxin removal. This is evident 
from a number of clinical trials where intra-dialytic exercise has shown its potential for 
removal of uremic toxins. In the study of Parson et al., a consistent decrease in pre-
dialysis serum creatinine concentration was observed; this is equivalent to increased 
creatinine removal [98]. In the study of Kong et al., both urea and creatinine % rebound 
(equation 3.24) decreased by statistically significant amounts [100]. Vaithilingam et al. 
oberserved increased phosphate removal due to intra-dialytic exercise [99]. Few other 
studies have also discussed the benefits of exercise for toxin removal [119, 120]. Exercise 
not only improves toxin removal but also provides numerous other benefits such as 
improved physical functioning [98, 121], decreased heart disease risk factors [122], 
decreased use of antihypertensive medicines [123], and most importantly, improved 
quality of life such as improved cognitive function, decreased stress levels, etc. [121].  
Despite the documented benefits, nephrologists as well as patients are not enthusiastic to 
accommodate exercise in routine dialysis care, and exercise is still considered as 






routine HD setting is poor [124]. It will not be a mistake to say that exercise is one of the 
most underrated clinical interventions in HD care. One reason behind this could be the 
requirement of individualized prescription for intra-dialytic exercise [124]. Before we aim 
for individualized prescription, it is important to understand what physiological changes 
are responsible for enhanced toxin removal. In addition to increased CO and decreased 
peripheral vascular resistance, exercise induced physiological changes may also occur 
due to increased body core temperature. This is discussed in the following section. 
4.2.1 Exercise and Temperature 
It is hypothesized that exercise will increase the body core temperature which will further 
dilate the blood vessels or vasculature, i.e. decrease the inter-compartmental resistance. 
This hypothesis is based on results from another clinical research which studied the effect 
of dialysate temperature on urea removal and patient hemodynamic stability [125]. 
Dialysate temperature plays an important role in patient hemodynamic stability and 
conventional dialysate temperature is set at 36°C or 36.5°C, while body core temperature 
is presumably 37°C. In the study of Kaufmann et al. comprising 15 HD subjects, effect of 
cool dialysate (35.5°C) and thermo-neutral dialysate (37°C) was studied. It was noted that 
cooled dialysate decreased the body core temperature by 0.22 ± 0.04 °C, while thermo-
neutral dialysate increased it by 0.31 ± 0.05 °C. The increase in body core temperature in 
thermo-neutral dialysate was associated with inflammatory response. The cool dialysate 
provided better hemodynamic stability. Nevertheless, cooling also resulted in ~400% 
increase in peripheral vascular resistance index, when compared with thermo-neutral 
dialysate. Interestingly, increased peripheral vascular resistance index did not affect the 






Peripheral vascular resistance index, also known as systemic vascular resistance index, 
can be considered as surrogate of inter-compartmental resistance. Increased peripheral 
vascular resistance index could not affect the urea removal, because urea is small in size 
and its kinetics is primarily flow controlled (Sub-section 2.3.4) [84]. Also, rapid 
equilibration of urea across the cell membrane is essentially due to facilitated transport by 
selective urea transporters [126]. This suggests that, even with vasoconstriction, urea can 
easily pass through the cellular membrane and its removal is not affected. However, the 
conclusion should not be extrapolated to other uremic toxins, and their removal may be 
compromised in cool dialysate.  
It is known that exercise increases the body core temperature due to increased oxygen 
uptake and increased metabolism in cells [127]. To decrease the body core temperature or 
to remove the accumulated heat, the blood flow to skin increases, and the person sweats. 
In the context of HD subjects under intra-dialytic exercise, this increased blood flow will 
mobilize toxins from remote compartments. However, there is no clinical study to 
investigate the effect of intra-dialytic exercise on body core temperature. It is 
hypothesized that exercise will increase the body core temperature, which will decrease 
the inter-compartmental resistance and result in increased toxin removal. To study change 
in peripheral vascular resistance index, patients were subjected to echocardiogram during 
the exercise session. 
4.3 Clinical Trial Design 
Following the preceding discussion, the proposed clinical trial was aimed to investigate 
the exercise induced physiological changes. The inter-compartmental resistance cannot be 
measured, and so change in peripheral resistance index is used as surrogate. The 






which is a non-invasive way to quantify the physiological changes (see Sub-section 
4.3.4). The specific aims of study are: 
1. Investigate the effect of intra-dialytic exercise on physiological changes, namely, 
decrease in inter-compartmental resistance, increase in CO, and increase in body 
core temperature due to exercise. The decrease in inter-compartmental clearance 
will be assessed by decrease in peripheral vascular resistance index. 
2. Investigate the effect of intra-dialytic exercise on removal of middle molecule 
marker toxin, β2-micorglobulin and compare the same with CHD and HDF. This 
is the first study to investigate the effect of exercise on β2-micorglobulin removal. 
The toxin removal outcome will be assessed by 2 hour post-dialysis % rebound. 
The rebound % will also be compared for conventional toxins: urea, creatinine, 
and phosphate. 
4.3.1 Study Design and Ethics Approval 
This study was single center, open label, self-controlled (within subject design), 
randomized prospective, efficacy study involving patients undergoing conventional high-
flux HD. Blinding is an important aspect for randomized study; this helps in preventing 
the investigator and subject bias. However, blinding was not feasible because the changes 
in conventional HD are immediately visible to both study subjects and investigators.  
The domain specific review board affiliated with the National Healthcare Group (NHG), 
Singapore has approved the trial. The study has undergone routine quality assurance 
review conducted by the ethics board. The ethics board also received timely progress 
status report and promptly informed of any adverse events owing to the intervention 






the National University Hospital (NUH), Singapore. The study is registered in 
ClinicalTrials.gov with trial registration NCT01674153. 
4.3.2 Patient Recruitment and Inclusion-Exclusion Criteria 
Patient safety is the uppermost in any clinical research. The inclusion-exclusion criteria 
ensure the uniformity of recruited subjects and minimize the occurrence of any adverse 
event during the conduct of clinical research. Before contacting the patients, existing 
patients’ database was reviewed for a number of conditions such as hemoglobin level and 
ejection fraction on prior test results, existing chronic obstructive pulmonary disease 
(COPD), angina, and history of heart-attack. All the study subjects have negligible 
residual renal function (defined by urine output < 200 mL/day). Potential subjects 
satisfying the above mentioned criteria were identified and subsequently contacted for 
preliminary tests where patients were explained about the study protocol, effectiveness of 
HDF, and intra-dialytic exercise. Agreed patients satisfying the inclusion-exclusion 
criteria signed the patient information sheet and consent form. A copy of signed form was 
given to the patients. Total of 15 subjects consented for the study. All study procedures 
followed the declaration of Helsinki and adhered to Good Clinical Practices (GCP) 
guidelines. Below is the list of all inclusion-exclusion criteria pre-defined in the research.  
Inclusion Criteria
1. Adult patients male or female (Age > 21 years) 
: 
2. Minimum dialysis vintage of 2 months 
3. Stable on hemodialysis 
4. Minimum Hemoglobin level of 10 g/dL 
5. Blood access capable of delivering the blood flow rate greater than 250 mL/min 






7. Desirable performance in 6-min walk test (6 MWT) 
Exclusion Criteria
1. History of recurring or persistent hypotension in the past 2 months 
: 
2. Pregnant woman 
3. Severely Hypertensive patients (systolic blood pressure > 180 mmHg and/or 
diastolic blood pressure > 115 mmHg) 
4. History of recent myocardial infarction or unstable angina (within the past 6 
months) 
5. Significant valvular disease, i.e. severe aortic stenosis and moderate-severe mitral 
regurgitation. 
6. Patients with end stage organ disease e.g. COPD, recent or debilitating 
cerebrovascular accident (CVA) 
7. Patient with recent stroke (within the past 6 months) 
8. Anemic patients 
9. History of known arrhythmia 
10. Participation in another clinical intervention trial 
11. Moderate to severe osteoarthritis of knee(s) 
12. Unable to consent 
The consented subjects were called for 6 MWT, which was performed according to the 
standard guidelines prescribed by American Thoracic Society [128]. This test has been 
considered as appropriate sub-maximum test to assess patient’s functional and 
physiological response, cardiovascular fitness, and suitability for intra-dialytic exercise in 
ESRD population [129]. Patients walked along a measured circuit (30 m), instructed to 






pressure (BP), heart rate (HR) and rate of perceived exertion (RPE) were assessed at pre- 
and post- 6 MWT. HR and RPE were measured at every minute of the test, as well as at 8 
and 10 min to assess heart rate recovery (HRR) and blood pressure. Patients who 
ambulated less than 300 m over 6 min were excluded from the test due to the likelihood 
that they may not tolerate the exercise protocol (described in Sub-section 4.3.4). Patients 
were also supposed to demonstrate acceptable physiological response during the test, e.g. 
HRR, hemodynamic parameters within safe guidelines for exercise. The 6 MWT was 
conducted by a trained physiotherapist. 
4.3.3 Study Interventions 
All recruited study subjects underwent three different study dialysis sessions, namely, 
HD, HDF, and HD with intra-dialytic exercise (HD-Ex) within a maximum time interval 
of 6 months between the first and last study session. Minimum one week gap was 
maintained between study sessions for each individual patient. The one-week gap should 
remove any carry-over effect of previous study session and bring the patients to their 
nominal toxin concentration level. High-flux HD was conducted as per the patient routine 
dialysis session; HDF was conducted with 18 L of target replacement fluid. Patients’ 
medications such as phosphate binder, medication for hypertension, erythropoietin dose, 
etc. were not changed during the study period. Patients were also advised to keep their 
diet fairly constant during the study period. The study sessions were conducted in mid-
week or end-week setting; however, study sessions for an individual subject were on the 
same day of the week. To avoid the effect of confounding factors, same dialysis 
conditions were used in all study dialysis sessions. 
The intra-dialytic exercise was conducted in conventional high-flux HD setting with 






second from 80–100 min, and third from 120–140 min. If patients were unable to adhere 
to the prescribed exercise intervention, then they were advised to perform a total of 60 
min exercise during the dialysis. The exercise was sustained till the achievement of 70% 
of maximum heart rate, and given via active cycling movement (ACM) using calibrated 
Monark 881E cycle ergometer (Monark, Sweden). The maximum heart rate is calculated 
by subtracting patient age from 220. Various hemodynamic responses, namely, heart rate, 
blood pressure, arterial and venous blood temperature were measured during all study 
sessions. Additional hemodynamic responses, namely, CO and peripheral vascular 
resistance index, were also assessed by measuring left ventricular stroke volume using 
Doppler echocardiography. The echocardiogram images were taken just before starting of 
HD-Ex session, before starting first bout of exercise, at 5-minute intervals during 
exercise, and after termination of first exercise bout. But they were not taken during the 
second and third bouts of exercise because similar cardiac responses were anticipated. 
Systemic vascular resistance and parameters of ventricular-arterial coupling were derived 
to determine the stroke volume response to exercise. The echocardiography was also used 
to assess cardiac structure and function before and during exercise – any new or 
unexpected abnormality, e.g. regional dysfunction. Any abnormality was recorded and 
best possible clinical judgment was taken to ensure patient safety. If during exercise, 
patient’s systolic blood pressure exceeds beyond 180 mm Hg, the patient was asked to 
stop exercise till the pressure attains the safe level of below 180 mm Hg. 
4.3.4 Data collection 
Blood sampling
Three arterial blood samples, namely, pre-dialysis (t = 0 min), end-dialysis (t = 240 min), 







was analyzed for uremic toxins, namely, urea, creatinine, phosphate, and β2M. The 
volume of each collected blood sample was ~4 mL. All the blood samples were sent to 
NUH clinical laboratory immediately after collection. These toxins/solutes concentrations 
were used for calculating the post-dialytic % rebound for each toxin. Conventionally, the 
blood samples are collected in tubes containing EDTA, which is a strong anticoagulant 
[74]. The anticoagulant prevents the blood clotting. This practice can plausibly equilibrate 
the toxin concentration between blood cells and plasma. However, as discussed earlier 
(Figure 3.5), dialysis process results in the concentration gradient between inaccessible 
cellular/interstitial compartments and accessible blood compartment. To prevent the 
concentration equilibration, all blood samples were collected in serum separator tubes 
(SST II), also referred as gold cap tubes. These tubes are coated with clot activator which 
expedites the blood clotting. The faster blood clotting prevents the equilibration of toxin 
among blood plasma and blood cells. The gel inside SST II tubes separates the blood 
plasma and blood cells, so that plasma extraction after centrifugation becomes relatively 
easier. 
Blood temperature monitoring
Arterial and venous blood temperature was continuously monitored using blood 
temperature monitor, abbreviated as BTM (Fresenius, Bad Homburg, Germany). As 
discussed earlier, intra-dialytic exercise will increase the body core temperature (Sub-
section 4.2.1). The dialysate temperature directly affects the blood temperature; hence, it 
was kept same for all three study sessions for each individual patient. The dialysate 
temperature was measured during HD-Ex session alone. During standard HD or HDF, the 
blood temperature change is insignificant (Figure 4.3); hence, during these sessions, 







presented in Figure 4.4. To maintain patient confidentiality, all the collected samples and 
data were assigned a unique study number. 
 
Figure 4.3 Blood temperature snapshot during HD session for two sample patients. In panel 
A, the kink in dialysate and venous temperatures is due to the measurement of access 
recirculation. 
4.4 Patient and Dialysis Information 
A total of 15 patients consented to participate in the study. Two patients could not fulfill 
the inclusion-exclusion criteria. Information pertaining to individual subjects who 
underwent the study intervention is provided in Table 4.1. Among 13 patients, one patient 
was prohibited to continue on HD-Ex session owing to poor baseline ejection fraction 
(25%); according to the inclusion-exclusion criteria, the baseline ejection fraction should 
be at least 50%. To prevent any adverse event, this particular patient was not allowed to 
undergo HD-Ex session. Hence, a total 38 study sessions were performed. Among the 12 
patients who completed all 3 study sessions, echocardiogram could not be performed for 






discussed in Sub-section 4.3.3 and blood samples were collected as per the protocol 
discussed in Sub-section 4.3.4.  
Table 4.1: Patient demographics at the time of consent 
Patient 
ID 
Gender Age Hemoglobin 
(mg/dL) 
Ejection fraction 
(on prior imaging) 
Distance covered 
in 6 MWT (m) 
P1 M 51 11.6 74 470 
P2 M 66.5 13.9 75 460 
P3 F 42 10.1 67 360 
P4 M 55 12.7 56 423 
P5 M 56 12.7 61 510 
P6 F 63 12.6 72 368 
P7 M 52 12 56 405 
P8 F 40.5 11.6 58 425 
P9 F 42 12.7 54 375 
P10 F 55 11.5 55 397 
P11 M 56 11.2 61 430 
P12 F 54 11.4 55 570 
P13 M 23 11.6 72 576 
Mean ± std 50.5 ± 11.3 12 ± 0.95 63 ± 8 % 444 ± 71 
All HD and HD-Ex sessions were conducted on Fresenius 4008S, and HDF sessions were 
performed on Gambro AK200. The dialyzer was same in all study sessions for an 
individual patient. All dialysis related parameters such as dialysate temperature, dialysate 
composition, were kept same in the study sessions of an individual patient to minimize 
the confounding factors. However, the ultrafiltration or fluid removal rate during each 
study session was calculated based on inter-dialytic weight gain, and was different for 
different sessions. It is assumed that excess fluid removal via ultrafiltration will 
insignificantly contribute towards toxin removal. The mean convective fluid volume in 







Figure 4.4: Schematic flow-chart of clinical trial 
Identify mobile subjects:
- Obtain list of mobile patients
- Access mobile patients’ existing clinical history
- Check for existing cardiovascular and/or 
orthopedic diseases
Explain to the identified subjects:
- Satisfying inclusion-exclusion criteria
- Information on intra-dialytic exercise and HDF
- Post-dialysis stay for 2 hours
- Blood sampling
- Echocardiogram in intra-dialytic exercise study
- Information about 6 min-walk-test 
- Report all relevant study results
Consent and 6 min-walk-test
- Obtain patient consent in the presence









of dialysis sessions 
– Study visit 1/2/3
3 study sessions per patient in random order
• High-flux Hemodialysis (HD)
• Hemodiafiltration (HDF)
• HD with intra-dialytic exercise (HD-Ex)
• Collection of arterial blood samples
• Analysis of collected samples for urea, 
creatinine, phosphate, sodium, potassium, and 
β2-microglobulin
• Perform ultrasound echocardiography (HD-Ex)






 Compare % rebound outcome
Secondary outcome measure
 Study change in peripheral vascular 






4.5 Results from the Clinical Study 
The toxin removal is adjudged by % rebound calculation. The mean % rebound in HD, 
HDF, and HD-Ex for uremic toxins: urea, creatinine, phosphate, and β2M are presented in 
Table 4.2. The rebound was calculated using pre-dialysis (t = 0 min), end-dialysis (t = 
240 min), and post-rebound (t = 360 min) plasma toxin concentration (equation 3.24). 
Table 4.2: Percentage rebound for each uremic toxin in different dialysis protocols 
Dialysis Protocol Urea Creatinine Phosphate β2-microglobulin 
HD 13.4 ± 3.3 22.7 ± 4.2 37 ± 8.1 29.1 ± 14.5 
HDF 14.4 ± 5.4 22.8 ± 4.5 23.5 ± 16.5 24.5 ± 3.0 
HD-Ex 13.5 ± 4.0 22.0 ± 3.6 52.1 ± 21.6 27.4 ± 5.9 
In Table 4.2, the mean % rebound results for HD corresponds to 12 patients. For one 
patient, the post-rebound sample was corrupted due to dilution while sampling blood. For 
HDF, phosphate rebound for one patient was negative because the post-dialysis phosphate 
concentration was lower than the end-dialysis concentration, which seems unrealistic. 
This was considered as wrong phosphate concentration measurement; thus the phosphate 
% rebound calculation in HDF is from 12 patients. Similarly, the % rebound presented for 
HD-Ex is based on 12 patients, as one patient was not allowed to continue with the 
exercise due to poor baseline ejection fraction. 
The blood temperature profiles during HD-Ex session are presented in Figure 4.5, where 
three peaks in arterial blood temperature can be observed. These three peaks correspond 
to three bouts of exercise. On the other hand, insignificant changes are seen in venous 
temperature. Small variations in venous temperature can be attributed to fluctuations in 






three peaks, rather four small peaks can be observed. This is because patient completed 
the prescribed exercise protocol in four bouts. The venous temperature for the same 
patient P6 is also perturbed due to unexpected change in dialysate temperature. The 
difference between maximum and minimum arterial temperature was 0.96 ± 0.23 °C. The 
variation denotes the inter-patient variability, i.e. each patient hemodynamic response is 
different to exercise intervention. Also the intensity of exercise was not controlled, and 
patients exercised at their comfort levels. 
The results for change in cardiac output and peripheral vascular resistance index for 
individual patients are presented in Figure 4.6. Although patients started the exercise bout 
at different times (Figure 4.5), it is assumed that all patients started their first exercise 
bout at 40 min during dialysis. This assumption is made to standardize the change in CO 
and resistance index for all patients. The mean increase in CO is 4.34 ± 1 L/min, while 
mean decrease in resistance index is 874 ± 272 dyn.s/cm5. The mean maximum-
percentage increase in CO is 106 ± 32%, with maximum and minimum increment being 
147% and 61%, respectively. Similarly, the mean maximum-percentage decrease in 







Figure 4.5: Arterial (red - -) and Venous (blue - -) blood temperature during HD-Ex session 

























































































































Figure 4.6: Patients' cardiac output and peripheral vascular resistance index during the first bout of exercise. In bottom panel, cardiac 
output and resistance index are presented as mean ± standard deviation.
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In this study, the toxin removal is adjudged by % rebound after dialysis. Comparison of 
% rebound in different dialysis protocols will prove the efficacy of one over another. It 
should be noted that magnitude of % rebound and time required for equilibration in body 
compartments can be different for different toxins, e.g. % rebound of large-sized toxins 
can be more pronounced due to slower diffusion of large-sized molecules. In this clinical 
study, it was assumed that toxins will equilibrate within two hours post-dialysis and 
rebound will recede thereafter. Comparing the urea rebound values in Table 4.2, it can be 
observed that mean % rebound is comparable among HD, HDF, and HD-Ex, except HDF 
results in slightly larger mean % rebound. These results suggest that urea removal is 
primarily controlled by diffusion and is not affected by convection, which is the 
augmented characteristic of HDF. The reason for slightly larger % urea rebound in HDF 
is unknown, but may be ascribed to interference between diffusion and convection [130]. 
Toxin removal via convection is dependent on fluid transport from blood to dialysate 
steam, i.e., it is independent of concentration gradient. Increased removal of fluid in HDF 
will plausibly move more urea into dialysate stream and decrease the urea concentration 
difference between blood and dialysate stream, and thus hamper the diffusive urea 
transport. The assumption in this argument is that there is sufficient amount of toxin in 
blood plasma compartment and there is no or insignificant resistance between 
physiological compartments. Urea conforms to this assumption because urea is small in 
size and inter-compartmental urea transport is boosted by urea transporters in cellular 
wall. For other small as well as large-sized uremic toxins, no such specific transporters 
exist on the cellular wall, and their removal is restricted by inter-compartmental 
resistance. This is evident from % rebound results for creatinine. The mean % rebound of 





lower for HD-Ex (22.0 %). The similar creatinine rebound from HD and HDF points out 
to the similar contribution of diffusion and convection towards creatinine removal from 
blood to dialysate stream. However, physiological resistance still plays the dominant role, 
which is reduced by exercise. The slight drop in creatinine rebound in HD-Ex can be 
associated with increased blood flow to remote peripheral compartments during exercise 
and decreased peripheral resistance, quantified by resistance index (Figure 4.6).  
The mean % rebound for β2M is lowest in HDF (24.5 %), which suggest that removal of 
large-sized toxins is significantly contributed by convection. At the same time, the mean 
% rebound of β2M in HD-Ex was 27.4 % which is lower than that obtained in HD 
(29.1%). This indicates that, even without convection (i.e., with diffusion alone), the % 
rebound can be reduced (i.e. toxin removal can be increased). These results suggests that 
exercise can not only augment the removal of small-sized toxins [120], but also has 
potential to increase the removal of large-sized uremic toxins. Comparing the toxin 
removal outcomes for urea, creatinine, and β2M, it can be inferred that urea removal in 
dialyzer is influenced by diffusion alone, creatinine removal is influenced by both 
diffusion and convection, and β2M removal is primarily influenced by convection. 
Interestingly, the mean % rebound for phosphate is significantly pronounced in HD-Ex 
(52.1%) than that obtained in HD (37%) and HDF (23.5%). Vaithilingam et al. have 
found that intra-dialytic exercise increases the phosphate removal [99]. The unexpected 
high phosphate rebound in the present clinical study can only be explained by 
significantly delayed mobilization of phosphate from bones or remote intracellular 
compartments, which manifests much after completion of dialysis. It is important to note 
that in this study, the first exercise bout was implemented on or after 40 min from the 
start of dialysis, but in the study of Vaithilingam et al. the exercise intervention was 





the phosphate removal, but delayed mobilization can be the root cause of pronounced 
rebound in this study. In other words, the post-dialytic wait of 2 hours is too small for 
complete equilibration of phosphate, i.e. the rebound of phosphate may be delayed by as 
much as 4 hours. In summary, to improve the phosphate removal, immediate pre-dialysis 
exercise intervention may be more helpful than the intra-dialytic exercise intervention. 
The important question then is whether this is true for all uremic toxins or only for 
phosphate whose kinetics is most complex among all studied uremic toxins [56, 69]? 
At the same time, the % rebound for phosphate is lowest in HDF, but prolonged HDF 
interventions could not decrease the pre-dialysis phosphate concentration than that 
obtained in high-flux HD [110]. If HDF reduces the phosphate rebound to such great 
extent as observed in this pilot study then why it does not reflect in reduced pre-dialysis 
serum phosphate concentration? This can be attributed to the fact that the efficacy of HDF 
is primarily restricted to blood compartment only [74]. During 4h dialysis, the HDF will 
plausibly decrease the plasma phosphate concentration to very low levels. Post-dialysis, 
the phosphate rebound does occur but the 2h rebound period may be too small to see the 
significant phosphate rebound. To further strengthen the above mentioned claims, more 
clinical studies should be designed where patients should be asked to wait for 4h post-
dialysis. However, this is difficult and inconvenient for many patients. The other method 
to adjudge the superiority of one dialysis protocol over another will be to collect the 
whole spent dialysis and analyze a representative sample for removal of total toxin mass. 
This is the first clinical study to investigate the effect of exercise on body core 
temperature. As hypothesized, the intra-dialytic exercise results in increase in body core 
temperature which was inferred from measured arterial blood temperature. In Figure 4.5, 
three distinct peaks can be observed which correspond to three successive bouts of 





exercise. Although all recruited patients were unconditioned to exercise, all of them were 
able to complete the 60 min exercise intervention without any adverse event requiring 
clinical intervention. The key reason for this is that the exercise protocol was performed 
at zero resistance, which was easily tolerated by this cohort of patients. The venous 
temperature is almost constant throughout the dialysis sessions (Figure 4.5), because inlet 
(arterial) blood comes in contact with dialysate which is at constant temperature. Within 
the length of dialyzer module, the heat transfer from inlet blood to dialysate stream will 
bring the outlet (venous) blood to the dialysate temperature. However, the venous blood 
temperature is always lower than the dialysate temperature. This is because, after exiting 
from the dialyzer, the venous blood circuit comes in contact with environmental 
temperature, which is much lower than the dialysate temperature. This environmental 
heat loss plausibly decreases the venous blood temperature below dialysate temperature. 
During HD-Ex session, patient’s cardiac output was also measured during the first bout of 
exercise using Doppler echocardiogram. As expected, the patient’s CO peaks during 
exercise intervention (Figure 4.6). At the same time, the vascular resistance index reached 
the nadir during exercise. The decrease in peripheral resistance index can be attributed to 
increased CO as well as increased blood core temperature, which results in increased 
blood flow to remote compartments so that the excess heat can be removed via skin. It 
remains unclear that between CO and temperature which one is the dominant factor for 
decreasing the peripheral resistance. Nevertheless, without delving into the contribution 
from individual factors, it is ascertained that exercise increases the body core temperature 
(besides cardiac output) and decreases the inter-compartmental resistance which 
eventually results in enhanced toxin removal. 
Notably, the baseline (t = 0) CO drops from 5.41 ± 0.97 L/min to 4.62 ± 1.19 L/min just 





This can be attributed to the reduced venous blood temperature, which is much lower than 
the arterial or systemic blood temperature (Figure 4.3). The systemic blood temperature 
decreases, when cooled venous blood mixes with the systemic circulation. To reconcile 
for this sudden decrease in blood temperature, the vasoconstriction occurs which reduces 
the blood flow to remote compartments or manifest in the form of decreased cardiac 
output. The vasoconstriction prevents the heat loss from skin or peripheral organs. 
Although increased body core temperature may lead to incidence of intra-dialytic 
hypotension, increased core temperature induces the blood flow to remote peripheral 
compartments so that the body core temperature can be reduced. In the process, the 
central blood volume decreases which can potentially result in IDH episode. The same 
principle is used to achieve the hemodynamic stability via cool dialysate. Nevertheless, in 
the present clinical tests, no episode of IDH requiring clinical intervention was 
experienced. This can be credited to the inclusion-exclusion criteria which prevented the 
IDH prone patients to participate in the clinical study. The IDH prone patients were 
prevented to participate because the objective here was to compare the physiological 
changes and toxin removal, rather than to test the compliance of IDH prone patients on 
exercise intervention. 
One should note that, among the four studied uremic toxins, % rebound is highest for 
phosphate. Although phosphate is much smaller in size than β2M, its rebound is much 
more pronounced. This is because phosphate is distributed in both IC and EC, but β2M is 
distributed in EC alone. Additionally, the phosphate mobilization can occur from 
pathologic stores of phosphate in bones. Following the model of Spalding et al. to explain 
phosphate kinetics [56], the phosphate mobilization need to overcome at least three 





physiological resistances – the first resistance when phosphate mobilizes from bone 
matrix to cellular compartment, the second resistance by cellular membrane when 
phosphate mobilizes from IC to EC, and the third resistance by capillary endothelium 
when phosphate mobilizes from interstitial space to accessible blood compartment. On 
the other hand, β2M, distributed in EC has to overcome only one resistance due to 
capillary endothelium. Multiple resistances delay the phosphate removal and eventually 
manifest in significantly high post-dialytic rebound. Although most uremic toxins do not 
behave like phosphate, these toxins are still distributed in both IC and EC, and experience 
at least two resistances by cellular membrane and by capillary endothelium. This 
questions the credibility of β2M being designated as potential marker toxin instead of 
conventional marker urea. Urea cannot be the marker because its removal kinetics does 
not even coincide with other small-sized uremic toxins [67]. At the same time, caution 
should be exercised before β2M is authoritatively accepted as the marker of toxin milieu. 
Historically, urea is considered as marker toxin because of its high plasma concentration 
and low cost of analysis, which seems to have played an important role in favoring urea 
as marker toxin [25]. Hence, not only the toxin distribution but also the cost of analysis 
should be considered while deciding a better representative of uremic toxins. 
4.7 Summary 
This is the first pilot clinical study to investigate the exercise induced physiological 
change(s) responsible for enhanced toxin removal. It is also perhaps the first one that 
compares the toxin removal outcome for both small and middle-sized toxins. The toxin 
removal outcomes are compared for HD, HDF, and HD-Ex. The urea rebound is higher in 
HDF, while creatinine rebound in HD-Ex is slightly lower than that obtained in HD or 
HDF. The β2M rebound is lowest for HDF, but HD-Ex still results in lower rebound than 





overcoming the inter-compartmental resistance rather than focusing on improvement of 
RRTs. The rebound for phosphate (true to its complex kinetics) was highest in HD-Ex, 
which is attributed to delayed mobilization of phosphate from remote bone matrix to 
blood compartment. Results demand for an optimal exercise intervention for enhancing 
the removal of phosphate as well as other uremic toxins. Note that the obtained results are 
based on single session study on patients unconditioned to exercise. With prolonged 
exercise intervention, it can be hypothesized that intra-dialytic exercise will culminate in 
improved physical function or improved performance towards exercise. Patients will be 
able to tolerate higher resistance exercise protocol which will further increase the toxin 
removal. Long term clinical studies comparing the toxin removal in HDF and HD-Ex are 
required to test the proposed hypotheses. With the obtained results, it can be proposed 
that exercise during HDF can improve the removal of both small and large uremic toxins. 
The present clinical study also proves that exercise intervention not only increases the 
cardiac output but also increases the body core temperature which potentially decreases 
the vascular resistance. Note that the decrease in vascular resistance is only an indication 
towards reduced cellular resistance. It is impossible to measure the changes in inter-
compartmental resistance. To quantify the decrease in compartmental resistance, 
previously discussed diffusion adjusted regional blood flow model (Chapter 3) can be 
employed. The increase in inter-compartmental clearance (Kip, model parameter) can 
quantify the decrease in inter-compartmental resistance. This requires the precise 
estimation of Kip, which requires appropriate experimental data. The next part of the 
thesis deals with experimental design aspects that lead to enhancing the precision of 
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5. Multi-Objective Framework for Model-based Design of 
Experiment Techniques§
Conflict is the beginning of consciousness. 
 
- Mary Esther Harding 
In Part 1, a comprehensive toxin kinetic model for β2-microglobulin was proposed. The 
model was subsequently employed to explain the effect of exercise and new hypotheses 
were proposed. To test the hypotheses, a pilot clinical study was carried out. The clinical 
study validated the hypotheses that exercise during dialysis increases the toxin removal 
by decreasing the inter-compartmental resistance. It also appears that decrease in inter-
compartmental resistance is not only due to increased cardiac output which dilates the 
vasculature but also due to increased body core temperature which further dilates the 
vasculature. However, the clinical study did not quantify the decrease in inter-
compartmental resistance. Quantifying the decrease in this resistance can provide a better 
understanding of exercise induced physiological changes and pave way for personalized 
prescription of intra-dialytic exercise. The model parameter Kip that characterizes the 
inter-compartmental clearance can quantify the decrease in this compartmental resistance. 
To estimate Kip, blood samples need to be collected. The important question addressed in 
Part 2 of this thesis is related to the timing of collection of those samples so that Kip and 
other model parameters can be precisely estimated. Towards this end, model-based design 
of experiment (MBDOE) techniques can play an important role.  
Before getting into the implementation details of MBDOE techniques for elucidating the 
optimal HD sampling protocol, the importance of experiments and MBDOE paradigm are 
                                                 
§The contents of this chapter have been published in: Vaibhav Maheshwari, Gade Pandu Rangaiah, 
Lakshminarayanan Samavedham, Multi-objective framework for model-based design of experiments to 
improve parameter precision and minimize parameter correlation, Industrial and Engineering Chemistry 





reviewed. It is observed that existing MBDOE techniques such as D-, A-, and E-optimal 
designs have inherent drawbacks, which can potentially lead to poor precision of model 
parameters and so defeats the objective of optimal experimental design. To overcome 
these drawbacks, a new strategy is proposed and evaluated on two case studies. 
5.1 Mathematical Models and Experiment 
Mathematical models for processes form the foundation for their performance 
improvement through optimization, control of product quality within pre-specified limits, 
developing soft sensors for predicting and monitoring “difficult to measure” states, in 
silico testing of new strategies, and/or for the development of new products/processes. 
Success of all these activities relies significantly on precise and accurate description of 
the system in the form of mathematical equations. Therefore, building a high-fidelity 
model is a crucial step before employing the model as a proxy to the real system. 
Model building can be regarded as an iterative process: starting with the objective of 
model building, followed by a priori process knowledge in the form of physical, 
chemical, or biological laws governing the system, preliminary tests, and initial 
hypotheses; then a model structure in the form of algebraic equations (AEs), differential-
algebraic equations (DAEs), or partial differential equations (PDEs), is decided. This will 
culminate in one or more model structures, which invariably contain adjustable model 
parameters. Selecting the most appropriate model out of all proposed models requires a 
maximally discriminating experiment; this aspect is studied under the category of 
experimental design for model discrimination. Once the appropriate model is selected, 
parameter estimation (also known as model calibration) is compulsory before using the 
model, because a mathematical model is only as good as its estimated parameters [131]. 
For estimating the model parameters, experiments need to be conducted. Experiments 




require resources, time, and money. Hence it is imperative that intelligent experiments are 
designed for estimating the model parameters. 
To obtain maximum information from limited resources, MBDOE techniques continues 
to play a pivotal role, and serve as a vital link between the modeling and experimental 
worlds. Informative data collected after such intelligent experiment(s) is used for model 
parameter estimation or for improving the precision of weakly known parameters. 
Subsequently, statistical validity of parameters must be checked, and if not satisfied, the 
DOE procedure is successively iterated. A schematic of the process of model 
development is shown in Figure 5.1, where two MBDOE perspectives, namely, design of 
experiments for model discrimination and design of experiments for precise parameter 
estimation are portrayed. In this work, the focus is on DOE for parameter estimation, and 
specifically on overcoming the drawbacks of traditional MBDOE techniques 
Initially, MBDOE methodology was considered only for steady-state algebraic systems. 
Following this, researchers have successfully extended the concepts to dynamic systems, 
with applications in chemical kinetics [132], crystallization [133], systems biology [134-
136], fermentation processes [137, 138], heat/mass transfer [139], etc. For more details 
and applications, readers are referred to the state-of-the-art review on MBDOE practices 
[140]. Along with these existing and emerging applications, research focus has been on 
improving the DOE methods by proposing new objectives [141] and new approaches 
[142]. 
All MBDOE problems culminate in an optimization problem; however, solving the 
optimization problems can be difficult in systems with significant parameter interactions. 
Often large correlation among model parameters is noticed, unless one resorts to properly 





or consecutive steps are examples of kinetic models recognized as systems with highly 
correlated model parameters that pose challenges to successful experimental design and 
subsequent parameter identification [140, 145]. The objective of DOE techniques is to 
devise intelligent experiments such that the resulting experimental data can provide 
parameter estimates of improved statistical quality measured in terms of parameter 
precision and de-correlation [138, 146]. 
 
Figure 5.1: Schematic of model development following the principles of model-based design 
of experiments techniques 
Existing MBDOE techniques that employ D-, A-, E-optimality criteria (discussed in 
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precision, but overlook the parameter de-correlation. The increase in information content 
of the data often comes at the cost of increased correlation among parameters, which can 
lead to incorrect and imprecise point estimates of parameters; this violates the inherent 
objective of existing experiment design techniques [144, 147, 148]. To overcome the 
problem of correlated parameters, anti-correlation based formulations have been proposed 
and their successful applications have been reported [144, 149, 150]. 
This work here presents a distinct approach to overcome the correlation among 
parameters; essentially, we propose a multi-objective optimization (MOO) based DOE 
framework that considers two conflicting objectives: maximize the information measure 
and minimize the correlation among parameters. With this approach, a trade-off between 
conflicting objectives (in the form of Pareto-optimal front) is obtained; this can suggest 
the optimal experiment depending on the permissible trade-off. MOO based experimental 
design techniques have also been discussed earlier with the focus on reaping the benefit 
of multiple alphabetical designs, and overcoming their drawbacks [137, 146]. Here, we 
aim to overcome the drawback(s) of individual optimal experimental design technique by 
simultaneously de-correlating the parameters and maximizing the information for 
parameter estimation. 
In the next section, a brief overview of various MBDOE techniques is presented. 
Subsequently, the correlation aspect among model parameters and the associated issues 
are also outlined in Section 5.3. The proposed MOO based formulations and the solution 
techniques employed are described in Sections 5.4 and 5.5, respectively. In Section 5.6, 
two case studies, namely, the modified Bergman Minimal model for Type 1 diabetes 
subjects and the Baker’s yeast fermentation reactor model are employed to apply the 





traditional alphabetical designs. The chapter ends with discussion and summary presented 
in Sections 5.7 and 5.8, respectively. 
5.2 Mathematics of MBDOE 
MBDOE techniques are formal and statistically well-founded procedures to select the 
best experimental settings corresponding to maximum information under pre-defined 
operational constraints. Their goal is to assist in rapid development, refinement, and 
statistical validation of process models. As the name suggests, a mathematical model 
structure with possibly imprecisely known parameters is an indispensable requirement of 
MBDOE techniques. In this work, a general deterministic, non-linear dynamic model, 
described by DAEs is considered. A DAE model can be described as follows: 
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time derivative of system states (t)x , (t)u  is the vector of time-varying control or 
manipulated variables in the process, θ is the p-dimensional vector of parameters to be 
estimated, f is the neq-dimensional set of DAEs, y  is the vector of measured response 
variables that are function of state variables (t)x , ( (t))h x  are the known functions that 
relates system states to the measured response variables. In most cases, ( (t))h x is simply 
a selector function, i.e. some or all of the system states are measured. An experiment is 
defined by the vector of initial conditions 0(t ) (0)=x x , control moves and corresponding 
switch time for (t)u , and sampling instances within the experiment duration. 
At this stage, MBDOE techniques focus on identifying the experiment(s) which will 
result in maximally informative data for estimating unknown model parameters with high 




degree of precision. Hence, before collecting the data, based on the current mathematical 
description of the process, in silico experiment(s) is/are designed, where the objective is 
to adjust the available manipulated inputs so as to minimize the effect of errors on 
estimated values of parameters, i.e. to make the output as ‘sensitive’ as possible to the 
parameters. Data collected from the implementation of such optimal experiment(s) is used 
for parameter estimation of process model under consideration. Factors such as the initial 
condition for various states in the process, the experiment duration, sampling instances, 
how and when the system should be perturbed, which manipulated variable(s) should be 
perturbed, the best sensor locations, etc. can be the decision variables that are decided 
based on the optimal solution of experimental design problem. All the decision variables 
are collected in a design vector ϕ, subjected to equality or inequality constraints defining 
the pre-specified operational restrictions in mathematical form. Each decision variable is 
bounded between the pre-set lower and upper bounds, constituting the design space (Φ). 
In addition to the operational constraints, an experiment may also involve system 
constraints which must be satisfied whilst designing the optimal experiment. 
Characteristically, given the initial model structure and initial guess for its parameters, the 
aim of the classical DOE approaches is to minimize the parameter variance or minimize 
the parameter confidence interval i.e. to make the elements of parameter variance-
covariance matrix small. A typical experiment design thus involves minimizing a metric 
of variance-covariance matrix (V), or maximizing that of its inverse, the Fisher 
Information Matrix (FIM). Mathematically, 
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where ijσ  is the (i,j)
th element of inverse of variance-covariance matrix of experimental 
measurements, yn is the number of measured states (outputs), 0FIM  is prior FIM from 
previous experiment(s), (used in sequential experiment design). Gi is s×p matrix of first 
order sensitivity coefficients at ith measured state at spn sampling instances, 
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Various real-valued functions are used to quantify the FIM or variance-covariance matrix 
into a scalar metric. All of them essentially focus on the eigenvalue(s) of FIM. The most 
common criteria include: 
1. D-optimality criterion maximizes the determinant (product of eigenvalues) of FIM, 
or equivalently, minimizes the determinant of the variance-covariance matrix. 
2. A-optimality criterion maximizes the trace (sum of eigenvalues) of FIM, or 
equivalently, minimizes the trace of variance-covariance matrix. 
3. E-optimality criterion aims to maximize the smallest eigenvalue of FIM, or 
equivalently, minimizes the largest eigenvalue of variance-covariance matrix. 
The geometrical interpretation of these criteria is provided in Figure 5.2. A distinct 
interpretation is that A- and D-optimal designs minimize the arithmetic and geometric 
mean of the identification errors, respectively, whereas the E-optimal design minimizes 
the largest error [146]. 





Figure 5.2: Geometrical interpretation of the D-, A-, and E-optimal design for two 
parameters 
Though FIM based criteria are frequently discussed in the literature, their inherent 
limitations are also known. FIM is based on local first-order approximation, obtained 
from the Taylor series approximation of expectation function [140], and thus apply only 
approximately to non-linear systems and may not be applicable for highly non-linear 
systems [151]. Notwithstanding this, only the joint confidence region based on linear 
approximation of FIM is considered here, as is the common practice in MBDOE literature 
[135, 140, 141, 144]. Alternatively, other approaches like bootstrap, jackknife, or Monte 
Carlo simulations can be employed to characterize the uncertainty in estimated 
parameters, but with associated high computational costs [152]. 
5.3 Parameter correlation 
As mentioned earlier, the purpose of MBDOE approaches is to devise the intelligent 
experiments such that the parameters estimates from the resulting experimental data are 
of improved statistical quality, measured in terms of precision and de-correlation of 
estimated parameters [139]. Traditional designs aim at maximizing the information 
content in experimental data, resulting in improved precision of parameter estimates, 
which is usually judged by a t-test [151]. However, the statistical quality of parameter 
estimates cannot be decided by precision measure alone; correlation among different 
model parameters should also be taken into consideration, as high parameter correlation 
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afflicts the inverse problem of parameter identification [140, 145]. Interestingly, the 
conventional objective of increasing the information measure alone inadvertently 
increases the parameter correlation [144, 147]. Correlation among parameters can 
potentially lead to convergence problems while estimating parameters [146]. Owing to 
the correlation, change in one parameter can be offset by the change in other(s), leading 
to the situation where various parameter combinations result in comparable values of the 
objective function [146, 152, 153]. This poses problems for optimization algorithms 
because no definite direction can be found in which the objective function value will 
improve, leading to premature convergence of the optimization algorithm [146]. This 
makes the unique identification of model parameters difficult, or even leads to inaccurate 
estimates of parameters [138]. Correlation can reduce parameter precision despite good 
experimental design and/or increased number of samples [147]. 
Correlation in parameters can manifest due to model structure (structural identifiability 
issue) and/or due to noisy/sparse experimental data (practical identifiability issue) [152]. 
A model is structurally identifiable when under the condition of noise-free infinite 
observations, one is able to uniquely identify the model parameters; otherwise, the model 
is structurally unidentifiable. Existing solutions to overcome the structural unidenfiability 
or structural correlation are model re-parameterization [147], parameter separation [154], 
or redefining the model structure. Structural identifiability of a model does not guarantee 
the unique identification of model parameters using real experimental data. The 
identifiability issue owing to experimental data is addressed under practical 
identifiability, which enables evaluation of the possibility of finding unique values of 
parameters from the available experimental data. Here, the application of MBDOE 
techniques can be very useful. Both identifiability aspects can be understood from the 
simple algebraic models (equation 5.5). 















In the first model, estimation of the parameter combination i.e. 1 2k k is possible from 
suitable experimental data, but individual estimation of 1k  and 2k  is impossible even 
with infinite samples. Hence, the model is structurally unidentifiable. On the other hand, 
in the second model, it seems that both the parameters can be estimated uniquely. 
However, for very small ‘ 2xk ’ values, 2
x
21 e x
k k−− ≈  and model 2 reduces to model 1, 
which we know to be structurally unidentifiable. Thus, to estimate both the parameters in 
model 2, samples should be collected for appropriate values of ‘x’. This renders model 2 
an example where parameter correlation issues can arise owing to poor experimental data. 
The issue can, however, be dealt with using intelligent experimental design. It may be 
relatively easier to detect the practical/structural correlation for algebraic systems, but 
such insights are difficult to obtain for dynamic systems [153]. 
Whilst researchers have discussed the issue of parameter correlation, only a few studies 
have investigated the problem in detail and proposed solutions. The D-optimal design can 
both reduce the parameter correlation and improve the parameter precision for two-
parameter systems, but the approach cannot be extended to model systems with three or 
more parameters [140]. Modified E-optimal design, where the objective is to minimize 
the condition number (ratio of maximum and minimum eigenvalues of the FIM), has also 
been suggested for reducing parameter correlation [144]. Again, similar to the D-optimal 
criterion, the method is effective for two-parameter systems only. A promising solution to 
reduce the parameter correlation was proposed by Pritchard and Bacon [145], who instead 
of opting for traditional maximization of a metric of FIM, explicitly considered an 


















∑  (5.6) 
where ijr  corresponds to thij  correlation element of correlation matrix. The approach was 
successful in reducing the parameter correlation, but at the expense of wider confidence 
interval for the individual parameters [147, 155]. Recently, Franceschini and Macchietto 
proposed a solution to this problem [144]; they introduced anti-correlation (AC) design 
criteria and proposed four different criteria. All four criteria considered an objective 
function either for minimizing correlation or for maximizing information in eigenvalue(s) 
of FIM, with constraints on eigenvalues or correlation elements, respectively [144]. An 
algorithm and a priori model analysis for implementing the AC design criteria were also 
suggested [150]. Subsequently, the AC criteria were validated on an experimental bio-
diesel process [149]. In this work, we propose a distinct approach, namely, MOO based 
DOE framework, to overcome the correlation among parameters. 
5.4 Multi-Objective Optimization based DOE framework 
As mentioned earlier, traditional alphabetical designs may improve parameter precision, 
but could result in higher correlation among parameters. Hence, there is a trade-off 
between improvement in parameter precision and increase in parameter correlation. 
Acknowledging this fact, we propose an MOO framework by considering two objectives: 
maximize information for improving parameter estimation (as in traditional alphabetical 
designs) and minimize the correlation among parameters, simultaneously. For each 
alphabetical design, its complementary MOO based design is proposed. Essentially, three 
different MOO based designs – DMOO, AMOO, and EMOO are considered. In the 
proposed MOO framework, the correlation matrix (R) is calculated from variance-
covariance matrix (V), 
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where ijV  and ijr  are the thij  element of matrix V and R, characterizing the covariance 
and correlation between thi  and thj  parameters, respectively. For i = j, ijV  will be the 
diagonal element of variance-covariance matrix and corresponds to variance of thi  
parameter. SSE is the sum of squared errors between model predictions and 
corresponding experimental data for obtained experimental design, and DOF corresponds 
to degrees of freedom, calculated as the difference between total number of data samples 
and number of estimated parameters.  
The correlation matrix is symmetric with principal diagonal elements as one. The 
objective function for minimizing the correlation is denoted as R . For a three parameter 
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In equation 5.12, minλ denotes the minimum eigenvalue of FIM. The second objective in 
the above MOO formulations (equations 5.10 to 5.12) is one of the many possible ways 
of minimizing parameter correlation. One other approach is to minimize specific 
correlation elements larger than a pre-specified limit [144]. However, care should be 
taken to ensure that minimizing one correlation element will not result in increasing other 
correlation(s). While the MOO framework can handle more than two objectives, scope of 
the present work is restricted to two objectives only.  
5.5 Solution Approach (Genetic algorithm) 
Non-dominated sorting genetic algorithm (NSGA-II) based solver (NGPM) available at 
MATLAB Central [156], is used for solving the formulated optimization problems. 
Genetic algorithm (GA) is a stochastic global optimization method that mimics the 
process of natural biological evolution. It repeatedly modifies a population of individual 
solutions. At each step, the GA selects individuals from the current population to be 
parents and uses them to produce children for the next generation. Three main rules are 
applied at each step for producing the improved population. (1) Selection rule to select 
better individuals that contribute to the population at the next generation. These 
individuals are also called Parents. (2) Crossover rule to combine two randomly chosen 
parents to form children. (3) Mutation rule that applies random change to the children, to 
form the population for the next generation. Over successive generations, the population 
advances towards an optimal solution [157]. NSGA-II is an adaptation of GA for multiple 
objectives. Solution of an MOO problem by this algorithm gives many equally good 
optimal solutions. Set of these non-dominated solutions is also known as the Pareto-




optimal solutions or front [158]. Selection of an optimal point from the obtained Pareto-
optimal front depends on the desired trade-off between the conflicting objectives. In our 
case, each Pareto-optimal solution corresponds to trade-off between information and 
correlation measure, and an optimal experiment design. 
A factor to note here is the computationally intensive nature of GA. Owing to the number 
of function evaluations, the GA requires longer time to reach to the optima. For large 
complex systems, the GA can be time-consuming. A simple approach to alleviate the 
problem is to use a hybrid approach that combines stochastic and deterministic algorithms 
[146]. Another plausible approach is to use appropriate termination criteria [158]. Since 
the primary focus of this work is on the benefits of MOO in DOE, we leave out further 
discussion on the computational aspects of GA. 
5.6 Case Studies 
To illustrate the effectiveness and applicability of the proposed MOO based DOE 
framework, two case studies are considered. In both the case studies, D-, A-, E-optimal 
designs, and their corresponding MOO based designs are compared. Experimental data 
are simulated using true values of parameters (known a priori as this is a simulation 
study) and inputs recommended by the chosen optimal experimental design. Normally 
distributed random errors with pre-specified error variance-covariance matrix are added 
to the simulated data to mimic, as close as possible, the characteristics of real data. The 
extreme point in the Pareto-optimal front, corresponding to maximum information–
maximum correlation, belongs to alphabetical design, while the other extreme 
corresponding to minimum information–minimum correlation can be considered 
equivalent to Pritchard and Bacon criterion (equation 5.6). Between these two extremes, 





method and rough set method can be employed for ranking Pareto optimal solutions and 
selection [159]; however, these methods require preferences from the decision maker 
(here, experimenter/modeler). Since the scope of this work is limited to illustration of 
conflicting objectives in traditional DOE techniques, a relatively simple way of Pareto-
point selection is employed. In the case studies discussed, the optimal trade-off for MOO 
based design and corresponding design vector are selected after transforming the obtained 
Pareto-optimal front to 0 to 1 scaled Pareto-optimal front. The optimal trade-off is 
selected such that the percentage decrease in information measure is less than the 
percentage decrease in correlation measure. The trade-off selection is obvious when there 
is significant loss in correlation measure, but little loss in information measure, e.g. see 
Figure 5.8. On the other hand, for not so obvious cases, the selection is based on 
eyeballing the obtained Pareto-optimal front. 
 
Figure 5.3: Schematic representation of trade-off between information measure and 
correlation measure. Between the two extremes of alphabetical (D-, A-, E-) design criterion 
and Pritchard and Bacon criterion, experimenter has freedom to select appropriate optimal 
experiment design from the Pareto-optimal front. Star is one chosen design for illustration. 
After implementation of the selected experiment design, model parameters are estimated 
and their confidence intervals calculated. The t-value can indicate the reliable estimation 
[151]: 
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t θ=  (5.13) 
The obtained t-value for individual parameters is tested against reference t-distribution for 
n –p DOF; a t-value higher than the reference indicates that the estimate is reliable. Figure 
5.4 provides a detailed flow-sheet of the approach followed here.  
 
Figure 5.4: Schematic of the design procedure followed in the case studies 
The procedure can be iterated until the obtained point estimates are close to those in the 
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reduced correlation. Next, the case studies with their brief description, model equations, 
and corresponding results are presented. In both the case studies, the manipulated variable 
trajectory is parameterized as piecewise constant elements. The adopted piecewise 
constant trajectory has been found to give best experimental results, and also preferred 
from the operational point of view because it is easier to implement in practice [157]. 
5.6.1 Modified Bergman minimal model for Type 1 diabetes subjects 
A model describing glucose-insulin kinetics in Type 1 diabetics is considered. Diabetes, a 
disease of endocrine malfunction, is one of the most prevalent lifestyle diseases resulting 
in significantly increased mortality and morbidities. A diabetic subject is either non-
responsive to insulin secreted by the pancreatic cells or the insulin secretion is 
insufficient. Insulin deficient subjects are considered as Type 1 diabetes patients, and they 
depend on exogenous insulin infusion for maintaining the blood glucose at acceptable 
levels. In such patients, an optimal insulin infusion is required to maintain the glucose 
level within permissible limits. This can be obtained by employing an appropriate 
mathematical model that mimics the glucose-insulin dynamics in Type 1 diabetes patients 
[160]. In this work, the modified Bergman minimal model having three parameters is 
considered [161]. The model, earlier used in backoff based MBDOE [162], is given by 
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 (5.14) 
Here, G, X, and I represent the serum glucose concentration (mg/dL), the insulin 
concentration in non-accessible compartment (mU/L), and the serum insulin 




concentration (mU/L) above their basal values, respectively. Basal glucose concentration 
(Gb = 81 mg/dL), basal insulin concentration (Ib = 15 mU/L), insulin distribution volume 
(VI = 12 L), glucose distribution volume (VG = 16 L), and disappearance rate of insulin (n 
= 5/54 min-1) are constant parameters in the model; and u(t) is the rate of infusion of 
exogenous insulin (mU/min). The unknown model parameters are 1θ , 2θ  and 3θ . In 












=  (5.15) 
where 'A' is the amount of carbohydrates (CHO) in the meal (fixed at 75 g in this study), 
max 40mint =  is the time required to reach the maximum glucose concentration in the 
accessible compartment, f is the dimensionless factor which represents the fraction of 
CHO being absorbed (here, f = 0.8). The meal model suggests that ingested meal does not 
alter the glucose concentration immediately; rather, there is a lag between food ingestion 
and subsequent manifestation of glucose concentration in the blood serum. 
The exogenous insulin infusion, u(t), is expressed as: 
 bolus basal(t)u u u= +  (5.16) 
Here, bolusu  represents the subcutaneous bolus insulin kinetics for a bolus Ub (see equation 
5.17), given at the start of experiment (at t = 0). This subcutaneous insulin dose 
compensates for CHO ingestion in a "feed-forward" manner. In this in silico experiment, 
the time of CHO intake is decided by the experimenter, and it can vary between 2 to 30 

















where 50T  is the time required to reach 50% absorption of the bolus insulin. 50T is given 
by, 
 50 bT aU b= +  (5.18) 
In equations 5.17 and 5.18, the parameters a, b, and s depend on insulin type. For 
Humalog insulin, a, b, and s are 5.2 min/U, 41 min, and 1.6, respectively [166].  
In equation 5.16, basalu is time varying basal insulin infusion, approximated by a piecewise 
constant profile. The proposed clinical test is an adaptation of oral glucose tolerance test 
(OGTT), which is routinely conducted in clinical settings for measuing the glucose-
insulin sensitivity of Type 1 diabetes subjects. In OGTT, following the measurement of 
fasting glucose concentration, the patient ingests 75g of CHO. Subsequently, glucose 
measurements at 60 min and 120 min are taken. This test is not informative enough to 
give data for estimation of unknown model parameters. Hence, a modified OGTT is 
proposed here, which is similar to the one proposed by Galvanin et al. [162], with the 
only difference being that the experimental duration is restricted to a maximum of 300 
min. Also, only five piecewise constant moves are assumed for basal insulin infusion. 
The experimental design objective is to suggest optimal basal insulin infusion profile, 
amount of bolus dose at t = 0, time of meal ingestion, and corresponding blood glucose 
measurement instances which will result in information-rich data for precise estimation of 
θ1, θ2, and θ3, while ensuring that the correlation among estimated parameters is as low as 
possible. The experiment duration is decided based on the last sampling instance. Table 
5.1 lists all the design variables with their lower and upper bounds, and initial guess. 
 




Table 5.1: Design variables, their bounds, and initial guess for the proposed clinical test for 
Type 1 diabetes subjects 





Bolus insulin dose (mU) bU  0 10000 1000 
CHO ingestion time At 2 30 5 
Basal insulin (mU/min) basalu  16.67 300 [200, 100, 200, 0, 150] 
Switch time for basalu  s1t  10 300 [20, 10, 30, 25] 
Sampling instances (min) tsp 10 300 [20, 50, 70, 80, 95, 115, 140, 150, 162] 
The lower bound for exogenous basal insulin is fixed at 16.67 mU/min such that the 
blood glucose concentration is maintained at its basal value (81 mg/dL). Several 
operational constraints considered in this work are mentioned below.  
1. A total of 10 blood samples (including sample at t = 0) are taken for measuring 
glucose concentration [167]. 
2. Consecutive blood samples should have a minimum time interval of 10 min. The 
maximum allowed time interval between consecutive samples is 300 min, which is 
also the maximum allowed experiment duration. The last sampling instance 
decides the duration of clinical test. 
3. Minimum 10 min interval is mandated between two consecutive switches of basal 
insulin infusion rates. Similar to the sampling constraints, the maximum switching 
time is also constrained to be within 300 min. 
The proposed experimental design results in 20 decision variables and 22 linear 
constraints besides the model equations and physiological constraints, resulting in a fairly 
challenging optimization problem – a frequent situation for generic MBDOE 
implementation [141]. An intuitive approach of reducing the number of constraints is 





design variables, we considered time intervals as design variables, each bounded in [10, 
300]. This reduced the number of linear constraints from 22 in original optimization 
problem to just 2 in the modified optimization problem. Both optimization problems are 
essentially equivalent, but the latter is computationally more tractable than the original. 
The modification is schematically shown for basal insulin in Figure 5.5. Similar 
transformation is realized for sampling time instants.  
 
Figure 5.5: Transformation of exact time-instants into delta-time instants 
The transformation of constraints into bounds is illustrated in Table 5.2. The 22 
constraints in the original formulation are transformed into 2 constraints in the modified 
formulation. The switching constraint for last control move (ui5 in Figure 5.5B) is 
considered to ensure that it stays for at least 10 minutes (lower bound for each control 





























Table 5.2: Transformation of constraints into bounds 
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The problem of designing the clinical test is further complicated due to additional 
physiological constraints. The function of insulin is to maintain the glucose concentration 
within the window of 60-120 mg/dL. However, in diabetic patients, the upper limit is 
relaxed to a value such as 160 mg/dL [168]. Patients are categorized as having 
experienced a hyperglycemic episode if they exceed 160 mg/dL glucose limit; in a similar 
fashion, a hypoglycemic episode is said to occur when the patient’s blood glucose 
concentration goes below 60 mg/dL [168]. Hypoglycemia is more dangerous than 
hyperglycemia because it can result in coma or even death, thus the lower limit of 60 
mg/dL may be considered as hard constraint and the upper limit of 160 mg/dL may be 
regarded as soft constraint. However, for simplicity, both are considered as hard 
constraints in the present simulation study. These physiological constraints are handled 
using penalty function method [158]. In this approach, first the constraints are scaled and 
constraint violation pertaining to hypo- and hyperglycemia for each experimental design 
is calculated. The total violation is multiplied with a large weight and then added to each 
objective. The penalty weight is decided based on the objective function value for 





In the present simulation study, true parameters -5true  = [0.025, 0.015, 1.26 10 ]θ ×  are used 
in the patient model to generate the patient data for optimal experimental conditions. A 
constant relative variance of 0.01 is added to incorporate the real-world noise 
characteristics in glucose measurements. The initial parameter guess for designing the 
experiment is considered at 25% positive deviation from true parameter values. They 
were assumed equidistant from true parameter values so that obtained estimates and their 
precision characteristics cannot be attributed to better/worse initial guess [144]. Note that, 
the resulting experiment when implemented on real subjects can still violate the 
permissible glucose limits due to patient-model mismatch. To prevent such undesirable 
events, a conservative design approach has been considered in this work where the hypo- 
and hyperglycemia limits are set at 65 and 150 mg/dL, respectively. This conservative 
design may result in less information because functional value space is constrained; 
however, computationally intensive robust experimental design methods such as expected 
value criterion, min-max optimization [148] or backoff based technique for experiment 
design [162], can overcome this problem. The robust experimental design criteria can be 
incorporated in the proposed MOO based DOE framework, and will be explored in our 
future work. 
Traditional vs. MOO based DOE: In the simulations below, the alphabetical design (D-, 
A-, and E-) and corresponding MOO based design are compared. The results for 
alphabetical design typically correspond to the extreme Pareto-optimal point for 
maximum information–maximum correlation, while MOO based design refers to a 
chosen experimental design from the obtained Pareto-optimal front. First, the comparison 
of D-optimal and DMOO design is presented – the Pareto-optimal front for DMOO based 
design (Figure 5.6), the schematic of D-optimal design and the chosen DMOO based 
experimental design (Figure 5.7), followed by the parameter estimates for both the 




designs (Table 5.3). Similar sequence is followed for comparing simulation results for A-
optimal vs. AMOO design and E-optimal vs. EMOO design. In the Pareto-optimal fronts 
for DMOO, AMOO, and EMOO designs (Figure 5.6, 5.8, and 5.10), the data-tip (X,Y) 
corresponds to the selected optimal trade-off for implementation. 
Note that FIM is based on sensitivity coefficient (equation 5.4), which is dependent on 
initial guesses of parameters. The sensitivity coefficients based FIM may provide 
misleading experimental design due to order of magnitude difference in model 
parameters; hence, parameter-scaled sensitivity is considered for FIM calculation [169]. 









In equation 5.19, i, j, and s are the indices of measured state (Glucose), parameters (j = 1, 
2, 3), and sampling instances (s = 1, 2, 3…, 10), respectively. 
 
Figure 5.6: Pareto-optimal front for DMOO design 


































Figure 5.7: Time profiles of basal insulin infusion and blood glucose sampling instances (●) 
for D-optimal and DMOO design vectors and resulting glucose concentration profiles 
 















































Figure 5.8: Pareto-optimal front for AMOO design 
 
 
Figure 5.9: Time profiles of basal insulin infusion and blood glucose sampling instances (●) 
for A-optimal and AMOO design vectors and resulting glucose concentration profiles  
 
 















































































Figure 5.10: Pareto-optimal front for EMOO design 
 































Figure 5.11: Time profiles of basal insulin infusion and blood glucose sampling instances (●) 
for E-optimal and EMOO design vectors and resulting glucose concentration profiles 
 












































From the results in Tables 5.3 to 5.5, it can be observed that each MOO based 
experimental design performs better or equivalent to its alphabetical counterpart. For D 
vs. DMOO and E vs. EMOO scenarios, the decrease in correlation comes at a small cost 





closer to true values of parameters. Both D-optimal and DMOO-designs result in similar 
basal insulin profiles, however, a closer inspection will indicate that the DMOO-design 
results in slightly longer experiment duration and different sampling instances (Figure 
5.7). A-optimal design results in significantly high correlation among parameters, with all 
correlation elements close to 1. This results in poor point estimates as well as smaller t-
value for parameters (Table 5.4). It is clear from Figure 5.8 that the selected AMOO 
experimental design provides a precipitous decrease in correlation measure with little loss 
in information measure. The resulting point estimates for individual parameters are closer 
to true values with significantly high t-values (Table 5.4). 
The proximity of obtained parameter estimates is compared based on percentage 











δ = × =  
 
∑  (5.20) 
The results are summarized in Table 5.6. In all three scenarios, the percentage normalized 
Euclidean distance is smaller for MOO based designs, which confirms that the resulting 
parameter estimates from MOO based designs are closer to the true values of model 
parameters when compared with the corresponding alphabetical designs. 
Table 5.6: Percentage normalized Euclidean distance for alphabetical and MOO based 
designs for Type 1 diabetes model 
Alphabetical vs. MOO design δtraditional δMOO 
D vs. DMOO 16.62 11.12 
A vs. AMOO 210.59 5.83 
E vs. EMOO 7.29 5.57 




5.6.2 Baker’s Yeast Fermentation Reactor Model 
This case study corresponds to fed-batch model for Baker’s yeast fermentation [170]. 
This classical model has been widely employed for implementation of various DOE 
techniques such as D-optimal [171], E-optimal [142], SV-optimal [142], min-max robust 
optimal [148], P-optimal [141], and anti-correlation experimental design [150], and can 
be considered as a benchmark model in MBDOE literature. Assuming Monod kinetics for 
substrate consumption and biomass growth, the reactor model can be described by the 











dy r u y
dt













where 1y  and 2y are the biomass and substrate concentrations (g/L), respectively and r is 
the specific growth rate of bio-mass. The reactor system uses two piecewise constant 
manipulated variables 1u  (dilution factor, h
-1) and 2u  (feed substrate concentration, g/L). 
The reactor model has four unknown parameters, of which two are for the rate expression 
( 1θ , 2θ ) and the rest two are yield coefficients ( 3θ , 4θ ). At t = 0, the substrate 
concentration 02y  equals 0.1 and biomass concentration denoted by 01y  is a design 
variable, i.e. 00 1[ ,0.1]y y=  
The design variables comprise 01y , five manipulated variable moves for each of 1u and 2u , 
four switching times for each manipulated variable, and ten sampling instances. In effect, 
the design space constitutes a total of 29 decision variables. All the design variables with 





Table 5.7: Design variables, their bounds, and initial guess values for Baker's yeast 
fermentation reactor system 





Initial amount of Biomass 0
1y  1 10 5.5 
Sampling instances (h) 
spt  0.5 20 [2, 6, 9, 16, 21, 23, 27, 33, 36, 38] 
Dilution factor (L-1) 
1u  0.05 0.2 [0.12, 0.12, 0.12, 0.12, 0.12] 
Substrate in feed (g L-1) 
2u  5 35 [15, 15, 15, 15, 15] 
Switch time for 1u   s1t  0.5 20 [5, 15, 20, 30] 
Switch time for 2u   s2t  0.5 20 [5, 15, 20, 30] 
The operational constraints considered in the design are as follows: 
• Minimum and maximum duration between consecutive control switches is 0.5 and 
20 hours, respectively. 
• Two consecutive samples should be at least 0.5 hours apart and at most 20 hours 
apart [141]. 
• The first sample could only be taken after 0.5 hours of start of experiment. 
• Maximum allowable experiment duration is 40 hours. 
Based on the above constraints, a total of 30 linear constraints were obtained for 
experimental design, besides the model equations. These were reduced to 3 by employing 
the earlier mentioned approach of transforming the time instants to time intervals (Figure 
5.5 and Table 5.2), each bounded between [0.5, 20]. Corresponding to measured states, 
1y  and 2y , the error variance matrix ∑ is assumed to be diagonal and following a constant 







∑  (5.22) 




The true parameter values for this system were, θtrue = [0.31, 0.18, 0.55, 0.05]. These 
values were used to obtain the "experimental data" from the model. For all the 
experimental designs, the initial parameter guess, θ = [0.5, 0.5, 0.5, 0.5] is used. In the 
parameter estimation stage, following upper and lower bounds on parameters were 
imposed [141]: 
 1 2 3 40.05 , , 0.98 0.01 0.98< < < <θ θ θ θ  (5.23) 




: Similar to the first case study, comparison of parameter 
estimates, correlation, and t-value for D-, A-, and E-optimal design with their respective 
MOO counterparts are tabulated in Tables 5.8, 5.9, and 5.10, respectively. Figures 5.12, 
5.14, and 5.16 are Pareto-optimal fronts corresponding to DMOO, AMOO, and EMOO 
design, respectively; in these figures, the data-tip (X,Y) corresponds to the selected 
optimal trade-off for implementation. As in the first case study, parametric scaling of 
sensitivity coefficients is adopted. In addition, the sensitivity coefficients are also scaled 
with respect to states in order to remove the magnitude difference between different 
measured states. The modified scaled sensitivity is defined as response-ranged sensitivity 










In this equation, ‘i’ is the index of measured state (both states 1y  and 2y  are measured), 
‘s’ is the index for sampling instance (s = 1, 2,…,10), and ‘j’ is the index for parameters (j 
= 1, 2, 3, 4). 
Figures 5.13, 5.15, and 5.17 show the optimal time profiles for dilution factor ( 1u ) and 





MOO design counterpart along with sampling instances, and the dotted lines in the 
figures denote the lower and upper bounds for manipulated variables 1u  and 2u . 
 
Figure 5.12: Pareto-optimal front for DMOO design 
 
Figure 5.13: Time-profile of manipulated vairables ( 1u  and 2u ) and sampling instances (●) 
for D-optimal and DMOO design 
 












































































































θ2 (0.18) 0.242 ± 1.031 0.50* 
θ3 (0.55) 0.602 ± 0.199 6.42 
θ4 (0.05) 
0.061 ± 0.030 4.34 
DMOO- 
design 










θ2 (0.18) 0.222 ± 0.415 0.69* 
θ3 (0.55) 0.537 ± 0.193 5.14 
θ4 (0.05) 
0.049 ± 0.025 3.39 
* Statistically insignificant parameter(s) 
 
Figure 5.14: Pareto-optimal front for AMOO design 


































Figure 5.15: Time-profile of manipulated vairables ( 1u  and 2u ) and sampling instances (●) 
for A-optimal and AMOO design. 
 



























θ2 (0.18) 0.310 ± 0.246 2.66 
θ3 (0.55) 0.570 ± 0.203 5.95 
θ4 (0.05) 
0.053 ± 0.023 4.92 
AMOO- 
design 










θ2 (0.18) 0.210 ± 0.189 2.35 
θ3 (0.55) 0.620 ± 0.256 5.14 
θ4 (0.05) 
0.060 ± 0.027 4.68 
 
























































Figure 5.16: Pareto-optimal front for EMOO design 
 
 
Figure 5.17: Time-profile of manipulated vairables ( 1u  and 2u ) and sampling instances (●) 
for E-optimal and EMOO design. 
 










































































































θ2 (0.18) 0.176 ± 0.203 1.84* 
θ3 (0.55) 0.483 ± 0.131 7.84 
θ4 (0.05) 
0.042 ± 0.016 5.46 
EMOO- 
design 










θ2 (0.18) 0.173 ± 0.177 2.08* 
θ3 (0.55) 0.547 ± 0.172 6.75 
θ4 (0.05) 
0.050 ± 0.019 5.49 
* Statistically insignificant parameter(s) 
In all the three MOO based designs, point estimates of parameters are close to true 
parameter values (Table 5.8, 5.9, and 5.10). The proximity of these to true parameter 
values are compared based on percentage normalized Euclidean distance (δ), defined in 
equation 5.20. The results are summarized in Tables 5.6 and 5.11. Considering D- vs. 
DMOO designs, only a small decrease in correlation measure can be obtained for a 
somewhat large decrease in information measure (Figure 5.12). This is reflected in 
obtained parameter estimates for both designs, which are similar with two parameters 
turning out to be statistically insignificant (Table 5.8). D-optimal design results in more 
precise parameters, while DMOO design results in slightly better point estimates. This 
suggests that based on one’s requirement, the alphabetical design or MOO based design 
can be preferred. If the parameter precision is more important, then one should opt for D-
design, and if focus is on accurate point estimates then one should opt for DMOO design. 
Similarly, the AMOO design outperforms A-optimal design while considering point 
estimates, but result in slightly poor t-values or wider confidence interval (Table 5.9). 




Similar results are obtained for E-EMOO pair where improved point estimates are 
obtained at the cost of wider confidence interval (Table 5.10). 
Table 5.11: Percentage normalized Euclidean distance for alphabetical and MOO based 
designs for Baker’s yeast fermentation reactor model 
Alphabetical vs. MOO design δtraditional δMOO 
D vs. DMOO 43.30 39.07 
A vs. AMOO 76.87 28.40 
E vs. EMOO 32.59 11.84 
5.7 Discussion 
The foremost advantage of the proposed MOO based DOE framework is that it results in 
multiple optimal experiment designs in the form of a Pareto-optimal front. The two 
extremes of Pareto-optimal front can be considered equivalent to single objective designs: 
one extreme corresponds to maximum information–maximum correlation which is 
equivalent to the traditional alphabetical design, while the other extreme refers to 
minimum information–minimum correlation, equivalent to the design for Pritchard and 
Bacon criterion [145]. Between these two extremes, there exist a number of optimal 
trade-offs between information and correlation measures. This offers the experimenter the 
freedom to choose an optimal experiment design according to the desired trade-off. From 
the results on the two case studies, it can be concluded that MOO based designs result in 
better point estimates than the traditional alphabetical designs. The improved point 
estimates are obtained at the cost of slightly decreased precision in MOO based designs. 
The decreased precision is expected owing to the fact that MOO based experimental 
design opts for decreased information measure. This decreased information contributes 
towards poor precision of estimated parameters. Note that the comparison of results is 
based on the chosen optimal trade-off between information and correlation measure and 





Interestingly, the AMOO-design results for Type 1 diabetes model clearly outperforms 
those from the A-optimal design, both in the context of point estimates as well as 
parameter precision (Table 5.4). Even in the Baker’s yeast fermentation reactor case 
study, the A-optimal design results in poorer point estimates (Table 5.9); this is also 
evident from Table 5.11, where the worst percentage normalized Euclidean distance (δ) is 
obtained for A-optimal design. Earlier, it has been recommended that A-optimal criterion 
should not be employed for experimental design since it may lead to non-informative 
experiments due to high correlation in parameters [140]. Results of the present simulation 
study show that AMOO design can overcome the problems associated with A-optimal 
design and results in better parameter estimates. Among the discussed alphabetical 
designs, E-optimal design performs better for the two case studies, but EMOO-design 
performs even better than E-optimal design, as can be observed from percentage 
normalized Euclidean distance (δ) in Tables 5.6 and 5.11. The lower value of δ indicates 
that the obtained point estimates for parameters are closer to true parameter values.  
Further, comparison of the obtained Pareto-optimal fronts for DMOO, AMOO, and 
EMOO designs shows that the point corresponding to minimum correlation measure is 
very similar in all the designs (Figures 5.6, 5.8, and 5.10 for Type 1 diabetes model, and 
Figures 5.12, 5.14, and 5.16 for Baker’s yeast fermentation reactor model). The minor 
discrepancy could be attributed to the stochastic nature of genetic algorithm employed. 
Notably, the other extreme corresponding to maximum information–maximum 
correlation i.e. alphabetical design shows the least value for EMOO Pareto-optimal front, 
when compared with corresponding DMOO and AMOO Pareto-optimal fronts. This 
suggests that this particular extreme point in EMOO Pareto-optimal front or E-optimal 
design can also reduce parameter correlation. In other words, among the alphabetical 
designs, E-optimal design can better handle the correlation among parameters.  




Results of the case studies show that the obtained Pareto-optimal fronts for the two case 
studies are different for the same design. Also, for each case study, the Pareto-optimal 
front is different for different designs. This suggests that shape of the Pareto-optimal front 
depends on model equations, number of parameters, and the choice of design criteria. The 
other plausible factors affecting the shape of the Pareto-optimal front are number of 
measured states, number of samples, and input perturbation allowed. Generally, the 
correlation among parameters increases with increase in information, but the actual trade-
off needs to be established for each scenario by MOO. 
5.8 Summary 
An MOO based DOE framework, which provides an optimal trade-off between 
information for parameter estimation and correlation among parameters, is proposed. Two 
case studies, namely, a 3-parameter modified Bergman minimal model for Type 1 
diabetes patients and a 4-parameter Baker’s Yeast fermentation model are used to 
illustrate the effectiveness of the proposed approach. The results highlight the potential of 
MOO based DOE formulations to perform better than the traditional alphabetical designs. 
Specifically, the proposed approach can provide point estimates closer to the true values 
than those obtained by the traditional alphabetical designs; the AMOO design overcomes 
the problems associated with A-optimal design. Among the alphabetical designs, the E-
optimal design is superior in reducing the correlation among parameters, but EMOO 




























6. Optimal Sampling Protocol for Toxin Kinetic Modeling 
If your experiment needs statistics, you ought to have done a better experiment. 
- Ernest Rutherford 
Part 2 of the thesis started with the premise that, if better estimates of inter-
compartmental clearance (Kip) and/or other model parameters are obtained, then exercise 
induced physiological changes can be better quantified. To obtain precise estimates of the 
model parameters, an intelligent experiment design is a pre-requisite. Towards this end, 
the previous chapter proposed a novel MOO based DOE framework for experimental 
design. The proposed DOE framework was tested on two case studies. It was shown that 
though traditional MBDOE techniques maximize the information content for precise 
parameter estimation, they also increase the correlation among model parameters. In this 
chapter, the same framework will be used on the proposed toxin kinetic model (TKM) in 
Chapter 3. The objective here is not to compare the performance of alphabetical and 
MOO based DOE, but to provide the optimal sampling protocol for TKM. Hence, only D-
optimal design and its MOO based counterpart will be studied. The D-optimal design is 
chosen because it is the most popular experimental design criterion [140].  
6.1 Sampling protocols in TKM 
To improve the existing dialysis care i.e. obtaining enhanced toxin removal, TKM can 
play an important role [69]. For details of TKM and related literature, see Chapter 2 
where a review of TKM has been presented. Briefly, TKM relates to the mathematical 
approximation of physiology. A number of mathematical representations such as single-
pool model, two-pool model, regional blood flow model, and diffusion-adjusted regional 
blood flow model are available to approximate the physiology. Irrespective of the type of 
model employed, all of them have unknown model parameters whose estimation is 





decipher how the dialysis adequacy can be increased for pathophysiologically important 
toxins. A better understanding of the toxin kinetic behavior not only provides a rational 
for choosing dialysis dose [172], but also gives important insights about physiological 
resistance responsible for inadequate toxin removal [173]. The aspects related to 
physiological resistance were detailed in Chapter 3, and change in this resistance as a 
result of intra-dialytic exercise was presented in Chapter 4. The physiological changes 
related to inter-compartmental toxin transfer are lumped in a model parameter Kip, which 
is inversely proportional to inter-compartmental resistance. The precise estimation of Kip 
can not only quantify the exercise induced physiological changes, but also provide a 
better estimate of toxin removal. Apart from Kip, estimation of other model parameters 
can facilitate a better understanding of patient physiology [29, 173]. 
Parameter estimation necessitates toxin concentration measurement, and number of blood 
samples are collected during and post-dialysis phase. The importance of intelligent 
sampling is paramount considering the significance of TKM [69]. Numerous sampling 
practices exist in the TKM literature (Table 6.1); but an important question remains 
unanswered: Which sampling protocol is superior (to others)? Specifically, when and how 
many samples should be collected such that precise estimates for physiologically 
important model parameters can be obtained? MBDOE techniques can potentially play an 
important role in this regard, because a good physiological representation in the form of 
DA-RBF model already exists (Chapter 3). The MBDOE paradigm has already been 
realized in engineering, systems biology domain [140], and also in biomedical fields such 
as diabetes care [167]. Despite this, there is no mention or use of MBDOE in TKM 
literature. This chapter intends to fill this gap. 




Table 6.1: Existing sampling protocols for various uremic toxins 










Eloot et al.[67] Urea, Guanidino 
compounds  
HD Two-pool model 0, 5, 15, 30, 120, end dialysis No sample 6 
Schneditz et 
al.[51]* 
Urea, Creatinine HD DA-RBF model 0, 5, 15, 30, 120, end dialysis No sample 6 





Urea HD Bi- and Tri-
compartment model 
0, 5, 10, 30, 100, 240 5, 10, 30 ,60 10 
DeSoi et 
al.[55]** 
Phosphate HD Two-pool model 0, 15, 30, 45, 60, 90, 120, 
150, 180, 210, 240 
15, 30, 45, 60, 90, 120, 




Phosphate HD/HDF Four-pool model 0, 40, 80, 120, 160, 200, 240 2, 15, 30, 60 11 
Ursino et al.[63] K+, Na+, Cl-, Urea, 
HCO3-, H+ 
Profiled HD Two-pool model 0, 20, 40, 60, 80, 100, 120, 
140, 160, 180, 200, 220, 240 
No sample 13 
Leypoldt et 
al.[72]  
β2-microglobulin HD Two-pool model 0, 60, 120, 180, 210 20 sec, 2, 10, 20, 30, 60 11 
Stiller et al.[73] β2-microglobulin HD Two-pool model 0, 30, 60, 120, 180, 240  10, 20, 30, 40, 50, 60 12 





β2-microglobulin HDF DA-RBF model 0, 60, 120, 240 20 sec, 5, 10 ,30 ,60, 90 
120, 240 
12 
* Urea and creatinine concentrations reported by Eloot et al.[67] were used for the study. 
** Recruited study subjects dialyzed for different durations. The sampling protocol presented here reflects 4 hour dialysis. 






As mentioned earlier, different sampling protocols exist in the context of TKM. However, 
no definite consensus exists for sampling during and post-dialysis period (Table 6.1). 
Also, how many samples should be collected for precise estimation of model parameters 
remains an unstudied problem. Different clinical studies follow different sampling 
protocols, without accounting for the fact that those sampling protocols may be expensive 
due to too many samples and/or uninformative due to sampling decisions based on 
intuition. The objective of this work is to provide an optimal sampling protocol for 
precise estimation of DA-RBF model parameters. In the next section, experimental design 
details are presented. Obtained sampling protocols and results from MBDOE paradigm 
are presented in Section 6.3. A discussion on the obtained results is presented in Section 
6.4. The last section summarizes the important insights developed from this investigation. 
6.2 Materials and Methods 
The foremost requirement for MBDOE techniques is a mathematical model with some a 
priori knowledge of values for unknown model parameters. In this work, the DA-RBF 
model, which arguably is the most comprehensive TKM available at present, is employed 
for elucidating the optimal sampling protocol. The toxin considered is β2-microglobulin, a 
marker of middle-sized uremic toxins and also an independent marker of mortality and 
morbidity in maintenance HD patients [75]. The model description, equations, and related 
details can be found in Chapter 3. The original model comprised seven parameters, which 
were reduced to three parameters using a priori identifiability analysis (Section 3.3). The 
three model parameters that need to be estimated are Kip, Vd, and fP. The measured state is 
arterial serum concentration (Cart).  
Toxin Kinetic Model 




As mentioned in the previous chapter, central to the MBDOE techniques is the Fisher 
Information Matrix (FIM) which is calculated from sensitivity coefficients. In this 
particular model, the corresponding sensitivity coefficient defined at each sampling 
instant (tj) is: 
 art , jij
i
Z ; where i 1, 2,3 j
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Note that ijZ  corresponds to ij
th element of sensitivity coefficient matrix (Z), whose size 
depends on the number of samples; e.g., if 10 samples are collected for estimating 3 
parameters, then the size of Z matrix is 10×3. 
The flowchart of employed MBDOE methodology is shown in a previous chapter (Figure 
5.4), which starts with model selection and initialization of model parameters. The model 
structure corresponds to the DA-RBF model. The initial guess for parameters can be 
obtained from the literature or from an understanding of patient physiology; e.g., β2-
microglobulin distribution volume (Vd) corresponds to extracellular fluid volume which is 
typically 33% of total body water. In this simulation study, the true value of patient 
parameters is known and the design objective is to obtain the output samples at optimal 
times that will result in point estimates closer to the true values. The true values of model 
parameters were taken as the mean estimates from Chapter 3. The initial guess for Kip, Vd, 
and fP were chosen at 50%, 20%, and 20% negative deviation from known true values. 
The inter-compartmental clearance is considered to have a larger deviation because it 
cannot be measured, while the Vd and fP can be inferred from patient physiology. The true 
parameter values along with their initial guess values (for MBDOE purposes) are 
presented in Table 6.2. 





Table 6.2: Model parameters with their known true values and initial guesses used for 
model-based design of experiment techniques  
Parameter True Value [173] 
Initial guess (% deviation 
from true values) 
Kip 44 mL/min 22 mL/min (-50%) 
Vd 14 L 11.2 L (-20%) 
fP 0.39 0.31 (-20%) 
Two important considerations in the experimental design for TKM are the experiment 
duration and the number of samples. From Table 6.1, it can be noted that different TKM 
studies have followed different criteria for both these aspects. First, for the experiment 
duration, it can be suggested that smaller the experiment duration the more convenient it 
is for the patients; however, it cannot be less than 240 min dialysis duration and so the 
decision variable with clinician/experimenter is the post-dialysis wait. In Table 6.1, the 
post-dialysis ranges from 0 to 240 min. To ascertain the optimal duration of experiment, 
different experiment duration (including post-dialysis wait), namely, 240 min, 300 min, 
360 min, and 480 min are studied independently. The second important aspect for TKM 
experiment design is the total number of samples. Again, from Table 6.1, it is clear that a 
wide variety of sampling protocol exists. The important question is: should all the 
samples be collected in intra-dialytic phase, or more samples should be collected during 
intra-dialytic phase and less in post-dialysis phase, or vice-versa? Here, four different 
scenarios for total number of samples are considered (Table 6.3). The MBDOE will 
automatically decide the distribution of sampling instances in intra-dialysis phase as well 
as post-dialysis phase. For each of the experiment duration, individual sampling scenario 
is considered. In effect, total 16 scenarios as mentioned in Table 6.3 are considered. Note 
that, in design procedure, the pre-dialysis sample (at t = 0) and end-dialysis sample (t = 
240 min) are mandatory because these are conventionally required for estimation of 




D ureat / VK  or toxin reduction ratio. To account for this, the decision variables in Table 
6.3 exclude the sample at t = 0, but sample at t = 240 is decided by MBDOE itself. If 
MBDOE does not result in t = 240 min in the final sampling protocol, then sampling t = 
240 is included for final parameter estimation. Few operational constraints were also 
incorporated in the experimental design: a minimum gap of 5 minutes is maintained 
between two consecutive samples. At the same time, maximum time interval between two 
consecutive samples is restricted to 120 min.  
Table 6.3: Two factors – Experiment duration and number of decision variables, 
each at 4 levels  
 











































Here, the objective is to suggest the optimal sampling instances for TKM, based on D-
optimal design. At the same time, the DMOO design is also studied. In all the 16 
scenarios, the arterial serum toxin concentration is obtained at these optimal sampling 
instances using the model with true parameter values. To incorporate the characteristics 
of real-time data, 10% relative noise was added to all the samples. In clinical setting, the 
data will be obtained from actual measurement during intra- and post-dialysis. This data 
is used for parameter estimation and subsequent calculation of parameter confidence 
interval. The entire procedure highlighted above was repeated for all the 16 scenarios 
shown in Table 6.3. In all the scenarios, it is assumed that post-dialysis fluid intake is at 






The MBDOE and parameter estimation procedure was repeated for each scenario. The 
sampling instances for each experiment scenario are shown in Table 6.4. In Table 6.5, 
only optimal sampling instances are shown. The mandatory samples at t = 0 and t = 240 
min are not shown. In some scenarios, t = 240 is the sampling instance from optimizer 
itself, and hence included in Table 6.5. For DMOO-design, the presented sampling 
instances correspond to chosen trade-off solution from the Pareto-optimal front. For each 
of the 16 scenarios, one Pareto-optimal front was obtained. For illustration, only four of 
these Pareto-optimal fronts for the case of 8 decision variables, one each for experimental 
duration, are presented in Figures 6.1 to 6.4. The data-tip in each of these figures 
corresponds to the chosen experimental design. 
 
Figure 6.1: Pareto-optimal front for 240 min

























DMOO Pareto for experiment dutation 240 min
 experiment duration and 8 decision variables 





Figure 6.2: Pareto-optimal front for 300 min
 
 experiment duration and 8 decision variables 
 
Figure 6.3: Pareto-optimal front for 360 min

























DMOO Pareto for experiment duration 300 min
 experiment duration and 8 decision variables 






























Figure 6.4: Pareto-optimal front for 480 min
As mentioned earlier, in this simulation study, the patient model with known true 
parameter values is assumed as proxy to the patient, and it is simulated to obtain the toxin 
concentration at the optimal sampling instances. The obtained data was used to estimate 
the unknown model parameters Kip, Vd, and fP. To evaluate the individual parameter 
precision, the t-value for individual parameter is calculated. At the same time, the point 
estimates were compared using percentage normalized Euclidean distance (δ) between 
obtained parameter estimates and true parameters (equation 5.20). In Table 6.5, obtained 
point estimates with t-value and the δ are shown for comparative analysis. Larger t-value 
for individual parameter indicates improved precision while smaller value of δ denotes 
superior point estimates. 
 experiment duration and 8 decision variables 
 



























DMOO Pareto for experiment duration 480 min




Table 6.4: Decision variables (d.v.) or optimal sampling instances in different experiment duration (during dialysis + post-dialysis). Sampling 
instances during dialysis (normal text) and post-dialysis (bold text), respectively. 
 240 min 300 min 360 min 480 min 










25 22 22 19 25 25 21 19 23 23 20 20 29 27 31 28 
30 27 28 24 30 30 26 24 28 28 25 25 34 32 36 33 
101 32 33 29 105 107 31 29 110 108 30 30 154 105 41 38 
115 98 94 34 120 115 97 34 151 113 106 98 274 172 161 95 
235 110 99 41 240 120 102 95 271 118 111 103 370 292 281 170 
240 115 105 94 300 240 107 100 360 240 117 108 480 355 298 290 
 235 110 99  294 120 105  355 240 120  475 350 304 
 240 230 105  300 240 110  360 350 131  480 470 330 
  235 110   295 170   355 230   475 450 
  240 229   300 290   360 350   480 470 
   235    295    355    475 









25 22 23 21 21 20 18 19 22 22 20 20 32 27 27 24 
93 27 28 26 26 25 23 24 27 27 25 25 152 32 32 29 
98 90 90 31 101 30 28 29 107 101 30 30 272 148 109 34 
115 95 95 78 120 97 97 34 120 107 100 93 355 267 168 112 
235 101 100 88 240 102 102 95 240 112 107 99 475 350 288 165 
240 115 105 93 300 120 107 100 360 120 112 104 480 470 345 285 
 235 110 98  240 120 105  240 117 110  475 465 339 
 240 230 105  300 240 110  360 235 115  480 470 459 
  235 110   295 120   355 120   475 465 
  240 230   300 240   360 240   480 470 
   235    295    355    475 





Table 6.5: Point estimates (θ), t-value, and Percentage normalized Euclidean distance (δ) from true parameter for each scenario 
  
 240 min 300 min 360 min 480 min 
  




















33.77 Vd 14.39 3.8 15.86 2.69 16.11 2.32 14.52 9.63 
fP 0.44 4.7 0.35 3.31 0.35 3.2 0.42 13.86 
DMOO 
design 







33.37 Vd 14.49 3.46 15.74 2.83 16.05 1.97 15.36 11.2 




















27.81 Vd 16.74 2.05 14.15 3.4 14.72 5.43 14.26 16.22 
fP 0.27 2.29 0.37 5.15 0.40 9.73 0.35 6.91 
DMOO 
design 







24.77 Vd 16.92 1.92 13.37 4.29 14.28 7.47 14.35 14.6 



















19.29 Vd 16.66 2.56 13.1 11.65 15.39 8.94 13.7 19.98 
fP 0.38 3.20 0.38 8.2 0.33 15.14 0.45 8.2 
DMOO 
design 







17.74 Vd 15.08 3.25 13.1 11.32 14.29 7.49 13.77 19.76 




















11.46 Vd 15.19 3.01 13.43 14.64 13.72 20.27 13.62 25.1 
fP 0.43 3.74 0.37 12.23 0.42 9.02 0.42 10.66 
DMOO 
design 







11.56 Vd 13.32 4.86 13.36 14.09 14.93 11.1 13.64 19.98 
fP 0.47 4.72 0.44 10.9 0.34 10 0.4 8.57 





6.4 Discussion and Sampling Recommendation  
The importance of TKM has been widely recognized in dialysis community and recently 
elucidated in an editorial review titled “What can the dialysis physician learn from kinetic 
modeling beyond Kt/Vurea?” by Eloot et al. [69]. The review recommends further clinical 
research for kinetic studies especially for the toxins whose impact on patient outcome is 
well established. A number of clinical studies have been performed to improve HD care 
through improved understanding of toxin kinetics via TKM. The information from 
clinical trials completely depends on the blood samples collected. These blood samples 
are used to estimate the unknown model parameters in the TKM. From a preliminary 
study of 2 patients, Eloot et al. determined that 14 samples during dialysis can 
characterize the toxin kinetics [67]. A number of TKM studies prescribe the sampling at 
equal time-intervals during dialysis, and frequent sampling after dialysis [73, 74]. There 
is no consensus among medical professionals or modelers about the sampling instances 
and sampling for TKM remains an intuition driven strategy. To the best of our 
knowledge, there is no simulation/clinical study which explores the optimal sampling 
protocol for TKM in maintenance HD subjects. Acknowledging the importance of 
sampling in TKM, an MBDOE based approach was employed in this work to elucidate 
the optimal sampling instances. Specifically, the D-optimal design was employed to 
suggest the optimal sampling instances. The foremost and important observation from the 
optimal sampling instances reported in Table 6.4 is that more samples should be collected 
during early phase of dialysis when maximum change in arterial serum toxin 
concentration takes place. The discussion below details the important outcome of 
MBDOE based sampling in comparison with existing literature. 
Intra-dialytic sampling: Sampling during dialysis is important because plasma 






Eloot et al. have qualitatively highlighted the importance of intra-dialytic sampling 
protocol and suggested that logarithmic sampling intervals should be observed rather than 
a linear sampling interval protocol [69]. In other words, unlike sampling at regular 
intervals, more samples should be collected in the early phase of dialysis. The MBDOE 
based sampling results presented in Table 6.4 corroborate the logarithmic sampling 
protocol in intra-dialytic phase. The prescribed sampling in the intra-dialytic phase 
typically manifest in pairs or triplets, e.g. in 240 min experiment duration with 6 decision 
variables scenario, sampling at 25 min is followed by sampling at 30 min (Table 6.4). The 
5 min interval between successive samples is due to the inherent constraint that the 
minimum difference between consecutive samples should be 5 min. This minimum 
interval can be adjusted based on the available resources. It is recommended that 
minimum sampling interval should not be decreased beyond 5 min because when samples 
are too close the effect of noise can be more pronounced, e.g. toxin concentration at t = 30 
min should be less that at t = 25 min. If noise is high or samples are too close then owing 
to randomized nature of noise it may so happen that concentration at t = 30 min is higher 
than that at t = 25 min. The intra-dialytic sampling results from MBDOE are different 
from the sampling protocols in the existing TKM studies [55, 67, 73, 174] (see Table 6.1). 
Also, the sampling instance results in all scenarios suggest that there is no need for 
sampling during the first 20 min of dialysis.  
Post-dialysis sampling: Though intra-dialytic samples are important, steep change of 
toxin concentration in post-dialysis phase renders the post-dialysis sampling important as 
well. This is evident from the point estimates for 240 min experiment duration (Table 
6.5), where irrespective of the number of samples, it is not possible to estimate all model 
parameters accurately as well as precisely. The results here also advocate the importance 
of post-dialysis samples.  





In the simulation here, the post-dialysis sampling is restricted to 4 hours maximum i.e. 
patient waits for 4 hours post-dialysis. Three different scenarios are considered – 60 min, 
120 min, and 240 min post-dialysis wait. It can be understood that, the shorter the post-
dialysis wait, the more convenient it is for patients. The important question is what post-
dialysis wait is optimal for precise and accurate estimation of model parameters?  
Firstly, the post-dialysis sampling results suggested by MBDOE are in contrast with 
existing literature. From Table 6.1, it can be observed that post-dialysis sampling should 
be frequent [55, 56, 73, 74, 174], which is based on the assumption that there is 
significant change in toxin concentration. This is due to the fact that during dialysis the 
high dialyzer clearance causes faster removal of toxins from blood compartment. The 
rapid decrease in serum toxin concentration leads to a considerably wider gap between 
the IC and the EC toxin concentrations, since only a small proportion of toxins pass over 
from the IC to the EC space during dialysis. This results in a rapid increase of plasma 
concentration after dialysis. This increase is referred to as rebound. The argument in 
favor of post-dialytic sampling is that the magnitude of rebound is higher when Kip is low 
(as in case of middle-sized toxins). However, similar argument can be proposed for 
concentration change during dialysis, i.e. when Kip is low, then a steep decline in serum 
toxin concentration is observed (again as in case of middle-sized marker toxins or 
intracellular toxins). The MBDOE results appear to favor the second argument and 
suggest that more samples should be collected during intra-dialytic phase rather than 
during rebound (Table 6.4 – see 300 and 360 min experiment duration). Popovich et al. 
have also suggested that steep decline in serum toxin concentration can be used to 
calculate the cell membrane mass transfer coefficient (Kip) [175]. The post-dialysis 






sample(s) is/are required which should be collected towards the end of experiment 
duration.  
Secondly, as the experiment duration increases, the point estimates improve. The best 
point estimates both in terms of accuracy and precision are obtained for 480 min duration 
with 12 decision variables. Nevertheless, 60 min post-dialysis wait (i.e. 300 min 
experiment duration) is adequate for estimating all three parameters of DA-RBF model. It 
is interesting to note that unlike the MBDOE results for 300 min and 360 min 
experimental duration, the MBDOE results for 480 min experiment duration recommends 
more samples in post-dialysis phase and less during the dialysis phase itself. The 
plausible reason behind this exception can be that 4 hours post-dialysis wait is sufficient 
time for toxin equilibration or to characterize the Kip. Frequent sampling during this phase 
will capture the role of inter-compartmental resistance in delayed toxin transfer from IC 
to EC. On the other hand, MBDOE results for 300 min or 360 min experiment duration 
suggest frequent sampling in intra-dialytic phase where sharp change in toxin 
concentration takes place. One major problem of note in longer experiment duration is the 
fluid intake by patient. The fluid intake will affect the bodily fluid volume which will 
change the toxin distribution volume (Vd). A patient cannot restrict his/her thirst, but for 
shorter experiment duration the frequency of fluid intake will be less than that in longer 
experiment. This further recommends the 300 min experiment. 
Total number of samples: Irrespective of experiment duration, sampling at 6 time points 
are too little to obtain good quality estimates of model parameters. It can be anticipated 
that as the number samples increases, the parameter precision will improve. This is 
evident from the results in Table 6.5 – for the same experiment duration, as the number of 
samples increases, the t-value for individual parameter i.e. parameter precision improves. 





It appears that 10 decision variables is the optimal number of samples. Further increasing 
the decision variables will inevitably increase the cost of laboratory analysis with little 
improvement in the precision of estimates. In effect, the experiment duration of 300 min 
with 10 decision variables will suffice for precise as well as accurate point estimates. 
D-optimal vs. DMOO design
6.5 Summary 
: The DMOO design clearly outperforms the D-optimal 
design. In almost all the scenarios, the percentage normalized Euclidean distance (δ) is 
smaller for DMOO design, i.e. the DMOO based sampling protocol results in slightly 
superior point estimates than those obtained by D-optimal design. The improved point 
estimates are obtained at some cost – the parameter precision becomes poorer. This can 
be anticipated because DMOO design compromises between information and correlation. 
In a few instances, DMOO based experimental design results in better precision than that 
obtained by D-optimal design; e.g., the t-values for Vd and fP in experiment duration of 
240 min with 12 decision variables are larger in DMOO design. However, DMOO design 
does not improve the precision of all parameters. This indicates that MOO based design 
provides a better distribution of information for estimation of model parameters. The 
sampling instances and corresponding parameter estimates in D- vs. DMOO design can 
be found in Tables 6.4 and 6.5, respectively. Unlike the case studies discussed in Chapter 
5, the HD experimental design does not involve any manipulated variable which can be 
used to perturb the system. The only design variables are sampling instances. This may be 
one of the reasons why D- and DMOO designs provide similar point estimates for model 
parameters. 
MBDOE techniques can provide optimal moves for available manipulated variables and 






estimates can be minimized. Hence, an MBDOE based sampling protocol for TKM was 
studied for the first time. Conventional sampling protocols recommend sampling during 
intra-dialytic and post-dialysis phase; however, different TKM studies used different 
sampling times. In this study, four distinct experiment durations, namely 240 min, 300 
min, 360 min, and 480 min were considered. For each of these durations, distinct 
experimental protocols with 6, 8, 10, or 12 decision variables were investigated using 
DA-RBF model as basis for MBDOE. The results indicate that, irrespective of the 
number of measurement samples, the 240 min experiment is inadequate for precise and 
accurate estimation of model parameters. Similarly, irrespective of experiment duration, 
sampling at 6 time points are too little to obtain good quality estimates of model 
parameters. Among 300 min, 360 min, and 480 min experiment duration, the point 
estimates from 480 min outperform the rest. The sampling instances in 480 min 
experiment duration are primarily in the post-dialysis phase, while for 300 and 360 min 
experiment duration, the sampling instances are primarily in the intra-dialytic phase. 
Though the point estimates from 300 min and 360 min experiment are inferior to those 
obtained in 480 min experiment, they are reasonably good when compared based on 
percentage normalized Euclidean distance. Also, the 480 min experiment duration can be 
too long and logistically expensive. Considering these aspects, this work recommends a 
sampling protocol of 11 samples collected over 300 min experiment duration, as adequate 
for both precise and accurate point estimates. 
 





7. Conclusions and Recommendations for Future Works 
The important thing is not to stop questioning. Curiosity has its own reason for existing. 
- Albert Einstein 
Hemodialysis, a method to detoxify blood, is an established life-saving treatment for 
ESRD patients. Remarkable improvements in HD care in the last five decades has 
rendered HD as the most sought after renal replacement therapy [4]. For more than 2.3 
million patients worldwide, HD is part of life [12]. Nevertheless, patients on HD still 
have poor quality of life, high morbidity and mortality. The pertinent question is “what 
can be done to improve the existing HD care?” Improvement can be achieved via several 
ways. The direction followed in this thesis is to suggest approaches to enhance the toxin 
removal, which is the chief aim of HD. Improvement in toxin removal can be studied via 
experimental studies and/or computer simulations. The experimental focus can be on 
aspects such as clinical testing of more efficient dialyzer for enhanced toxin removal, 
comparing the performance of daily dialysis vs. conventional 3 times × 4 hours dialysis, 
etc. One should note that conducting experiments without sound hypotheses rarely 
provides good outcomes, and one may end up wasting useful resources. Indeed, a good 
understanding of system is the foremost requirement to form sound hypotheses, and 
clinicians can provide that understanding. The system understanding can also be obtained 
via computer simulation, which is a common Process System Engineering (PSE) 
technique. The PSE approach represents the underlying system as a mathematical model 
which can be simulated beyond the conventional settings. These simulations can form the 
basis of generating new hypotheses and thus suggesting new clinical studies. This 
research work has followed this combined approach of modeling as well as clinical 






for simulations and subsequent clinical studies, the aspects pertaining to model 
improvement are also explored. The approach for model improvement is based on 
improved estimates of model parameters, which are obtained via MBDOE approach.  
The salient contributions from this thesis work are highlighted in Section 7.1. This thesis 
work has also led to more research questions which need to be addressed in future. The 
potential future works are presented in Section 7.2. 
7.1 Contributions 
The contributions from this thesis work are highlighted in the order of their occurrence in 
the preceding chapters. Since the thesis focuses on two different aspects – the first on 
TKM and clinical testing of model generated hypothesis, and the second on improvement 
of TKM itself via MBDOE for improvement of model parameter estimates, the 
contributions pertaining to each aspect are discussed separately in Sub-sections 7.1.1 and 
7.1.2. 
7.1.1 Toxin Kinetic Modeling and Clinical Study 
TKM and clinical study constituted Part 1 of this thesis. Chapter 2 provided the 
foundation for TKM paradigm in HD care. Starting with the toxin classification and 
concept of marker toxin(s), the importance of TKM was elucidated and related literature 
was reviewed. The evolution of TKM starting from single-pool model assumption to the 
two-pool model and physiological RBF model to the present state-of-the-art DA-RBF 
model was presented. An overview of TKM studies for a number of uremic toxins such as 
urea, creatinine, guanidino compounds, phosphate, and β2-microglobulin, was also 
provided. It was noted that the DA-RBF model, despite being a fairly comprehensive 
representation of physiology, is limited to characterizing the kinetics of small-sized 
uremic toxins urea and creatinine only. Cognizant of this gap in the TKM literature, the 





Chapter 3 of this thesis explored the extension of DA-RBF model for middle-sized 
marker toxin, β2-microglobulin. 
DA-RBF model for β2-microglobulin and model application
Note that the model application is not restricted to explain the underlying HD process; 
rather it should be further employed to study aspects which can improve the toxin 
removal. Accordingly, this research contribution simulated the effect of exercise on toxin 
removal. Based on the simulation results, a new hypothesis is proposed to explain the 
effect of intra-dialytic exercise toxin removal. It was suggested that exercise not only 
increases the cardiac output (CO), but also decreases the peripheral vascular resistance. 
More importantly, the simulation results suggest that decrease in inter-compartmental 
resistance is the dominant factor contributing towards enhanced toxin removal. This work 
on DA-RBF model for β2-microglobulin and its application has been published [173]; this 
: In this research contribution, 
a comprehensive model of middle-sized marker toxin β2-microglobulin was presented. 
The model is an adaptation and refinement of existing DA-RBF model [51], which was 
proposed for urea. However, this model by Schneditz et al. suffers from the drawback of 
having too many model parameters. This has limited the acceptability of DA-RBF by 
dialysis research community [69, 86]. Also, the model was never validated with real 
clinical data. To overcome the mentioned drawbacks, first a priori identifiability analysis 
was employed to elucidate the estimable subset of model parameters. This step reduced 
the number of unknown parameter from seven to three. Subsequently, the model was 
validated with the clinical data of 10 patients obtained from Dr. Richard Ward (of 
University of Louisville). The parameter estimates for proposed DA-RBF model were 
better representative of HD patient physiology than those obtained from the existing two-






has been reviewed post-publication by Dr. Daniel Schneditz, who designated this research 
contribution as a recommended read in Faculty of 1000 [176]. To advance further, 
clinical studies are required to test the proposed hypotheses. 
Clinical study to investigate the effect of exercise on physiological changes: Exercise 
during dialysis has been shown to improve the removal of small-sized toxins, but no such 
study exists for middle-sized uremic toxins. In Chapter 3, it was hypothesized that intra-
dialytic exercise not only increases the perfusion of remote peripheral compartments but 
also decrease the inter-compartmental resistance, which is often designated as major 
barrier for toxin removal [74]. To test this hypothesis and to understand the exercise 
physiology, a pilot clinical study was designed. The study obtained prior ethics approval 
from the National Healthcare Group, Singapore, and was registered in 
www.clinicaltrials.gov with trial identifier NCT01674153. In this self-controlled, open 
label, randomized prospective clinical study, a total of 15 subjects satisfying the pre-
defined inclusion-exclusion criteria were enrolled. Each study subject underwent three 
study sessions - HD, HDF, and HD-Ex. Here, HDF is also studied because HDF is widely 
proclaimed as superior to HD. Out of these 15 subjects, 12 completed all three sessions, 
one subject completed HD and HDF, while two subjects withdrew prior to their initiation 
into study sessions. The questions asked in this clinical study were as follows: (1) what 
physiological changes are responsible for decrease the inter-compartmental resistance? 
(2) will those physiological changes be sufficient to increase the removal of middle-sized 
uremic toxins? and (3) can intra-dialytic exercise provide the similar quantum of toxin 
removal as that obtained in HDF? 
It is known that exercise increases the CO which mobilizes the toxins from remote 
peripheral compartments [85, 98]. However, the factors responsible for decreased inter-





compartmental resistance are not explicitly known as yet. It was hypothesized that 
exercise increases the body core temperature thereby decreasing the peripheral resistance. 
To test this hypothesis, the arterial and venous blood temperatures were measured using 
BTM. The clinical results confirmed that intra-dialytic exercise increase the body core 
temperature. The change in core temperature from baseline was as much as 0.96 ± 0.23 
°C. To quantify the corresponding physiological changes, the Doppler Ultrasound 
Echocardiography was employed. Echocardiography provided information about the 
increase in CO and decrease in peripheral vascular resistance index, which can be 
associated with increase in body core temperature. The maximum mean percentage 
increase in CO is 106 ± 32%, while the maximum mean percentage reduction in 
peripheral vascular resistance index was 94 ± 45%. This answers the first question and 
elucidates the factors responsible for increased toxin removal. 
To answer the next questions, the quantum of toxin removed was assessed via % toxin 
rebound. A lower % toxin rebound indicates higher toxin removal. The studied toxins 
space was not restricted to β2-microglobulin. Other uremic toxins namely, urea, 
creatinine, and phosphate were also studied. For β2-microglobulin, it was observed that 
HD-Ex outperformed that HD and resulted in lower post-dialytic rebound, but HDF still 
outperformed HD-Ex and resulted in still lower post-dialytic rebound. Nevertheless, one 
should note that the patients were unconditioned to exercise and exercise intensity was 
minimum (set at zero resistance). It can be hypothesized that prolonged intra-dialytic 
exercise intervention can lead to equivalent or even more toxin removal than that 
obtained in HDF. For urea and creatinine, all three study sessions (i.e. HD, HDF, and 
HD-Ex) gave similar results for post-dialytic rebound. Interestingly, for phosphate, the 
HD-Ex resulted in significantly higher toxin rebound than that obtained in HD and HDF. 






bone matrix. This hypothesis is further strengthened due to the existing studies where pre-
dialysis exercise has shown its potential to decrease the serum phosphate concentration 
[99]. Only long term clinical studies can prove the validity of above mentioned 
hypothesis. The clinical study related content is presented in Chapter 4 of the thesis. A 
portion of this chapter has been published in [177]. 
7.1.2 Model-based Design of Experiments 
Part 1 of the thesis focused on the DA-RBF model for β2-microglobulin, its application, 
and testing of model generated hypotheses. It is the model simulations that helped in 
explaining the effect of intra-dialytic exercise. This culminated in the clinical study where 
the effect of exercise on physiological changes and toxin removal was investigated. A 
good model is the foremost requirement for model-based hypotheses testing and clinical 
studies. It is known that a model is as good as its estimated parameters [131]. Hence, Part 
2 of the thesis contributed toward improvement of the DA-RBF model parameters 
proposed in this thesis. To improve or estimate the model parameters, appropriate data 
needs to be collected. The important question is: what is the best experiment and 
sampling protocol? In this context, MBDOE techniques have become an essential tool to 
plan and conduct experiments that provide high information for a given experimental 
effort. However, an inherent drawback in existing MBDOE techniques was observed. 
These techniques not only maximize the system information for improvement of 
parameter precision but also result in increased correlation among model parameters 
which corrupt the final point estimates. Second part of the thesis contributed to the 
scientific literature by proposing a novel MOO based experimental design solution which 
appropriately addressed the correlation issue (Chapter 5). Subsequently, the sampling 
protocol for newly proposed DA-RBF model was elucidated (Chapter 6). 





Multi-objective optimization based MBDOE framework
To obtain the maximum system information from limited experimental work, MBDOE 
techniques have played a pivotal role serving as a vital link between the modeling and 
experimental worlds. The purpose of MBDOE techniques is to devise intelligent 
experiments such that the parameter estimates from the resulting experimental data are of 
“best” statistical quality. However, it was noted that existing MBDOE techniques, such as 
D-, A-, and E-optimal designs suffer from inherent drawback of maximizing the 
correlation among model parameters; this can deteriorate the point estimates and/or 
reduce the parameter precision. To overcome this drawback, a novel MOO based 
MBDOE framework was proposed. The proposed framework incorporates the traditional 
alphabetical design objective to maximize the information measure and another objective 
to minimize the correlation measure (between parameters), thus resulting in DMOO, 
AMOO, and EMOO designs, which are counterparts of D-, A-, and E-optimal designs, 
respectively. The MOO based designs result in a Pareto-optimal front from which an 
appropriate trade-off solution can be chosen as MOO based experimental design. The 
proposed framework was tested for two case studies, namely, a three parameter Type 1 
diabetes model and a four parameter Baker’s yeast fermentation reactor model. The 
results show that proposed MOO designs outperform the existing single objective 
alphabetical designs. This research contribution has already been published [178]. 
:  
Optimal sampling protocol for TKM
The aim of this research contribution was to elucidate the sampling protocol for TKM. 
The TKM literature is rich in modeling studies for a number of uremic toxins, but the 
important question – “when should one collect the blood samples so that TKM 







parameters can lead to new hypotheses and ideas for further clinical studies. In the 
existing TKM literature, there is no mention of optimal sampling protocol, except a 
qualitative recommendation from Eloot et al. who suggested logarithmic sampling i.e. 
frequent sampling in early phase of dialysis [69]. However, there is no recommendation 
for post-dialytic sampling. Also, there is no definite consensus for sampling, as different 
TKM studies have followed different sampling protocols (see Table 6.1). This research 
contribution provided the optimal sampling protocol for “best” or precise estimation of 
DA-RBF model parameters. The results suggested that 300 min experiment duration with 
10 samples (excluding sample at t = 0) interspersed in dialysis as well as post-dialytic 
phase is sufficient to obtain precise estimates for model parameters. The obtained results 
are important because it specifies the optimal post-dialytic wait and restricts it to 60 min. 
The suggested optimal sampling instances have potential to encourage nephrologists and 
TKM researchers to explore kinetic studies for other uremic toxins. The characterization 
of TKM can also pave ways for identifying global marker(s) for uremia in the future. 
7.2 Recommendations for Future Works 
This section highlights the important topics that may be studied by interested researchers 
in future. 
7.2.1 One TKM for All Marker Toxins 
Currently there appears to be little or no investigation on the kinetic behavior for both 
small and large-sized uremic toxins in a single clinical study, i.e. when the marker toxins 
are measured and analyzed within the same experiment. Eloot et al. have explored the 
kinetics of number of guanidino compounds in same experiment [29, 67], but all the 
studied toxins are small-sized molecules and are found in both IC and EC. Also, their 
objective was to test the hypothesis that kinetic behavior of other small-sized uremic 





toxins is different from urea. It does not answer the question “which model is better for 
majority of uremic toxins?” Studying both small (urea, creatinine) and large-sized marker 
toxins (β2-microglobulin) in a single session can provide this information based on the 
estimates of respective toxin distribution volume (Vd). The urea or creatinine distribution 
volume will correspond to total fluid volume, while the β2-microglobulin distribution 
volume corresponds to extracellular fluid volume. These distribution volume estimates 
can be compared with those obtained from anthropometric formulae [96] or bioelectrical 
impedance method [97]. A global TKM study of this kind can provide insight of fluid 
distribution in HD patients and a better understanding of physiology. More importantly, it 
can highlight the relative superiority of DA-RBF and the two-compartment models. One 
TKM (with toxin specific parameters) can provide guidelines for removal of a wide-
spectrum of uremic toxins. 
7.2.2 Clinical Study: HDF vs. HD-Ex 
HDF has been proclaimed as more efficient than the conventional HD. The convection 
augmented toxin removal is supposed to enhance the toxin removal in HDF, but long 
term clinical outcomes with regard to pre-dialysis toxin concentration remained similar in 
both HD and HDF [109-111, 179]. On the other hand, a randomized clinical study 
comparing HDF and HD has shown that HDF potentially improves the cardiovascular 
status of ESRD patients but could not reduce mortality rate [109]. The debate on the 
superiority of HDF over conventional HD is still on. A pro-con debate about HDF 
controversy in the recent ERA-EDTA conference (http://www.era-edta2013.org/en-
US/industry-symposium-15) further suggest that, before HDF is universally accepted, 






As of now, it is understood that the efficacy of HDF is restricted by inter-compartmental 
resistance [20, 74, 117]. The clinical study results in presented in Chapter 4 indicated that 
this resistance can be overcome by intra-dialytic exercise (HD-Ex). This leads to the 
following questions: 
1. Will this decrease in resistance translate into reduced pre-dialysis toxin 
concentration? 
2. Will prolonged HD-Ex result in lower pre-dialysis toxin concentration than HDF?  
The clinical study performed as part of this doctoral thesis research was a single session 
study and was not designed to answer the above questions. To answer these questions, a 
long-term clinical study could be designed so as to compare HDF and HD-Ex.  
Based on the existing evidence, it can be hypothesized that HD-Ex can perform similar or 
better in terms of toxin removal compared to HDF. This hypothesis is based on the 
clinical study results where HD-Ex performed much better than HD for β2-microglobulin 
removal, but HD-Ex still performed poorer that HDF. This may be due to the fact that 
recruited patients were unconditioned to exercise. Prolonged HD-Ex may not only 
enhance the toxin removal but also the patient’s quality of life, which is one the major 
goals for HD patients. Intra-dialytic exercise prescription is reported to be useful for 
treatment of depression in ESRD patients [180]. Can HDF also alleviate the depression? 
All these hypotheses should be tested via randomized prospective clinical study. 
7.2.3 Clinical Study: Cool vs. Warm Dialysate 
The focus of this research has been on enhancing the toxin removal. The notion is that 
increased toxin removal will culminate in improved patient outcome in long term. While 
this may be the case, short-term outcomes are also important. One of the common short-





term complications for HD patients is the intra-dialytic hypotension (IDH) which affects 
almost 30% of dialysis patients [181]. Though short-term in nature, IDH has been 
suggested as one of the most important cause of mortality and morbidity in dialysis 
patients [60]. It occurs when patient’s cardiovascular responses cannot compensate for 
large fluid losses that can occur with high UF. IDH can also occur when UF rate is more 
than the plasma refilling rate and persists for long enough to reach a critical threshold in 
the reduction of blood volume. The decrease in blood volume results in sudden drop in 
blood pressure which results in severe cramps, dizziness, headache, etc. The easy solution 
to this approach is to decrease the UF rate thereby preventing further reduction in blood 
volume. The downside of this approach is that patient is left “fluid overloaded”, which 
results in chronic hypertension and associated complications.  
The other important maneuver is the reduction in dialysate temperature. The conventional 
dialysate temperature is set at 36°C. The cool dialysate is recommended at 35 or 35.5°C. 
The cool dialysate decreases the blood temperature. When this cool blood mixes with the 
systemic circulation the body core temperature decreases. To adjust for the reduced body 
core temperature, vasoconstriction takes place preventing the blood flow to remote 
peripheral compartments and the central fluid volume is ultimately stabilized. The results 
presented in Chapter 4 of this thesis pointed out that increase in body core temperature 
leads to increased toxin removal. This implies that cool dialysate will potentially inhibit 
the toxin removal. The effect of cool dialysate on urea removal has been studied in 1995 
and 1998, and it was found that urea removal remains unaffected with cool dialysate [125, 
182]. Nevertheless, it has been mentioned repeatedly in this thesis that urea removal does 
not ensure the removal of other uremic toxins, because urea is small in size and urea 
exchange between compartments is facilitated by urea transporters on the cell wall. This 






dialysate not inhibit the removal of other small and large-sized uremic toxins? To answer 
this question, clinical studies could be conducted to study the effect of cool vs. warm 
dialysate (37°C). A pilot clinical study funded by National Kidney Foundation, Singapore 
(NKFRC/2012/01/08) is currently under progress. This study is designed to answer the 
above mentioned question. 
7.2.4 Model Predictive Controller and Dialysate Temperature 
The previous section highlighted the importance of cool dialysate for hemodynamic 
stability and also its unfortunate side-effect of reduced toxin removal. Therefore, a 
clinical study comparing cool and warm dialysate was proposed. If the above mentioned 
hypothesis is indeed correct, then warm dialysate should result in improved toxin removal 
but poor hemodynamic stability. This would lead to the temperature induced trade-off 
between toxin removal and hemodynamic stability. As future work, one could explore 
intelligent control of dialysate temperature. The Model Predictive Controller (MPC) 
technique could use the current hemodynamic response and a model to predict the future 
hemodynamic responses. Based on this information, the MPC can take appropriate 
corrective actions and either increase or decrease the dialysate temperature to elicit the 
enhanced toxin removal and hemodynamic stability and avoid IDH. 
7.2.5 Exploring Synergies between Exercise Regimen and Dialysate Temperature 
Experimental results in Chapter 4 indicate that intra-dialytic exercise leads to increase in 
body core temperature. For three bouts of exercise, three distinct peaks in arterial blood 
temperature were observed (Figure 4.5). On the other hand, it is also known that 
increased body core temperature can potentially lead to incidence of IDH (see Sub-
section 7.2.3) [60, 183]. This implies the possible hemodynamic instability due to intra-
dialytic exercise. In summary, intra-dialytic exercise and dialysate temperature can 





change the body core temperature. A synergy of these two aspects can further maximize 
the toxin removal and minimize the hemodynamic instability. In other words, exercise 
time, duration, intensity, and the dialysate temperature are primary handles to attain the 
improved patient outcomes. Careful experimentation and modeling of these aspects can 
help to decrease the mortality and morbidity in HD patients, and they are recommended 
as future work. 
7.2.6 MOO based DOE for Larger Systems 
In Chapter 5 of the thesis, the MOO based DOE framework was proposed. The 
framework was tested on two case studies, namely, the three-parameter type 1 diabetes 
model and the four-parameter Baker’s yeast fermentation reactor model. Those case 
studies were used to illustrate the effect of correlation on parameter estimates and to 
demonstrate that the proposed MOO based DOE performs better than the basic 
alphabetical experimental designs. Future work could study the performance of proposed 
framework on systems characterized by large number of parameters. Another important 
aspect in proposed DOE framework is the Pareto-optimal point selection. This aspect 
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